Salim Yusuf

Q: What Schools Are Affiliated With Salim Yusuf

Salim Yusuf is affiliated with the following schools: University of Washington, University of Utah, Harvard University, University of Western Ontario, National University of Ireland, Uppsala University, University of Oxford, McMaster University, Dalhousie University, Queen's University at Kingston, University of Valencia

Salim Yusuf's AcademicInfluence.com Rankings

Salim Yusuf

Medical

#36

World Rank

#69

Historical Rank

Epidemiology

#15

World Rank

#17

Historical Rank

medical Degrees

Salim Yusuf

Philosophy

#981

World Rank

#1879

Historical Rank

Logic

#111

World Rank

#277

Historical Rank

philosophy Degrees

Download Badge

Medical
Philosophy

Why Is Salim Yusuf Influential?

(Suggest an Edit or Addition)

According to Wikipedia, Salim Yusuf is an Indian-born Canadian physician, the Marion W. Burke Chair in Cardiovascular Disease at McMaster University Medical School. He is a cardiologist and epidemiologist. Yusuf has criticized the Dietary Guidelines for Americans and disputes the scientific consensus on dietary sodium and saturated fat intake.

(See a Problem?)

Salim Yusuf's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study (2004) (8941)
Dabigatran versus warfarin in patients with atrial fibrillation. (2009) (8312)
Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. (1991) (7693)
Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. (2000) (7520)
MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20536 high-risk individuals: a randomised placebo-controlled trial. Commentary (2002) (6062)
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. (2001) (4531)
Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions. (1992) (3699)
Collaborative overview of randomised trials of antiplatelet therapy Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients (1994) (3667)
Telmisartan, ramipril, or both in patients at high risk for vascular events. (2008) (3342)
Beta blockade during and after myocardial infarction: an overview of the randomized trials. (1985) (3268)
Global burden of cardiovascular diseases: part I: general considerations, the epidemiologic transition, risk factors, and impact of urbanization. (2001) (2897)
Risk factors for ischaemic and intracerebral haemorrhagic stroke in 22 countries (the INTERSTROKE study): a case-control study (2010) (2810)
Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-Preserved Trial (2003) (2785)
Obesity and the risk of myocardial infarction in 27 000 participants from 52 countries: a case-control study (2005) (2782)
Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study (2001) (2577)
Preventive cardiologyAbstractsEffect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): Case-control study (2004) (2509)
The effect of digoxin on mortality and morbidity in patients with heart failure. (1997) (2495)
Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting-enzyme inhibitors: the CHARM-Added trial (2003) (2428)
Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Heart Outcomes Prevention Evaluation Study Investigators. (2000) (2051)
Effect of coronary artery bypass graft surgery on survival: overview of 10-year results from randomised trials by the Coronary Artery Bypass Graft Surgery Trialists Collaboration (1994) (2014)
Albuminuria and risk of cardiovascular events, death, and heart failure in diabetic and nondiabetic individuals. (2001) (1938)
Association of psychosocial risk factors with risk of acute myocardial infarction in 11 119 cases and 13 648 controls from 52 countries (the INTERHEART study): case-control study (2004) (1933)
Effects of extended-release metoprolol succinate in patients undergoing non-cardiac surgery (POISE trial): a randomised controlled trial (2008) (1927)
Clopidogrel plus aspirin versus oral anticoagulation for atrial fibrillation in the Atrial fibrillation Clopidogrel Trial with Irbesartan for prevention of Vascular Events (ACTIVE W): a randomised controlled trial (2006) (1889)
Apixaban in patients with atrial fibrillation. (2011) (1889)
Effects of candesartan on mortality and morbidity in patients with chronic heart failure: the CHARM-Overall programme (2003) (1871)
Effect of clopidogrel added to aspirin in patients with atrial fibrillation. (2009) (1867)
Overview of Randomized Trials of Angiotensin-Converting Enzyme Inhibitors on Mortality and Morbidity in Patients With Heart Failure (1995) (1836)
ISIS-4: A randomised factorial trial assessing early oral captopril, oral mononitrate, and intravenous magnesium sulphate in 58 050 patients with suspected acute myocardial infarction (1995) (1755)
Effect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose: a randomised controlled trial (2006) (1681)
Vitamin E supplementation and cardiovascular events in high-risk patients. (2000) (1606)
Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to angiotensin-converting-enzyme inhibitors: the CHARM-Alternative trial (2003) (1573)
Long-term ACE-inhibitor therapy in patients with heart failure or left-ventricular dysfunction: a systematic overview of data from individual patients (2000) (1551)
Rivaroxaban with or without Aspirin in Stable Cardiovascular Disease (2017) (1499)
Radial versus femoral access for coronary angiography and intervention in patients with acute coronary syndromes (RIVAL): a randomised, parallel group, multicentre trial (2011) (1498)
Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study): a multicentre, randomised, double-blind, controlled trial (2008) (1488)
Basal insulin and cardiovascular and other outcomes in dysglycemia. (2012) (1458)
Prevalence, awareness, treatment, and control of hypertension in rural and urban communities in high-, middle-, and low-income countries. (2013) (1457)
Renal Insufficiency as a Predictor of Cardiovascular Outcomes and the Impact of Ramipril: The HOPE Randomized Trial (2001) (1442)
Global burden of cardiovascular diseases: Part II: variations in cardiovascular disease by specific ethnic groups and geographic regions and prevention strategies. (2001) (1433)
Comparison of neuroendocrine activation in patients with left ventricular dysfunction with and without congestive heart failure. A substudy of the Studies of Left Ventricular Dysfunction (SOLVD). (1990) (1426)
An overview of randomized trials of rehabilitation with exercise after myocardial infarction. (1989) (1413)
The burden of disease in older people and implications for health policy and practice (2015) (1319)
Adverse Impact of Bleeding on Prognosis in Patients With Acute Coronary Syndromes (2006) (1314)
Interpretation of the evidence for the efficacy and safety of statin therapy (2016) (1290)
Global and regional effects of potentially modifiable risk factors associated with acute stroke in 32 countries (INTERSTROKE): a case-control study (2016) (1172)
Homocysteine lowering with folic acid and B vitamins in vascular disease. (2006) (1166)
Risk of Bleeding With 2 Doses of Dabigatran Compared With Warfarin in Older and Younger Patients With Atrial Fibrillation: An Analysis of the Randomized Evaluation of Long-Term Anticoagulant Therapy (RE-LY) Trial (2011) (1141)
Prognostic value of grip strength: findings from the Prospective Urban Rural Epidemiology (PURE) study (2015) (1127)
Comparison of fondaparinux and enoxaparin in acute coronary syndromes. (2006) (1125)
Effects of long-term vitamin E supplementation on cardiovascular events and cancer: a randomized controlled trial. (2005) (1119)
Reduction in fatal pulmonary embolism and venous thrombosis by perioperative administration of subcutaneous heparin. Overview of results of randomized trials in general, orthopedic, and urologic surgery. (1988) (1058)
Radial versus femoral access for coronary angiography or intervention and the impact on major bleeding and ischemic events: a systematic review and meta-analysis of randomized trials. (2009) (1051)
Heart Outcomes Prevention Evaluation Study Investigators. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. N Engl J Med 2000;342:145-53. (2000) (1048)
Aspirin-Resistant Thromboxane Biosynthesis and the Risk of Myocardial Infarction, Stroke, or Cardiovascular Death in Patients at High Risk for Cardiovascular Events (2002) (1027)
Efficacy and safety of dabigatran compared with warfarin at different levels of international normalised ratio control for stroke prevention in atrial fibrillation: an analysis of the RE-LY trial (2010) (1009)
Risk factors for early myocardial infarction in South Asians compared with individuals in other countries. (2007) (933)
Emerging epidemic of cardiovascular disease in developing countries. (1999) (929)
Comparison of candesartan, enalapril, and their combination in congestive heart failure: randomized evaluation of strategies for left ventricular dysfunction (RESOLVD) pilot study. The RESOLVD Pilot Study Investigators. (1999) (924)
ISIS-3 - A RANDOMIZED COMPARISON OF STREPTOKINASE VS TISSUE PLASMINOGEN-ACTIVATOR VS ANISTREPLASE AND OF ASPIRIN PLUS HEPARIN VS ASPIRIN ALONE AMONG 41,299 CASES OF SUSPECTED ACUTE MYOCARDIAL-INFARCTION (1992) (920)
Analysis and interpretation of treatment effects in subgroups of patients in randomized clinical trials. (1991) (911)
Homocyst(e)ine and Cardiovascular Disease: A Critical Review of the Epidemiologic Evidence (1999) (909)
Benefit of Oral Anticoagulant Over Antiplatelet Therapy in Atrial Fibrillation Depends on the Quality of International Normalized Ratio Control Achieved by Centers and Countries as Measured by Time in Therapeutic Range (2008) (892)
Red cell distribution width as a novel prognostic marker in heart failure: data from the CHARM Program and the Duke Databank. (2007) (887)
Predictors of mortality and morbidity in patients with chronic heart failure. (2006) (882)
Renal Function as a Predictor of Outcome in a Broad Spectrum of Patients With Heart Failure (2006) (859)
Effects of fondaparinux on mortality and reinfarction in patients with acute ST-segment elevation myocardial infarction: the OASIS-6 randomized trial. (2006) (855)
Prediction of Mortality and Morbidity With a 6-Minute Walk Test in Patients With Left Ventricular Dysfunction (1993) (854)
Differences in risk factors, atherosclerosis, and cardiovascular disease between ethnic groups in Canada: the Study of Health Assessment and Risk in Ethnic groups (SHARE) (2000) (850)
Lower estimated glomerular filtration rate and higher albuminuria are associated with all-cause and cardiovascular mortality. A collaborative meta-analysis of high-risk population cohorts. (2011) (841)
Prevention of atrial fibrillation with angiotensin-converting enzyme inhibitors and angiotensin receptor blockers: a meta-analysis. (2005) (833)
Use of secondary prevention drugs for cardiovascular disease in the community in high-income, middle-income, and low-income countries (the PURE Study): a prospective epidemiological survey (2011) (832)
Effects of the angiotensin-receptor blocker telmisartan on cardiovascular events in high-risk patients intolerant to angiotensin-converting enzyme inhibitors: a randomised controlled trial (2008) (832)
Routine vs selective invasive strategies in patients with acute coronary syndromes: a collaborative meta-analysis of randomized trials. (2005) (827)
Impact of Diabetes on Long-Term Prognosis in Patients With Unstable Angina and Non–Q-Wave Myocardial Infarction: Results of the OASIS (Organization to Assess Strategies for Ischemic Syndromes) Registry (2000) (816)
n-3 fatty acids and cardiovascular outcomes in patients with dysglycemia. (2012) (814)
Benefits and Risks of the Combination of Clopidogrel and Aspirin in Patients Undergoing Surgical Revascularization for Non–ST-Elevation Acute Coronary Syndrome: The Clopidogrel in Unstable angina to prevent Recurrent ischemic Events (CURE) Trial (2004) (811)
Double-dose versus standard-dose clopidogrel and high-dose versus low-dose aspirin in individuals undergoing percutaneous coronary intervention for acute coronary syndromes (CURRENT-OASIS 7): a randomised factorial trial (2010) (808)
Tobacco use and risk of myocardial infarction in 52 countries in the INTERHEART study: a case-control study (2006) (797)
Cardiovascular sequelae of preeclampsia/eclampsia: a systematic review and meta-analyses. (2008) (793)
Early versus delayed invasive intervention in acute coronary syndromes. (2009) (781)
Risk factors for myocardial infarction in women and men: insights from the INTERHEART study. (2008) (776)
The effect of dabigatran plasma concentrations and patient characteristics on the frequency of ischemic stroke and major bleeding in atrial fibrillation patients: the RE-LY Trial (Randomized Evaluation of Long-Term Anticoagulation Therapy). (2014) (776)
Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study ☆ (2002) (747)
Effects of Aspirin Dose When Used Alone or in Combination With Clopidogrel in Patients With Acute Coronary Syndromes: Observations From the Clopidogrel in Unstable angina to prevent Recurrent Events (CURE) Study (2003) (743)
Effects of physiologic pacing versus ventricular pacing on the risk of stroke and death due to cardiovascular causes. Canadian Trial of Physiologic Pacing Investigators. (2000) (741)
Newly identified events in the RE-LY trial. (2010) (739)
Associations of fats and carbohydrate intake with cardiovascular disease and mortality in 18 countries from five continents (PURE): a prospective cohort study (2017) (738)
Randomized Trial of Benznidazole for Chronic Chagas' Cardiomyopathy. (2015) (738)
Associations of fats and carbohydrate intake with cardiovascular disease and mortality in 18 countries from five continents (PURE): a prospective cohort study (2017) (738)
Effects of Ramipril and Vitamin E on Atherosclerosis: The Study to Evaluate Carotid Ultrasound Changes in Patients Treated With Ramipril and Vitamin E (SECURE) (2001) (734)
Association between postoperative troponin levels and 30-day mortality among patients undergoing noncardiac surgery. (2012) (730)
Urinary sodium and potassium excretion, mortality, and cardiovascular events. (2014) (723)
Aspirin and extended-release dipyridamole versus clopidogrel for recurrent stroke. (2008) (711)
Why do we need some large, simple randomized trials? (1984) (706)
The effect of physical activity on mortality and cardiovascular disease in 130 000 people from 17 high-income, middle-income, and low-income countries: the PURE study (2017) (703)
Effect of enalapril on myocardial infarction and unstable angina in patients with low ejection fractions (1992) (692)
Aspirin in patients undergoing noncardiac surgery. (2014) (686)
Influence of Ejection Fraction on Cardiovascular Outcomes in a Broad Spectrum of Heart Failure Patients (2005) (686)
Report of the Conference on Low Blood Cholesterol: Mortality Associations (1992) (679)
Association of urinary sodium and potassium excretion with blood pressure. (2014) (676)
Myocardial Injury after Noncardiac Surgery: A Large, International, Prospective Cohort Study Establishing Diagnostic Criteria, Characteristics, Predictors, and 30-day Outcomes (2014) (669)
Cardiovascular risk and events in 17 low-, middle-, and high-income countries. (2014) (663)
Overview of randomized trials of angiotensin-converting enzyme inhibitors on mortality and morbidity in patients with heart failure. Collaborative Group on ACE Inhibitor Trials. (1995) (645)
Effect of glucose-insulin-potassium infusion on mortality in patients with acute ST-segment elevation myocardial infarction: the CREATE-ECLA randomized controlled trial. (2005) (643)
Lipids, lipoproteins, and apolipoproteins as risk markers of myocardial infarction in 52 countries (the INTERHEART study): a case-control study (2008) (638)
A genome-wide association study in Europeans and South Asians identifies five new loci for coronary artery disease (2011) (638)
Prognostic importance of weight loss in chronic heart failure and the effect of treatment with angiotensin-converting-enzyme inhibitors: an observational study (2003) (637)
Indications for ACE inhibitors in the early treatment of acute myocardial infarction: systematic overview of individual data from 100,000 patients in randomized trials. ACE Inhibitor Myocardial Infarction Collaborative Group. (1998) (632)
Association of Diet, Exercise, and Smoking Modification With Risk of Early Cardiovascular Events After Acute Coronary Syndromes (2010) (625)
Cholesterol Lowering in Intermediate-Risk Persons without Cardiovascular Disease. (2016) (621)
Off-pump or on-pump coronary-artery bypass grafting at 30 days. (2012) (616)
ACC/AHA guidelines for coronary artery bypass graft surgery (1999) (591)
Telmisartan to prevent recurrent stroke and cardiovascular events. (2008) (583)
Multiancestry genome-wide association study of 520,000 subjects identifies 32 loci associated with stroke and stroke subtypes (2018) (578)
Ramipril and the development of diabetes. (2001) (572)
Characteristics and Short-Term Prognosis of Perioperative Myocardial Infarction in Patients Undergoing Noncardiac Surgery (2011) (570)
Effect of ramipril on the incidence of diabetes. (2006) (569)
Intravenous and intracoronary fibrinolytic therapy in acute myocardial infarction: overview of results on mortality, reinfarction and side-effects from 33 randomized controlled trials. (1985) (564)
Effects of prophylactic antiarrhythmic drug therapy in acute myocardial infarction. An overview of results from randomized controlled trials. (1993) (561)
Emerging Epidemic of Cardiovascular Disease in Developing Countries (1998) (560)
Modifiable risk factors, cardiovascular disease, and mortality in 155 722 individuals from 21 high-income, middle-income, and low-income countries (PURE): a prospective cohort study (2020) (555)
Dose comparisons of clopidogrel and aspirin in acute coronary syndromes. (2010) (549)
Effects of CYP2C19 genotype on outcomes of clopidogrel treatment. (2010) (545)
Dabigatran Versus Warfarin in Patients With Atrial Fibrillation: An Analysis of Patients Undergoing Cardioversion (2010) (543)
Defining Obesity Cut Points in a Multiethnic Population (2007) (542)
Urinary sodium and potassium excretion and risk of cardiovascular events. (2011) (538)
Overview of results of randomized clinical trials in heart disease. I. Treatments following myocardial infarction. (1988) (536)
Influence of Nonfatal Hospitalization for Heart Failure on Subsequent Mortality in Patients With Chronic Heart Failure (2007) (535)
Impact of diabetes on outcomes in patients with low and preserved ejection fraction heart failure: an analysis of the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM) programme. (2008) (529)
Global burden of cardiovascular disease (2007) (528)
Reducing the Global Burden of Cardiovascular Disease, Part 1: The Epidemiology and Risk Factors. (2017) (527)
Randomized trial of primary PCI with or without routine manual thrombectomy. (2015) (520)
Epidemiology and causation of coronary heart disease and stroke in India (2007) (515)
Atrial fibrillation and risk of clinical events in chronic heart failure with and without left ventricular systolic dysfunction: results from the Candesartan in Heart failure-Assessment of Reduction in Mortality and morbidity (CHARM) program. (2006) (515)
Diabetes mellitus, a predictor of morbidity and mortality in the Studies of Left Ventricular Dysfunction (SOLVD) Trials and Registry. (1996) (514)
The Prospective Urban Rural Epidemiology (PURE) study: examining the impact of societal influences on chronic noncommunicable diseases in low-, middle-, and high-income countries. (2009) (511)
Prediction of mortality and morbidity with a 6-minute walk test in patients with left ventricular dysfunction. SOLVD Investigators. (1993) (509)
Emerging role of angiotensin-converting enzyme inhibitors in cardiac and vascular protection. (1994) (502)
Interventions on Prevention of Postoperative Atrial Fibrillation in Patients Undergoing Heart Surgery: A Meta-Analysis (2002) (502)
Blood-Pressure Lowering in Intermediate-Risk Persons without Cardiovascular Disease. (2016) (499)
Comparative Effects of Ramipril on Ambulatory and Office Blood Pressures: A HOPE Substudy (2001) (487)
Concomitant Use of Antiplatelet Therapy with Dabigatran or Warfarin in the Randomized Evaluation of Long-Term Anticoagulation Therapy (RE-LY) Trial (2013) (487)
The relationships of left ventricular ejection fraction, end-systolic volume index and infarct size to six-month mortality after hospital discharge following myocardial infarction treated by thrombolysis. (2002) (486)
Angiotensin-converting-enzyme inhibitors in stable vascular disease without left ventricular systolic dysfunction or heart failure: a combined analysis of three trials (2006) (477)
Novel therapeutic concepts: the epidemic of cardiovascular disease in the developing world: global implications. (2010) (474)
Treatment and outcomes of acute coronary syndromes in India (CREATE): a prospective analysis of registry data (2008) (472)
Reduction of Cardiovascular Risk by Regression of Electrocardiographic Markers of Left Ventricular Hypertrophy by the Angiotensin-Converting Enzyme Inhibitor Ramipril (2001) (465)
Rivaroxaban with or without aspirin in patients with stable coronary artery disease: an international, randomised, double-blind, placebo-controlled trial (2017) (464)
Incidence of stroke in paroxysmal versus sustained atrial fibrillation in patients taking oral anticoagulation or combined antiplatelet therapy: an ACTIVE W Substudy. (2007) (462)
Adherence to candesartan and placebo and outcomes in chronic heart failure in the CHARM programme: double-blind, randomised, controlled clinical trial (2005) (459)
ACC/AHA guidelines for coronary artery bypass graft surgery: executive summary and recommendations : A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to revise the 1991 guidelines for coronary artery bypass graft surgery). (1999) (458)
Excess of rare variants in genes identified by genome-wide association study of hypertriglyceridemia (2010) (455)
How strong is the evidence for the use of perioperative β blockers in non-cardiac surgery? Systematic review and meta-analysis of randomised controlled trials (2005) (447)
Dabigatran compared with warfarin in patients with atrial fibrillation and previous transient ischaemic attack or stroke: a subgroup analysis of the RE-LY trial (2010) (443)
Dietary Patterns and the Risk of Acute Myocardial Infarction in 52 Countries: Results of the INTERHEART Study (2008) (439)
Periprocedural Bleeding and Thromboembolic Events With Dabigatran Compared With Warfarin: Results From the Randomized Evaluation of Long-Term Anticoagulation Therapy (RE-LY) Randomized Trial (2012) (436)
Reduction in Fatal Pulmonary Embolism and Venous Thrombosis by Perioperative Administration of Subcutaneous Heparin (1989) (434)
Use of ramipril in preventing stroke: double blind randomised trial (2002) (427)
The Antioxidant Vitamins and Cardiovascular Disease: A Critical Review of Epidemiologic and Clinical Trial Data (1995) (425)
Calcium channel blockers in acute myocardial infarction and unstable angina: an overview. (1989) (416)
Unfractionated heparin and low-molecular-weight heparin in acute coronary syndrome without ST elevation: a meta-analysis (2000) (411)
Intracranial Hemorrhage in Atrial Fibrillation Patients During Anticoagulation With Warfarin or Dabigatran: The RE-LY Trial (2012) (409)
Effects of the Angiotensin Converting Enzyme Inhibitor Enalapril on the Long‐term: Progression of Left Ventricular Dysfunction in Patients With Heart Failure (1992) (408)
Effects of off-pump and on-pump coronary-artery bypass grafting at 1 year. (2013) (403)
Overcoming the limitations of current meta-analysis of randomised controlled trials (1998) (402)
Characteristics, complications, and gaps in evidence-based interventions in rheumatic heart disease: the Global Rheumatic Heart Disease Registry (the REMEDY study). (2015) (401)
Impact of right ventricular involvement on mortality and morbidity in patients with inferior myocardial infarction. (2001) (393)
Two decades of progress in preventing vascular disease (2002) (389)
Fruit, vegetable, and legume intake, and cardiovascular disease and deaths in 18 countries (PURE): a prospective cohort study (2017) (389)
Principles for national and regional guidelines on cardiovascular disease prevention: a scientific statement from the World Heart and Stroke Forum. (2004) (386)
Risk Factors Associated With Myocardial Infarction in Africa: The INTERHEART Africa Study (2005) (386)
Efficacy and safety of statin therapy in older people: a meta-analysis of individual participant data from 28 randomised controlled trials (2019) (377)
Baseline quality of life as a predictor of mortality and hospitalization in 5,025 patients with congestive heart failure. SOLVD Investigations. Studies of Left Ventricular Dysfunction Investigators. (1996) (376)
Risk Factors for Acute Myocardial Infarction in Latin America: The INTERHEART Latin American Study (2007) (375)
Myocardial Ischemic Events in Patients With Atrial Fibrillation Treated With Dabigatran or Warfarin in the RE-LY (Randomized Evaluation of Long-Term Anticoagulation Therapy) Trial (2012) (375)
Prognostic impact of body weight and abdominal obesity in women and men with cardiovascular disease. (2005) (374)
Variations between countries in invasive cardiac procedures and outcomes in patients with suspected unstable angina or myocardial infarction without initial ST elevation (1998) (371)
Dronedarone in high-risk permanent atrial fibrillation. (2011) (368)
Cardiac Biomarkers Are Associated With an Increased Risk of Stroke and Death in Patients With Atrial Fibrillation: A Randomized Evaluation of Long-Term Anticoagulation Therapy (RE-LY) Substudy (2012) (367)
Associations of urinary sodium excretion with cardiovascular events in individuals with and without hypertension: a pooled analysis of data from four studies (2016) (366)
Effects of vitamin E on cardiovascular and microvascular outcomes in high-risk patients with diabetes: results of the HOPE study and MICRO-HOPE substudy. (2002) (365)
Rationale, design, and baseline characteristics of 2 large, simple, randomized trials evaluating telmisartan, ramipril, and their combination in high-risk patients: the Ongoing Telmisartan Alone and in Combination with Ramipril Global Endpoint Trial/Telmisartan Randomized Assessment Study in ACE Int (2004) (363)
Rationale and design of RE-LY: randomized evaluation of long-term anticoagulant therapy, warfarin, compared with dabigatran. (2009) (363)
Does PTCA in acute myocardial infarction affect mortality and reinfarction rates? A quantitative overview (meta-analysis) of the randomized clinical trials. (1995) (363)
Cumulating evidence from randomized trials: utilizing sequential monitoring boundaries for cumulative meta-analysis. (1997) (359)
The novel biomarker-based ABC (age, biomarkers, clinical history)-bleeding risk score for patients with atrial fibrillation: a derivation and validation study (2016) (359)
Effectiveness of comprehensive disease management programmes in improving clinical outcomes in heart failure patients. A meta‐analysis (2005) (354)
Risk factors for acute myocardial infarction in Indians: a case-control study (1996) (350)
Natural history and patterns of current practice in heart failure (1993) (349)
Mortality and Morbidity Reduction With Candesartan in Patients With Chronic Heart Failure and Left Ventricular Systolic Dysfunction: Results of the CHARM Low–Left Ventricular Ejection Fraction Trials (2004) (349)
Effect of enalapril on 12-year survival and life expectancy in patients with left ventricular systolic dysfunction: a follow-up study (2003) (349)
Prognostic value of blood pressure in patients with high vascular risk in the Ongoing Telmisartan Alone and in combination with Ramipril Global Endpoint Trial study (2009) (348)
Efficacy and Safety of Dabigatran Compared With Warfarin in Relation to Baseline Renal Function in Patients With Atrial Fibrillation: A RE-LY (Randomized Evaluation of Long-term Anticoagulation Therapy) Trial Analysis (2013) (346)
Acute precipitants of congestive heart failure exacerbations. (2001) (346)
Effects of exercise training in patients with heart failure: the Exercise Rehabilitation Trial (EXERT). (2002) (344)
Overview of results of randomized clinical trials in heart disease. II. Unstable angina, heart failure, primary prevention with aspirin, and risk factor modification. (1988) (342)
Effects of a polypill (Polycap) on risk factors in middle-aged individuals without cardiovascular disease (TIPS): a phase II, double-blind, randomised trial (2009) (341)
Oral anticoagulant and antiplatelet therapy and peripheral arterial disease. (2007) (341)
Effects of intravenous magnesium in suspected acute myocardial infarction: overview of randomised trials. (1991) (338)
Body Mass Index and Prognosis in Patients With Chronic Heart Failure: Insights From the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM) Program (2007) (336)
Food Consumption and its Impact on Cardiovascular Disease: Importance of Solutions Focused on the Globalized Food System: A Report From the Workshop Convened by the World Heart Federation. (2015) (334)
Differences in risk factors, atherosclerosis and cardiovascular disease between ethnic groups in Canada: the study of health assessment and risk in ethnic groups (SHARE). (2000) (334)
The burden of cardiovascular disease in the Indian subcontinent. (2006) (331)
EFFECT OF INTRAVENOUS NITRATES ON MORTALITY IN ACUTE MYOCARDIAL INFARCTION: AN OVERVIEW OF THE RANDOMISED TRIALS (1988) (329)
Liver function abnormalities and outcome in patients with chronic heart failure: data from the Candesartan in Heart Failure: Assessment of Reduction in Mortality and Morbidity (CHARM) program (2009) (328)
The Clopidogrel in Unstable angina to prevent Recurrent Events (CURE) trial programme; rationale, design and baseline characteristics including a meta-analysis of the effects of thienopyridines in vascular disease. (2000) (328)
Need for expertise based randomised controlled trials (2005) (325)
Variations in Cause and Management of Atrial Fibrillation in a Prospective Registry of 15 400 Emergency Department Patients in 46 Countries: The RE-LY Atrial Fibrillation Registry (2014) (325)
Risk factors, atherosclerosis, and cardiovascular disease among Aboriginal people in Canada: the Study of Health Assessment and Risk Evaluation in Aboriginal Peoples (SHARE-AP) (2001) (324)
Variations in common diseases, hospital admissions, and deaths in middle-aged adults in 21 countries from five continents (PURE): a prospective cohort study (2020) (324)
Prevalence of coronary artery disease in Asian Indians. (1992) (322)
Effects of aspirin plus extended-release dipyridamole versus clopidogrel and telmisartan on disability and cognitive function after recurrent stroke in patients with ischaemic stroke in the Prevention Regimen for Effectively Avoiding Second Strokes (PRoFESS) trial: a double-blind, active and placebo (2008) (320)
Prognostic significance of plasma norepinephrine in patients with asymptomatic left ventricular dysfunction. SOLVD Investigators. (1996) (315)
Patient and Healthcare Provider Barriers to Hypertension Awareness, Treatment and Follow Up: A Systematic Review and Meta-Analysis of Qualitative and Quantitative Studies (2014) (312)
Early and Late Effects of Clopidogrel in Patients With Acute Coronary Syndromes (2003) (311)
Population pharmacokinetic analysis of the oral thrombin inhibitor dabigatran etexilate in patients with non‐valvular atrial fibrillation from the RE‐LY trial (2011) (310)
Candesartan in heart failure--assessment of reduction in mortality and morbidity (CHARM): rationale and design. Charm-Programme Investigators. (1999) (308)
Effects of prophylactic lidocaine in suspected acute myocardial infarction. An overview of results from the randomized, controlled trials. (1988) (307)
Interventions for preventing post-operative atrial fibrillation in patients undergoing heart surgery. (2004) (304)
Differences in the management and prognosis of women and men who suffer from acute coronary syndromes. (2005) (292)
WHO study on Prevention of REcurrences of Myocardial Infarction and StrokE (WHO-PREMISE). (2005) (292)
Overview of randomised trials of diuretics in pregnancy. (1985) (286)
Dabigatran Versus Warfarin: Effects on Ischemic and Hemorrhagic Strokes and Bleeding in Asians and Non-Asians With Atrial Fibrillation (2013) (284)
PCSK9 genetic variants and risk of type 2 diabetes: a mendelian randomisation study (2017) (283)
Availability, affordability, and consumption of fruits and vegetables in 18 countries across income levels: findings from the Prospective Urban Rural Epidemiology (PURE) study. (2016) (283)
Management and Outcomes of Major Bleeding During Treatment With Dabigatran or Warfarin (2013) (282)
Relationship of Metabolic Syndrome and Fibrinolytic Dysfunction to Cardiovascular Disease (2003) (281)
Prevention of atrial fibrillation in patients with symptomatic chronic heart failure by candesartan in the Candesartan in Heart failure: assessment of Reduction in Mortality and morbidity (CHARM) program. (2006) (280)
Prevalence of a healthy lifestyle among individuals with cardiovascular disease in high-, middle- and low-income countries: The Prospective Urban Rural Epidemiology (PURE) study. (2013) (279)
Reliability, validity, and responsiveness of the six-minute walk test in patients with heart failure. (2001) (278)
Clonidine in patients undergoing noncardiac surgery. (2014) (275)
Efficacy and safety of fondaparinux versus enoxaparin in patients with acute coronary syndromes undergoing percutaneous coronary intervention: results from the OASIS-5 trial. (2007) (274)
Update of effects of calcium antagonists in myocardial infarction or angina in light of the second Danish Verapamil Infarction Trial (DAVIT-II) and other recent studies. (1991) (271)
Comparative Impact of Multiple Biomarkers and N-Terminal Pro-Brain Natriuretic Peptide in the Context of Conventional Risk Factors for the Prediction of Recurrent Cardiovascular Events in the Heart Outcomes Prevention Evaluation (HOPE) Study (2006) (271)
Availability and affordability of cardiovascular disease medicines and their effect on use in high-income, middle-income, and low-income countries: an analysis of the PURE study data (2016) (266)
Albuminuria in chronic heart failure: prevalence and prognostic importance (2009) (264)
Heart failure with mid‐range ejection fraction in CHARM: characteristics, outcomes and effect of candesartan across the entire ejection fraction spectrum (2018) (264)
Glucose and insulin abnormalities relate to functional capacity in patients with congestive heart failure. (2000) (263)
The relationship between dysglycaemia and cardiovascular and renal risk in diabetic and non-diabetic participants in the HOPE study: a prospective epidemiological analysis (2005) (262)
Reduction in Fatal Pulmonary Embolism and Venous Thrombosis by Perioperative Administration of Subcutaneous Heparin: Overview of Results of Randomized Trials in General, Orthopedic, and Urologic Surgery (1989) (259)
Clinical Correlates and Consequences of Anemia in a Broad Spectrum of Patients With Heart Failure: Results of the Candesartan in Heart Failure: Assessment of Reduction in Mortality and Morbidity (CHARM) Program (2006) (257)
Effect of Candesartan on Cause-Specific Mortality in Heart Failure Patients: The Candesartan in Heart failure Assessment of Reduction in Mortality and morbidity (CHARM) Program (2004) (256)
Methylprednisolone in patients undergoing cardiopulmonary bypass (SIRS): a randomised, double-blind, placebo-controlled trial (2015) (254)
Safety of Proton Pump Inhibitors Based on a Large, Multi-year, Randomized Trial of Patients Receiving Rivaroxaban or Aspirin. (2019) (249)
Effects of radial versus femoral artery access in patients with acute coronary syndromes with or without ST-segment elevation. (2012) (248)
Changes in albuminuria predict mortality and morbidity in patients with vascular disease. (2011) (247)
Direct thrombin inhibitors in acute coronary syndromes: principal results of a meta-analysis based on individual patients' data (2002) (246)
Benefit of Clopidogrel in Patients With Acute Coronary Syndromes Without ST-Segment Elevation in Various Risk Groups (2002) (245)
Association of dairy intake with cardiovascular disease and mortality in 21 countries from five continents (PURE): a prospective cohort study (2018) (243)
Prevention of Heart Failure in Patients in the Heart Outcomes Prevention Evaluation (HOPE) Study (2003) (241)
Is a pre-operative brain natriuretic peptide or N-terminal pro-B-type natriuretic peptide measurement an independent predictor of adverse cardiovascular outcomes within 30 days of noncardiac surgery? A systematic review and meta-analysis of observational studies. (2009) (241)
Socioeconomic status and risk of cardiovascular disease in 20 low-income, middle-income, and high-income countries: the Prospective Urban Rural Epidemiologic (PURE) study. (2019) (240)
Sex Differences in Clinical Characteristics and Prognosis in a Broad Spectrum of Patients With Heart Failure: Results of the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM) Program (2007) (239)
Large-scale gene-centric meta-analysis across 32 studies identifies multiple lipid loci. (2012) (238)
Stemming the global tsunami of cardiovascular disease (2011) (236)
Risks and Benefits of Oral Anticoagulation Compared With Clopidogrel Plus Aspirin in Patients With Atrial Fibrillation According to Stroke Risk: The Atrial Fibrillation Clopidogrel Trial With Irbesartan for Prevention of Vascular Events (ACTIVE-W) (2008) (235)
The DREAM trial – Authors' reply (2006) (233)
Cardiovascular Outcomes With Atrial-Based Pacing Compared With Ventricular Pacing: Meta-Analysis of Randomized Trials, Using Individual Patient Data (2006) (233)
Major Adverse Limb Events and Mortality in Patients With Peripheral Artery Disease: The COMPASS Trial. (2018) (229)
Global mortality variations in patients with heart failure: results from the International Congestive Heart Failure (INTER-CHF) prospective cohort study. (2017) (228)
Achieved blood pressure and cardiovascular outcomes in high-risk patients: results from ONTARGET and TRANSCEND trials (2017) (228)
Metabolic syndrome and risk of acute myocardial infarction a case-control study of 26,903 subjects from 52 countries. (2010) (227)
Surveillance and prevention of major perioperative ischemic cardiac events in patients undergoing noncardiac surgery: a review (2005) (224)
Genetic Determinants of Dabigatran Plasma Levels and Their Relation to Bleeding (2013) (223)
Estimating modifiable coronary heart disease risk in multiple regions of the world: the INTERHEART Modifiable Risk Score. (2011) (223)
The Long-Term Multicenter Observational Study of Dabigatran Treatment in Patients With Atrial Fibrillation (RELY-ABLE) Study (2013) (222)
Lipid profile, plasma apolipoproteins, and risk of a first myocardial infarction among Asians: an analysis from the INTERHEART Study. (2009) (222)
Blood-pressure reduction and cardiovascular risk in HOPE study (2001) (221)
Risks for Stroke, Bleeding, and Death in Patients With Atrial Fibrillation Receiving Dabigatran or Warfarin in Relation to the CHADS2 Score: A Subgroup Analysis of the RE-LY Trial (2011) (219)
Strengths and limitations of meta-analysis: larger studies may be more reliable. (1997) (219)
Does hypoglycaemia increase the risk of cardiovascular events? A report from the ORIGIN trial. (2013) (217)
Causes of Death and Influencing Factors in Patients With Atrial Fibrillation: A Competing-Risk Analysis From the Randomized Evaluation of Long-Term Anticoagulant Therapy Study (2013) (216)
Increased risk of cognitive and functional decline in patients with atrial fibrillation: results of the ONTARGET and TRANSCEND studies (2012) (215)
Irbesartan in patients with atrial fibrillation. (2011) (215)
Characterization of health‐related quality of life in heart failure patients with preserved versus low ejection fraction in CHARM (2007) (213)
Effect of intravenous streptokinase on acute myocardial infarction: pooled results from randomized trials. (1982) (208)
Urinary sodium excretion, blood pressure, cardiovascular disease, and mortality: a community-level prospective epidemiological cohort study (2018) (207)
Prednisolone and Mycobacterium indicus pranii in tuberculous pericarditis. (2014) (206)
Studies of left ventricular dysfunction (SOLVD)--rationale, design and methods: two trials that evaluate the effect of enalapril in patients with reduced ejection fraction. (1990) (206)
Benznidazole and Posaconazole in Eliminating Parasites in Asymptomatic T. Cruzi Carriers: The STOP-CHAGAS Trial. (2017) (206)
Safety and efficacy of low blood pressures among patients with diabetes: subgroup analyses from the ONTARGET (ONgoing Telmisartan Alone and in combination with Ramipril Global Endpoint Trial). (2008) (202)
C-Reactive Protein as a Screening Test for Cardiovascular Risk in a Multiethnic Population (2004) (201)
Effects of Candesartan on the Development of a New Diagnosis of Diabetes Mellitus in Patients With Heart Failure (2005) (200)
Angiotensin-converting enzyme inhibitor as a risk factor for the development of anemia, and the impact of incident anemia on mortality in patients with left ventricular dysfunction. (2005) (200)
Coronary heart disease and its risk factors in first-generation immigrant Asian Indians to the United States of America. (1996) (199)
Saturated Fats and Health: A Reassessment and Proposal for Food-based Recommendations: JACC State-of -the-Art Review. (2020) (199)
Effects of long-term treatment with angiotensin-converting-enzyme inhibitors in the presence or absence of aspirin: a systematic review (2002) (198)
Clinical effects of anticoagulant therapy in suspected acute myocardial infarction: systematic overview of randomised trials (1996) (197)
Dabigatran in patients with myocardial injury after non-cardiac surgery (MANAGE): an international, randomised, placebo-controlled trial (2018) (197)
Prognostic Value of Troponin and Creatine Kinase Muscle and Brain Isoenzyme Measurement after Noncardiac Surgery: A Systematic Review and Meta-analysis (2011) (195)
Reducing the Global Burden of Cardiovascular Disease, Part 2: Prevention and Treatment of Cardiovascular Disease (2017) (194)
Rationale and design of a randomized placebo-controlled trial assessing the effects of etiologic treatment in Chagas' cardiomyopathy: the BENznidazole Evaluation For Interrupting Trypanosomiasis (BENEFIT). (2008) (194)
Clinical Outcomes in 3343 Children and Adults With Rheumatic Heart Disease From 14 Low- and Middle-Income Countries: Two-Year Follow-Up of the Global Rheumatic Heart Disease Registry (the REMEDY Study) (2016) (192)
Effect of age on mortality, hospitalizations and response to digoxin in patients with heart failure: the DIG study. (2001) (191)
Changes in Renal Function in Patients With Atrial Fibrillation: An Analysis From the RE-LY Trial. (2015) (190)
Validation and comparison of three formulae to estimate sodium and potassium excretion from a single morning fasting urine compared to 24-h measures in 11 countries (2014) (190)
Association of dietary nutrients with blood lipids and blood pressure in 18 countries: a cross-sectional analysis from the PURE study. (2017) (190)
Occurrence of death and stroke in patients in 47 countries 1 year after presenting with atrial fibrillation: a cohort study (2016) (190)
Effects of telmisartan, irbesartan, valsartan, candesartan, and losartan on cancers in 15 trials enrolling 138 769 individuals (2011) (189)
Dabigatran and Warfarin in Vitamin K Antagonist–Naive and –Experienced Cohorts With Atrial Fibrillation (2010) (189)
Canadian Trial of Physiological Pacing: Effects of Physiological Pacing During Long-Term Follow-Up (2004) (189)
Reference ranges of handgrip strength from 125,462 healthy adults in 21 countries: a prospective urban rural epidemiologic (PURE) study (2016) (188)
EARLY INTRAVENOUS ATENOLOL TREATMENT IN SUSPECTED ACUTE MYOCARDIAL INFARCTION Preliminary Report of a Randomised Trial (1980) (186)
Effects of Ramipril and Rosiglitazone on Cardiovascular and Renal Outcomes in People With Impaired Glucose Tolerance or Impaired Fasting Glucose (2008) (185)
Blood-Pressure and Cholesterol Lowering in Persons without Cardiovascular Disease. (2016) (185)
Effects of Ramipril on Coronary Events in High-Risk Persons: Results of the Heart Outcomes Prevention Evaluation Study (2001) (184)
Indications for Coronary Artery Bypass Surgery and Percutaneous Coronary Intervention in Chronic Stable Angina: Review of the Evidence and Methodological Considerations (2003) (182)
Improving clinical outcomes by reducing bleeding in patients with non-ST-elevation acute coronary syndromes. (2008) (182)
The BENEFIT trial: testing the hypothesis that trypanocidal therapy is beneficial for patients with chronic Chagas heart disease. (2009) (182)
Effects of exercise training in patients with congestive heart failure: a critical review. (1995) (182)
Analysing recurrent hospitalizations in heart failure: a review of statistical methodology, with application to CHARM‐Preserved (2014) (181)
Revascularization for unprotected left main stem coronary artery stenosis stenting or surgery. (2008) (181)
Pharmacological blood pressure lowering for primary and secondary prevention of cardiovascular disease across different levels of blood pressure: an individual participant-level data meta-analysis (2021) (181)
Glucose Levels Predict Hospitalization for Congestive Heart Failure in Patients at High Cardiovascular Risk (2007) (181)
Homocysteine and Coronary Heart Disease: Meta-analysis of MTHFR Case-Control Studies, Avoiding Publication Bias (2012) (180)
Ethnic Variation in Adiponectin and Leptin Levels and Their Association With Adiposity and Insulin Resistance (2010) (179)
The CHA2DS2-VASc score identifies those patients with atrial fibrillation and a CHADS2 score of 1 who are unlikely to benefit from oral anticoagulant therapy. (2013) (178)
Heart failure in the 1990s: evolution of a major public health problem in cardiovascular medicine. (1993) (177)
Kidney function after off-pump or on-pump coronary artery bypass graft surgery: a randomized clinical trial. (2014) (176)
Apixaban versus aspirin in patients with atrial fibrillation and previous stroke or transient ischaemic attack: a predefined subgroup analysis from AVERROES, a randomised trial (2012) (176)
Renin-angiotensin system blockade and cognitive function in patients at high risk of cardiovascular disease: analysis of data from the ONTARGET and TRANSCEND studies (2011) (176)
Relationship of current and past smoking to mortality and morbidity in patients with left ventricular dysfunction. (2001) (176)
Rationale and design of AVERROES: apixaban versus acetylsalicylic acid to prevent stroke in atrial fibrillation patients who have failed or are unsuitable for vitamin K antagonist treatment. (2010) (173)
Reduction in infarct size, arrhythmias and chest pain by early intravenous beta blockade in suspected acute myocardial infarction. (1983) (173)
Weight loss and mortality risk in patients with chronic heart failure in the candesartan in heart failure: assessment of reduction in mortality and morbidity (CHARM) programme. (2008) (170)
Prevalence of cardiovascular risk factors in the Middle East: a systematic review (2009) (168)
The polypill in the prevention of cardiovascular diseases: key concepts, current status, challenges, and future directions. (2010) (168)
Ethnic differences in the relationships between obesity and glucose-metabolic abnormalities: a cross-sectional population-based study (2005) (167)
Outcomes after thrombus aspiration for ST elevation myocardial infarction: 1-year follow-up of the prospective randomised TOTAL trial (2016) (166)
Prevalence and determinants of microalbuminuria in high-risk diabetic and nondiabetic patients in the heart outcomes prevention evaluation study (2000) (165)
Thrombus Aspiration in ST-Segment-Elevation Myocardial Infarction: An Individual Patient Meta-Analysis: Thrombectomy Trialists Collaboration. (2017) (165)
Environmental and societal influences acting on cardiovascular risk factors and disease at a population level: a review. (2009) (165)
Impact of ramipril in patients with evidence of clinical or subclinical peripheral arterial disease (2004) (163)
Low-dose vs standard-dose unfractionated heparin for percutaneous coronary intervention in acute coronary syndromes treated with fondaparinux: the FUTURA/OASIS-8 randomized trial. (2010) (163)
Left Atrial Appendage Occlusion during Cardiac Surgery to Prevent Stroke. (2021) (162)
From the HOPE to the ONTARGET and the TRANSCEND studies: challenges in improving prognosis. (2002) (162)
Clinical effects of early angiotensin-converting enzyme inhibitor treatment for acute myocardial infarction are similar in the presence and absence of aspirin: systematic overview of individual data from 96,712 randomized patients. Angiotensin-converting Enzyme Inhibitor Myocardial Infarction Collab (2000) (161)
Incidence and predictors of hyperkalemia in patients with heart failure: an analysis of the CHARM Program. (2007) (160)
Oral anticoagulants in patients with coronary artery disease. (2003) (160)
Quality-of-life Among 5,025 Patients With Left-ventricular Dysfunction Randomized Between Placebo and Enalapril - the Studies of Left-ventricular Dysfunction (1994) (159)
Changes in Hypertension Treatment and in Congestive Heart Failure Mortality in the United States (1989) (158)
Prevalence and determinants of microalbuminuria in high-risk diabetic and nondiabetic patients in the Heart Outcomes Prevention Evaluation Study. The HOPE Study Investigators. (2000) (157)
Erectile Dysfunction Predicts Cardiovascular Events in High-Risk Patients Receiving Telmisartan, Ramipril, or Both: The ONgoing Telmisartan Alone and in combination with Ramipril Global Endpoint Trial/Telmisartan Randomized AssessmeNt Study in ACE iNtolerant subjects with cardiovascular Disease (ONT (2010) (156)
The HOPE (Heart Outcomes Prevention Evaluation) Study: the design of a large, simple randomized trial of an angiotensin-converting enzyme inhibitor (ramipril) and vitamin E in patients at high risk of cardiovascular events. The HOPE study investigators. (1996) (155)
Effects of reviparin, a low-molecular-weight heparin, on mortality, reinfarction, and strokes in patients with acute myocardial infarction presenting with ST-segment elevation. (2005) (155)
Design and rationale of CURRENT-OASIS 7: a randomized, 2 x 2 factorial trial evaluating optimal dosing strategies for clopidogrel and aspirin in patients with ST and non-ST-elevation acute coronary syndromes managed with an early invasive strategy. (2008) (153)
Alcohol consumption and cardiovascular disease, cancer, injury, admission to hospital, and mortality: a prospective cohort study (2015) (153)
Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to angiotensin-converting enzyme inhibitors: the CHARM-alternative trial (2004) (153)
Association of heart rate and outcomes in a broad spectrum of patients with chronic heart failure: results from the CHARM (Candesartan in Heart Failure: Assessment of Reduction in Mortality and morbidity) program. (2012) (152)
Routine medical management of acute myocardial infarction. Lessons from overviews of recent randomized controlled trials. (1990) (152)
Sodium intake and cardiovascular health. (2015) (152)
The entry ECG in the early diagnosis and prognostic stratification of patients with suspected acute myocardial infarction. (1984) (151)
Clinical features and contemporary management of patients with low and preserved ejection fraction heart failure: baseline characteristics of patients in the Candesartan in Heart failure—Assessment of Reduction in Mortality and morbidity (CHARM) programme (2003) (150)
Pathology of Peripheral Artery Disease in Patients With Critical Limb Ischemia. (2018) (149)
Level of systolic blood pressure within the normal range and risk of recurrent stroke. (2011) (149)
Association of estimated sleep duration and naps with mortality and cardiovascular events: a study of 116 632 people from 21 countries. (2018) (148)
Specific barriers to the conduct of randomized trials (2008) (148)
Relationship Between Healthy Diet and Risk of Cardiovascular Disease Among Patients on Drug Therapies for Secondary Prevention: A Prospective Cohort Study of 31 546 High-Risk Individuals From 40 Countries (2012) (147)
RAS blockade with ARB and ACE inhibitors: current perspective on rationale and patient selection (2008) (146)
Hypertension prevalence, awareness, treatment, and control in 115 rural and urban communities involving 47 000 people from China (2016) (146)
Early Cerebral Small Vessel Disease and Brain Volume, Cognition, and Gait (2015) (144)
A multivariate model for predicting mortality in patients with heart failure and systolic dysfunction. (2004) (144)
Lipoprotein(a) Levels and the Risk of Myocardial Infarction Among 7 Ethnic Groups (2019) (143)
Off-pump or on-pump coronary-artery bypass grafting. (2012) (143)
Dual-chamber versus ventricular pacing. Critical appraisal of current data. (1996) (143)
Comparative neurohormonal responses in patients with preserved and impaired left ventricular ejection fraction: Results of the studies of left ventricular dysfunctions (SOLVD) registry (1993) (143)
Adipocyte Hypertrophy, Fatty Liver and Metabolic Risk Factors in South Asians: The Molecular Study of Health and Risk in Ethnic Groups (mol-SHARE) (2011) (141)
Multiple Infections and Subsequent Cardiovascular Events in the Heart Outcomes Prevention Evaluation (HOPE) Study (2003) (140)
Education and risk for acute myocardial infarction in 52 high, middle and low-income countries: INTERHEART case-control study (2009) (138)
Variation in Warfarin Dose Adjustment Practice Is Responsible for Differences in the Quality of Anticoagulation Control Between Centers and Countries: An Analysis of Patients Receiving Warfarin in the Randomized Evaluation of Long-Term Anticoagulation Therapy (RE-LY) Trial (2012) (138)
Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (2004) (138)
Accelerated surgery versus standard care in hip fracture (HIP ATTACK): an international, randomised, controlled trial (2020) (138)
Glucose-insulin-potassium therapy in patients with ST-segment elevation myocardial infarction. (2007) (137)
Effects of aspirin dose on ischaemic events and bleeding after percutaneous coronary intervention: insights from the PCI-CURE study. (2008) (137)
Variations in Diabetes Prevalence in Low-, Middle-, and High-Income Countries: Results From the Prospective Urban and Rural Epidemiological Study (2016) (137)
Increased sensitivity of the denervated transplanted human heart to isoprenaline both before and after beta-adrenergic blockade. (1987) (137)
Parental history and myocardial infarction risk across the world: the INTERHEART Study. (2011) (136)
Blood Pressure Targets Recommended by Guidelines and Incidence of Cardiovascular and Renal Events in the Ongoing Telmisartan Alone and in Combination With Ramipril Global Endpoint Trial (ONTARGET) (2011) (136)
Cardiovascular and Renal Outcomes With Telmisartan, Ramipril, or Both in People at High Renal Risk: Results From the ONTARGET and TRANSCEND Studies (2011) (135)
Development of renal disease in people at high cardiovascular risk: results of the HOPE randomized study. (2003) (135)
Rationale, Design and Baseline Characteristics of Participants in the Cardiovascular Outcomes for People Using Anticoagulation Strategies (COMPASS) Trial. (2017) (133)
Heart rate is associated with increased risk of major cardiovascular events, cardiovascular and all-cause death in patients with stable chronic cardiovascular disease: an analysis of ONTARGET/TRANSCEND (2010) (133)
Rationale, design and recruitment characteristics of a large, simple international trial of diabetes prevention: the DREAM trial (2004) (133)
Net Clinical Benefit of Adding Clopidogrel to Aspirin Therapy in Patients With Atrial Fibrillation for Whom Vitamin K Antagonists Are Unsuitable (2011) (133)
The evolution of the randomized controlled trial and its role in evidence‐based decision making (2003) (132)
Days alive and out of hospital and the patient journey in patients with heart failure: Insights from the candesartan in heart failure: assessment of reduction in mortality and morbidity (CHARM) program. (2011) (131)
Polygenic determinants of severe hypertriglyceridemia. (2008) (130)
The World Heart Federation's vision for worldwide cardiovascular disease prevention (2015) (130)
Availability and affordability of blood pressure-lowering medicines and the effect on blood pressure control in high-income, middle-income, and low-income countries: an analysis of the PURE study data. (2017) (128)
Why are we failing to implement effective therapies in cardiovascular disease? (2013) (127)
Effect of Telmisartan on Renal Outcomes (2009) (127)
Differential Clinical Outcomes Associated With Hypoglycemia and Hyperglycemia in Acute Myocardial Infarction (2009) (127)
Development and evaluation of cultural food frequency questionnaires for South Asians, Chinese, and Europeans in North America. (2003) (127)
Five-Year Outcomes after Off-Pump or On-Pump Coronary-Artery Bypass Grafting. (2016) (126)
Rationale, design, and organization of the PeriOperative ISchemic Evaluation (POISE) trial: a randomized controlled trial of metoprolol versus placebo in patients undergoing noncardiac surgery. (2006) (125)
Rationale, design, implementation, and baseline characteristics of patients in the DIG trial: a large, simple, long-term trial to evaluate the effect of digitalis on mortality in heart failure. (1996) (125)
Renal function and outcomes in acute coronary syndrome: impact of clopidogrel (2007) (125)
Unfractionated and Low-Molecular-Weight Heparin as Adjuncts to Thrombolysis in Aspirin-Treated Patients With ST-Elevation Acute Myocardial Infarction: A Meta-Analysis of the Randomized Trials (2005) (125)
Cognitive impairment and risk of cardiovascular events and mortality. (2012) (125)
Long-term cost-effectiveness of clopidogrel given for up to one year in patients with acute coronary syndromes without ST-segment elevation. (2005) (123)
Adherence to medication according to sex and age in the CHARM programme (2009) (122)
The relationship between estimated sodium and potassium excretion and subsequent renal outcomes. (2014) (122)
Risk factors, hospital management and outcomes after acute myocardial infarction in South Asian Canadians and matched control subjects. (2002) (122)
Comprehensive Analysis of Genomic Variation in the LPA Locus and Its Relationship to Plasma Lipoprotein(a) in South Asians, Chinese, and European Caucasians (2010) (122)
Randomized trial of candesartan cilexetil in the treatment of patients with congestive heart failure and a history of intolerance to angiotensin-converting enzyme inhibitors. (2000) (121)
Variations between women and men in risk factors, treatments, cardiovascular disease incidence, and death in 27 high-income, middle-income, and low-income countries (PURE): a prospective cohort study (2020) (121)
Regional Ischemic Ventricular Dysfunction in Myocardium Supplied by a Narrowed Coronary Artery with Increasing Halothane Concentration in the Dog (1981) (120)
Incidence, predictive factors, and prognostic significance of supraventricular tachyarrhythmias in congestive heart failure. (2000) (119)
Diet and kidney disease in high-risk individuals with type 2 diabetes mellitus. (2013) (118)
Efficacy and safety of dabigatran vs. warfarin in patients with atrial fibrillation--sub-analysis in Japanese population in RE-LY trial. (2011) (118)
Randomized, Blinded Trial Comparing Fondaparinux With Unfractionated Heparin in Patients Undergoing Contemporary Percutaneous Coronary Intervention: Arixtra Study in Percutaneous Coronary Intervention: A Randomized Evaluation (ASPIRE) Pilot Trial (2005) (118)
Effects of the Angiotensin Converting Enzyme Inhibitor Enalapril on the Long‐term Progression of Left Ventricular Dilatation in Patients With Asymptomatic Systolic Dysfunction (1993) (117)
The Relationship Between Trimethylamine-N-Oxide and Prevalent Cardiovascular Disease in a Multiethnic Population Living in Canada. (2015) (116)
Cognitive Function and Anticoagulation Control in Patients With Atrial Fibrillation (2010) (115)
Association between complications and death within 30 days after noncardiac surgery (2019) (115)
Rationale and design of ACTIVE: the atrial fibrillation clopidogrel trial with irbesartan for prevention of vascular events. (2006) (115)
Effect of long-term enalapril therapy on neurohormones in patients with left ventricular dysfunction (1995) (115)
CHOLESTEROL-LOWERING TRIAL RESULTS IN THEIR EPIDEMIOLOGIC CONTEXT (1985) (114)
Long-Term Effects of Ramipril on Cardiovascular Events and on Diabetes: Results of the HOPE Study Extension (2005) (113)
The protective effect of the obesity-associated rs9939609 A variant in fat mass- and obesity-associated gene on depression (2013) (113)
Prospective Urban Rural Epidemiology (PURE) study: Baseline characteristics of the household sample and comparative analyses with national data in 17 countries. (2013) (111)
Effect of vasodilators on survival in chronic congestive heart failure. (1985) (111)
A community-based comprehensive intervention to reduce cardiovascular risk in hypertension (HOPE 4): a cluster-randomised controlled trial (2019) (111)
Dysglycaemia and risk of cardiovascular disease (1996) (110)
Effects of vitamin E on cardiovascular outcomes in people with mild-to-moderate renal insufficiency: results of the HOPE study. (2004) (109)
Contemporary management of patients with left ventricular systolic dysfunction. Results from the Study of Patients Intolerant of Converting Enzyme Inhibitors (SPICE) Registry. (1999) (109)
Natural history and patterns of current practice in heart failure. The Studies of Left Ventricular Dysfunction (SOLVD) Investigators. (1993) (109)
Stroke risk and efficacy of apixaban in atrial fibrillation patients with moderate chronic kidney disease. (2012) (109)
Influence of Previous Heart Failure Hospitalization on Cardiovascular Events in Patients With Reduced and Preserved Ejection Fraction (2014) (108)
Chronic Pain Syndromes After Ischemic Stroke: PRoFESS Trial (2013) (108)
Salt intake and cardiovascular disease: why are the data inconsistent? (2013) (108)
Impact of ramipril in patients with evidence of clinical or subclinical peripheral arterial disease. (2004) (108)
Elevated lipoprotein(a) levels in South Asians in North America. (1998) (107)
Influence of Renal Function on the Efficacy and Safety of Fondaparinux Relative to Enoxaparin in NonST-Segment Elevation Acute Coronary Syndromes (2007) (107)
Rationale, design, and baseline characteristics for a large international trial of cardiovascular disease prevention in people with dysglycemia: the ORIGIN Trial (Outcome Reduction with an Initial Glargine Intervention). (2008) (107)
Calcium antagonists in coronary artery disease and hypertension. Time for reevaluation? (1995) (106)
Current status of safety and efficacy of calcium channel blockers in cardiovascular diseases: a critical analysis based on 100 studies. (2000) (106)
Relationship of Activated Partial Thromboplastin Time to Coronary Events and Bleeding in Patients With Acute Coronary Syndromes Who Receive Heparin (2003) (105)
Patient outcomes using the European label for dabigatran (2013) (105)
Toward Fairness in Data Sharing. (2016) (105)
Perioperative covert stroke in patients undergoing non-cardiac surgery (NeuroVISION): a prospective cohort study (2019) (104)
Blockade of the renin-angiotensin-aldosterone system (RAAS) for primary prevention of non-valvular atrial fibrillation: a systematic review and meta analysis of randomized controlled trials. (2013) (104)
Relationship Between Pacemaker Dependency and the Effect of Pacing Mode on Cardiovascular Outcomes (2001) (103)
Selection of patients for randomized controlled trials: implications of wide or narrow eligibility criteria. (1990) (103)
Polypill with or without Aspirin in Persons without Cardiovascular Disease. (2020) (103)
Perioperative aspirin and clonidine and risk of acute kidney injury: a randomized clinical trial. (2014) (103)
Mendelian randomization analysis supports the causal role of dysglycaemia and diabetes in the risk of coronary artery disease. (2015) (102)
Resequencing Genomic DNA of Patients With Severe Hypertriglyceridemia (MIM 144650) (2007) (102)
Randomized trial of aspirin and clopidogrel versus aspirin alone for the prevention of coronary artery bypass graft occlusion: the Preoperative Aspirin and Postoperative Antiplatelets in Coronary Artery Bypass Grafting study. (2010) (102)
Prognostic value of prolonged ventricular repolarization following myocardial infarction: the BHAT experience. The BHAT Study Group. (1990) (101)
Evaluating the benefit of event adjudication of cardiovascular outcomes in large simple RCTs (2009) (100)
Carbohydrate intake and HDL in a multiethnic population. (2007) (100)
Heart Failure in Africa, Asia, the Middle East and South America: The INTER-CHF study. (2016) (100)
Protocol for prospective collaborative overviews of major randomized trials of blood-pressure-lowering treatments. World Health Organization-International Society of Hypertension Blood Pressure Lowering Treatment Trialists' Collaboration. (1998) (99)
Physical activity levels, ownership of goods promoting sedentary behaviour and risk of myocardial infarction: results of the INTERHEART study. (2012) (99)
Association between the FTO rs9939609 polymorphism and the metabolic syndrome in a non-Caucasian multi-ethnic sample (2008) (99)
Discordance analysis of apolipoprotein B and non-high density lipoprotein cholesterol as markers of cardiovascular risk in the INTERHEART study. (2012) (99)
Effects of calcium antagonists on the risks of coronary heart disease, cancer and bleeding (1997) (98)
Effect of coronary artery bypass graft surgery on survival (1994) (98)
GWAS and colocalization analyses implicate carotid intima-media thickness and carotid plaque loci in cardiovascular outcomes (2018) (98)
Effects of ramipril on left ventricular mass and function in cardiovascular patients with controlled blood pressure and with preserved left ventricular ejection fraction: a substudy of the Heart Outcomes Prevention Evaluation (HOPE) Trial. (2004) (98)
Comparison of Dabigatran and Warfarin in Patients With Atrial Fibrillation and Valvular Heart Disease: The RE-LY Trial (Randomized Evaluation of Long-Term Anticoagulant Therapy). (2016) (97)
Two-year outcomes in patients admitted with non-ST elevation acute coronary syndrome: results of the OASIS registry 1 and 2. (2005) (97)
Availability and affordability of essential medicines for diabetes across high-income, middle-income, and low-income countries: a prospective epidemiological study. (2018) (97)
Randomized clinical trials--removing unnecessary obstacles. (2013) (97)
Health Effects of Household Solid Fuel Use: Findings from 11 Countries within the Prospective Urban and Rural Epidemiology Study (2019) (96)
Impact of resting heart rate on mortality, disability and cognitive decline in patients after ischaemic stroke. (2012) (96)
A polygenic basis for four classical Fredrickson hyperlipoproteinemia phenotypes that are characterized by hypertriglyceridemia (2009) (96)
Digitalis--a new controversy regarding an old drug. The pitfalls of inappropriate methods. (1986) (96)
Value of electrocardiogram in predicting and estimating infarct size in man. (1979) (95)
Penetrance of polygenic obesity susceptibility loci across the body mass index distribution: an update on scaling effects (2017) (95)
Short- and long-term oral antiplatelet therapy in acute coronary syndromes and percutaneous coronary intervention. (2003) (95)
Are the recommendations to use perioperative β-blocker therapy in patients undergoing noncardiac surgery based on reliable evidence? (2004) (95)
A Family-based Intervention to Promote Healthy Lifestyles in an Aboriginal Community in Canada (2007) (94)
Stroke in the TOTAL trial: a randomized trial of routine thrombectomy vs. percutaneous coronary intervention alone in ST elevation myocardial infarction. (2015) (94)
Homocysteine lowering with folic acid and B vitamins in people with chronic kidney disease--results of the renal Hope-2 study. (2007) (93)
Plasma ACE2 and risk of death or cardiometabolic diseases: a case-cohort analysis (2020) (92)
Efficacy and safety of apixaban compared with aspirin in the elderly: a subgroup analysis from the AVERROES trial. (2016) (92)
Relationship of dose of background angiotensin-converting enzyme inhibitor to the benefits of candesartan in the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM)-Added trial. (2006) (91)
The Effect of Chromosome 9p21 Variants on Cardiovascular Disease May Be Modified by Dietary Intake: Evidence from a Case/Control and a Prospective Study (2011) (91)
Association of risk factors with acute myocardial infarction in Middle Eastern countries: the INTERHEART Middle East study (2014) (91)
Impact of ramipril on the incidence of atrial fibrillation: results of the Heart Outcomes Prevention Evaluation study. (2007) (91)
Challenges of Establishing New Antithrombotic Therapies in Atrial Fibrillation (2007) (91)
Dabigatran compared with warfarin in patients with atrial fibrillation and symptomatic heart failure: a subgroup analysis of the RE‐LY trial (2011) (91)
Bleeding During Treatment With Aspirin Versus Apixaban in Patients With Atrial Fibrillation Unsuitable for Warfarin: The Apixaban Versus Acetylsalicylic Acid to Prevent Stroke in Atrial Fibrillation Patients Who Have Failed or Are Unsuitable for Vitamin k Antagonist Treatment (AVERROES) Trial (2012) (91)
Primary and secondary prevention of myocardial infarction and strokes: an update of randomly allocated, controlled trials. (1993) (90)
Community health worker-based intervention for adherence to drugs and lifestyle change after acute coronary syndrome: a multicentre, open, randomised controlled trial. (2016) (90)
Primary Prevention With Statin Therapy in the Elderly: New Meta-Analyses From the Contemporary JUPITER and HOPE-3 Randomized Trials. (2017) (90)
Infarct size, ejection fraction, and mortality in diabetic patients with acute myocardial infarction treated with thrombolytic therapy. (2007) (90)
Reduction of ventricular arrhythmias by early intravenous atenolol in suspected acute myocardial infarction. (1983) (90)
An Increased Burden of Common and Rare Lipid-Associated Risk Alleles Contributes to the Phenotypic Spectrum of Hypertriglyceridemia (2011) (89)
Effects of β-blockers and calcium channel blockers in acute myocardial infarction (1993) (89)
Physical Activity and Anger or Emotional Upset as Triggers of Acute Myocardial Infarction: The INTERHEART Study (2016) (89)
Modifiable lifestyle and social factors affect chronic kidney disease in high-risk individuals with type 2 diabetes mellitus. (2015) (88)
Multi-ancestry genetic study of type 2 diabetes highlights the power of diverse populations for discovery and translation (2020) (88)
Tackling the challenge of cardiovascular disease burden in developing countries. (2004) (87)
High-sensitivity cardiac troponin I measurement for risk stratification in a stable high-risk population. (2011) (87)
Sexual function, satisfaction, and association of erectile dysfunction with cardiovascular disease and risk factors in cardiovascular high-risk patients: substudy of the ONgoing Telmisartan Alone and in Combination with Ramipril Global Endpoint Trial/Telmisartan Randomized AssessmeNT Study in ACE-IN (2007) (87)
Intravenous Magnesium in Acute Myocardial Infarction An Effective, Safe, Simple, and Inexpensive Intervention (1993) (87)
Relationship between baseline haemoglobin and major bleeding complications in acute coronary syndromes. (2010) (86)
Clinical characteristics and outcomes of young and very young adults with heart failure: The CHARM programme (Candesartan in Heart Failure Assessment of Reduction in Mortality and Morbidity). (2013) (86)
Meta-Analysis of the INSIG2 Association with Obesity Including 74,345 Individuals: Does Heterogeneity of Estimates Relate to Study Design? (2009) (85)
A biomarker-based risk score to predict death in patients with atrial fibrillation: the ABC (age, biomarkers, clinical history) death risk score (2017) (85)
The 2002/3 Canadian Cardiovascular Society consensus guideline update for the diagnosis and management of heart failure. (2003) (85)
Progression of renal insufficiency in type 2 diabetes with and without microalbuminuria: results of the Heart Outcomes and Prevention Evaluation (HOPE) randomized study. (2003) (84)
Plasma renin activity predicts cardiovascular mortality in the Heart Outcomes Prevention Evaluation (HOPE) study. (2011) (84)
Reducing Premature Cardiovascular Morbidity and Mortality in People With Atherosclerotic Vascular Disease: The World Heart Federation Roadmap for Secondary Prevention of Cardiovascular Disease. (2015) (84)
Social disadvantage and cardiovascular disease: development of an index and analysis of age, sex, and ethnicity effects. (2006) (83)
Rivaroxaban Plus Aspirin Versus Aspirin in Relation to Vascular Risk in the COMPASS Trial. (2019) (83)
Effects of long-term, moderate-intensity oral anticoagulation in addition to aspirin in unstable angina (2001) (83)
The Hemoglobin A 1 c Level as a Progressive Risk Factor for Cardiovascular Death , Hospitalization for Heart Failure , or Death in Patients With Chronic Heart Failure (2008) (83)
Diagnostic strategies to detect glucose intolerance in a multiethnic population. (2003) (82)
HFSA guidelines for management of patients with heart failure caused by left ventricular systolic dysfunction--pharmacological approaches. Heart Failure Society of America. (2000) (81)
Excess of Rare Variants in Non–Genome-Wide Association Study Candidate Genes in Patients With Hypertriglyceridemia (2012) (81)
Carotid Intima-Media Thickness Progression as Surrogate Marker for Cardiovascular Risk (2020) (81)
Association of handgrip strength to cardiovascular mortality in pre-diabetic and diabetic patients: a subanalysis of the ORIGIN trial. (2014) (80)
Secretory phospholipase A(2)-IIA and cardiovascular disease: a mendelian randomization study. (2013) (80)
Peri-Procedural Bleeding and Thromboembolic Events with Dabigatran Compared to Warfarin: Results from the RE-LY Randomized Trial (2012) (80)
Protocol for a prospective collaborative overview of all current and planned randomized trials of cholesterol treatment regimens. Cholesterol Treatment Trialists' (CTT) Collaboration. (1995) (79)
The 2001 Canadian Cardiovascular Society consensus guideline update for the management and prevention of heart failure. (2001) (79)
Pantoprazole to Prevents Gastroduodenal Events in Patients Receiving Rivaroxaban and/or Aspirin in a Randomized, Double-blind, Placebo-controlled Trial. (2019) (79)
Albuminuria and decline in cognitive function: The ONTARGET/TRANSCEND studies. (2011) (79)
Mortality and cardiovascular and respiratory morbidity in individuals with impaired FEV1 (PURE): an international, community-based cohort study. (2019) (79)
Efficacy and safety of fondaparinux versus enoxaparin in patients with acute coronary syndromes treated with glycoprotein IIb/IIIa inhibitors or thienopyridines: results from the OASIS 5 (Fifth Organization to Assess Strategies in Ischemic Syndromes) trial. (2009) (79)
Interrelation of saturated fat, trans fat, alcohol intake, and subclinical atherosclerosis. (2008) (79)
Performance and Validation of a Novel Biomarker-Based Stroke Risk Score for Atrial Fibrillation (2016) (78)
Secretory Phospholipase A2-IIA and Cardiovascular Disease (2013) (78)
Procedural volume and outcomes with radial or femoral access for coronary angiography and intervention. (2014) (78)
Achieved diastolic blood pressure and pulse pressure at target systolic blood pressure (120–140 mmHg) and cardiovascular outcomes in high-risk patients: results from ONTARGET and TRANSCEND trials (2018) (78)
Practice patterns and outcomes after stroke across countries at different economic levels (INTERSTROKE): an international observational study (2018) (77)
Practice patterns and outcomes after stroke across countries at different economic levels (INTERSTROKE): an international observational study (2018) (77)
Long-term cost-effectiveness of early and sustained clopidogrel therapy for up to 1 year in patients undergoing percutaneous coronary intervention after presenting with acute coronary syndromes without ST-segment elevation. (2006) (76)
Glucose levels are associated with cardiovascular disease and death in an international cohort of normal glycaemic and dysglycaemic men and women: the EpiDREAM cohort study (2011) (76)
Impact of candesartan on nonfatal myocardial infarction and cardiovascular death in patients with heart failure. (2005) (76)
Dual inhibition of the renin–angiotensin system in high-risk diabetes and risk for stroke and other outcomes: results of the ONTARGET trial (2013) (76)
External applicability of the COMPASS trial: an analysis of the reduction of atherothrombosis for continued health (REACH) registry (2018) (76)
Wealth and cardiovascular health: a cross-sectional study of wealth-related inequalities in the awareness, treatment and control of hypertension in high-, middle- and low-income countries (2016) (76)
The Association of Basal Insulin Glargine and/or n-3 Fatty Acids With Incident Cancers in Patients With Dysglycemia (2014) (76)
Joint association of urinary sodium and potassium excretion with cardiovascular events and mortality: prospective cohort study (2019) (76)
Prevention of atrial fibrillation in patients with symptomatic chronic heart failure by candesartan in the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM) program. (2006) (76)
Comparison of Risk Factor Reduction and Tolerability of a Full-Dose Polypill (With Potassium) Versus Low-Dose Polypill (Polycap) in Individuals at High Risk of Cardiovascular Diseases: The Second Indian Polycap Study (TIPS-2) Investigators (2012) (75)
Comparison of dabigatran versus warfarin in diabetic patients with atrial fibrillation: Results from the RE-LY trial. (2012) (75)
Efficacy and safety of dabigatran compared to warfarin in patients with paroxysmal, persistent, and permanent atrial fibrillation: results from the RE-LY (Randomized Evaluation of Long-Term Anticoagulation Therapy) study. (2012) (75)
International Geographic Variation in Event Rates in Trials of Heart Failure With Preserved and Reduced Ejection Fraction (2015) (75)
Protein intake is inversely associated with abdominal obesity in a multi-ethnic population. (2005) (74)
Extracranial Systemic Embolic Events in Patients With Nonvalvular Atrial Fibrillation: Incidence, Risk Factors, and Outcomes (2015) (74)
Systolic Blood Pressure Variation and Mean Heart Rate Is Associated With Cognitive Dysfunction in Patients With High Cardiovascular Risk (2015) (74)
Effect of Telmisartan on Functional Outcome, Recurrence, and Blood Pressure in Patients With Acute Mild Ischemic Stroke: A PRoFESS Subgroup Analysis (2009) (74)
Effects of dabigatran according to age in atrial fibrillation (2017) (74)
Genetic Variants Associated With Myocardial Infarction Risk Factors in Over 8000 Individuals From Five Ethnic Groups: The INTERHEART Genetics Study (2009) (74)
Angiotensin-converting enzyme 2 (ACE2) levels in relation to risk factors for COVID-19 in two large cohorts of patients with atrial fibrillation (2020) (74)
Diet and Major Renal Outcomes: A Prospective Cohort Study. The NIH-AARP Diet and Health Study. (2016) (74)
Clopidogrel does not suppress blood markers of coagulation activation in aspirin-treated patients with non-ST-elevation acute coronary syndromes. (2002) (74)
Is there a role for antioxidant vitamins in the prevention of cardiovascular diseases? An update on epidemiological and clinical trials data. (1997) (73)
Early invasive compared with a selective invasive strategy in women with non-ST-elevation acute coronary syndromes: a substudy of the OASIS 5 trial and a meta-analysis of previous randomized trials. (2012) (72)
Combination pharmacotherapy to prevent cardiovascular disease: present status and challenges. (2013) (72)
Doctors' strikes and mortality: a review. (2008) (72)
Cardiovascular risk factors and non-invasive assessment of subclinical atherosclerosis in youth. (2010) (72)
Resource Effective Strategies to Prevent and Treat Cardiovascular Disease. (2016) (72)
Alteplase for Acute Ischemic Stroke: Outcomes by Clinically Important Subgroups in the Third International Stroke Trial (2015) (72)
Understanding the modifiable health systems barriers to hypertension management in Malaysia: a multi-method health systems appraisal approach (2015) (71)
Comparative impact of enalapril, candesartan or metoprolol alone or in combination on ventricular remodelling in patients with congestive heart failure. (2003) (71)
Global differences in lung function by region (PURE): an international, community-based prospective study. (2013) (70)
Benefit of clopidogrel according to timing of percutaneous coronary intervention in patients with acute coronary syndromes: further results from the Clopidogrel in Unstable angina to prevent Recurrent Events (CURE) study. (2005) (70)
Relationship of Anti-60 kDa Heat Shock Protein and Anti-Cholesterol Antibodies to Cardiovascular Events (2002) (70)
Correction of Population Stratification in Large Multi-Ethnic Association Studies (2008) (70)
Association of ultra-processed food intake with risk of inflammatory bowel disease: prospective cohort study (2021) (70)
Inequalities in the use of secondary prevention of cardiovascular disease by socioeconomic status: evidence from the PURE observational study (2018) (70)
Alcohol consumption and the risk of incident atrial fibrillation among people with cardiovascular disease (2012) (70)
Effect of potentially modiﬁable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study (70)
Risk of intracranial haemorrhage with bolus versus infusion thrombolytic therapy: a meta-analysis (2000) (69)
Baseline characteristics and outcomes of patients with heart failure receiving bronchodilators in the CHARM programme (2010) (69)
Sodium intake and renal outcomes: a systematic review. (2014) (69)
The association between ownership of common household devices and obesity and diabetes in high, middle and low income countries (2014) (69)
Rivaroxaban With or Without Aspirin in Patients With Heart Failure and Chronic Coronary or Peripheral Artery Disease (2019) (69)
Usefulness of temporal changes in neurohormones as markers of ventricular remodeling and prognosis in patients with left ventricular systolic dysfunction and heart failure receiving either candesartan or enalapril or both. (2005) (68)
Aspirin in Patients With Previous Percutaneous Coronary Intervention Undergoing Noncardiac Surgery (2018) (68)
Balancing the benefits and risks of 2 doses of dabigatran compared with warfarin in atrial fibrillation. (2013) (68)
Glycemic Index, Glycemic Load, and Cardiovascular Disease and Mortality. (2021) (68)
Association of Symptoms of Depression With Cardiovascular Disease and Mortality in Low-, Middle-, and High-Income Countries. (2020) (68)
Patients’ Knowledge, Attitudes, Behaviour and Health Care Experiences on the Prevention, Detection, Management and Control of Hypertension in Colombia: A Qualitative Study (2015) (68)
Thrombus Aspiration in ST Elevation Myocardial Infarction: An Individual Patient Meta-analysis (2017) (67)
Early intravenous atenolol treatment in suspected acute myocardial infarction. (2009) (66)
Patterns of Alcohol Consumption and Myocardial Infarction Risk: Observations From 52 Countries in the INTERHEART Case–Control Study (2014) (66)
Rationale and Design of a Large Study to Evaluate the Renal and Cardiovascular Effects of an ACE Inhibitor and Vitamin E in High-Risk Patients With Diabetes: The MICRO-HOPE Study (1996) (66)
Prevalence and prognostic impact of bundle branch block in patients with heart failure: Evidence from the CHARM programme (2007) (66)
Prevalence and prognostic importance of precipitating factors leading to heart failure hospitalization: recurrent hospitalizations and mortality (2018) (65)
Stroke Outcomes in the COMPASS Trial (2019) (65)
Salt and cardiovascular disease: insufficient evidence to recommend low sodium intake. (2020) (65)
Rivaroxaban, Aspirin, or Both to Prevent Early Coronary Bypass Graft Occlusion: The COMPASS-CABG Study. (2019) (65)
C-reactive protein is a bystander of cardiovascular disease. (2010) (65)
APOA5 genetic variants are markers for classic hyperlipoproteinemia phenotypes and hypertriglyceridemia (2008) (65)
Combination neurohormonal blockade with ACE inhibitors, angiotensin II antagonists and beta-blockers in patients with congestive heart failure: design of the Randomized Evaluation of Strategies for Left Ventricular Dysfunction (RESOLVD) Pilot Study. (1997) (65)
Rationale and design of a Global Rheumatic Heart Disease Registry: the REMEDY study. (2012) (64)
Design and rationale of the TOTAL trial: a randomized trial of routine aspiration ThrOmbecTomy with percutaneous coronary intervention (PCI) versus PCI ALone in patients with ST-elevation myocardial infarction undergoing primary PCI. (2014) (64)
Systolic and Diastolic Blood Pressure Changes in Relation With Myocardial Infarction and Stroke in Patients With Coronary Artery Disease (2015) (64)
Associations of outdoor fine particulate air pollution and cardiovascular disease in 157 436 individuals from 21 high-income, middle-income, and low-income countries (PURE): a prospective cohort study. (2020) (64)
The HOPE (Heart Outcomes Prevention Evaluation) Study and its Consequences (2005) (64)
Magnesium in acute myocardial infarction (1995) (63)
The role of fondaparinux as an adjunct to thrombolytic therapy in acute myocardial infarction: a subgroup analysis of the OASIS-6 trial. (2008) (63)
Effect of Intravenous Nitrates on Mortality in Acute Myocardial Infarction (1993) (63)
The household economic burden of non-communicable diseases in 18 countries (2020) (63)
The impact of time to thrombolytic treatment on outcome in patients with acute myocardial infarction (2000) (63)
Potentially modifiable risk factors associated with myocardial infarction in China: the INTERHEART China study (2009) (63)
Dysglycaemia and risk of cardiovascular disease (1996) (63)
Dysglycaemia and the risk of acute myocardial infarction in multiple ethnic groups: an analysis of 15,780 patients from the INTERHEART study (2010) (63)
Prognostic importance of temporal changes in resting heart rate in heart failure patients: an analysis of the CHARM program. (2015) (63)
Causal Relationship between Adiponectin and Metabolic Traits: A Mendelian Randomization Study in a Multiethnic Population (2013) (63)
Predictors of Development of Diabetes in Patients With Chronic Heart Failure in the Candesartan in Heart Failure Assessment of Reduction in Mortality and Morbidity (CHARM) Program (2009) (62)
The relationship between dysglycemia and atherosclerosis in South Asian, Chinese, and European individuals in Canada: a randomly sampled cross-sectional study. (2003) (62)
Associations of plasma homocysteine and the methylenetetrahydrofolate reductase C677T polymorphism with carotid intima media thickness among South Asian, Chinese and European Canadians. (2004) (62)
Need for a large randomized trial to evaluate the effects of digitalis on morbidity and mortality in congestive heart failure. (1992) (61)
Interpreting Geographic Variations in Results of Randomized, Controlled Trials. (2016) (61)
Re-Ly study of stroke prevention in atrial fibrillation Dabigatren versus warfarin in patients with atrial fibrillation N Engl J Med 2009; 361.10: 1056 (2009) (61)
Identifying Novel Biomarkers for Cardiovascular Events or Death in People With Dysglycemia (2015) (61)
Effect of ramipril and of rosiglitazone on carotid intima-media thickness in people with impaired glucose tolerance or impaired fasting glucose: STARR (STudy of Atherosclerosis with Ramipril and Rosiglitazone). (2009) (61)
Obtaining medically meaningful answers from an overview of randomized clinical trials. (1987) (60)
Age-stratified and blood-pressure-stratified effects of blood-pressure-lowering pharmacotherapy for the prevention of cardiovascular disease and death: an individual participant-level data meta-analysis (2021) (60)
Physical activity and genetic predisposition to obesity in a multiethnic longitudinal study (2016) (60)
Association of Household Wealth Index, Educational Status, and Social Capital with Hypertension Awareness, Treatment, and Control in South Asia (2017) (59)
Prevalence of mitral valve prolapse in ethnic groups. (2004) (59)
Effect of Combined Aspirin and Extended-Release Dipyridamole Versus Clopidogrel on Functional Outcome and Recurrence in Acute, Mild Ischemic Stroke: PRoFESS Subgroup Analysis (2010) (59)
Development of a semi-quantitative food frequency questionnaire for use in United Arab Emirates and Kuwait based on local foods (2005) (59)
Effect of Ramipril in Reducing Sudden Deaths and Nonfatal Cardiac Arrests in High-Risk Individuals Without Heart Failure or Left Ventricular Dysfunction (2004) (59)
Blood pressure-lowering treatment strategies based on cardiovascular risk versus blood pressure: A meta-analysis of individual participant data (2018) (59)
Prevalence and prognostic implications of electrocardiographic left ventricular hypertrophy in heart failure: evidence from the CHARM programme (2006) (59)
Ambulatory Blood Pressure Values in the Ongoing Telmisartan Alone and in Combination with Ramipril Global Endpoint Trial (ONTARGET) (2012) (58)
Blood CSF1 and CXCL12 as Causal Mediators of Coronary Artery Disease. (2018) (58)
REDUCTION IN MAJOR MORBIDITY AND MORTALITY BY HEPARIN IN ACUTE MYOCARDIAL-INFARCTION (1989) (57)
Acute change in glomerular filtration rate with inhibition of the renin-angiotensin system does not predict subsequent renal and cardiovascular outcomes. (2017) (57)
Stroke in Relation to Cardiac Procedures in Patients With Non–ST-Elevation Acute Coronary Syndrome: A Study Involving >18 000 Patients (2001) (57)
Effects of nonpersistence with medication on outcomes in high-risk patients with cardiovascular disease. (2013) (56)
Patterns of Medication Use in Patients With Heart Failure: A Report From the Registry of Studies of Left Ventricular Dysfunction (SOLVD) (1995) (56)
Beta-carotene, vitamin C, and vitamin E and cardiovascular diseases (2000) (56)
Incidence, predictive factors and prognostic significance of supraventricular tachyarrhythmias in congestive heart failure (1998) (56)
Cost‐effectiveness of clopidogrel in acute coronary syndromes in Sweden: a long‐term model based on the cure trial (2004) (56)
Design and rationale of the MICHELANGELO Organization to Assess Strategies in Acute Ischemic Syndromes (OASIS)-5 trial program evaluating fondaparinux, a synthetic factor Xa inhibitor, in patients with non-ST-segment elevation acute coronary syndromes. (2005) (56)
Comparison of Characteristics and Outcomes of Dabigatran Versus Warfarin in Hypertensive Patients With Atrial Fibrillation (from the RE-LY Trial). (2015) (55)
Impact of transradial and transfemoral coronary interventions on bleeding and net adverse clinical events in acute coronary syndromes. (2011) (55)
Effect of candesartan on New York Heart Association functional class. Results of the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM) programme. (2004) (55)
Comparative neurohormonal responses in patients with preserved and impaired left ventricular ejection fraction: results of the Studies of Left Ventricular Dysfunction (SOLVD) Registry. The SOLVD Investigators. (1993) (54)
Implantable cardioverter defibrillators in cardiovascular practice: report of the policy conference of the North American Society of Pacing and Electrophysiology. (1991) (54)
Worsening renal function and outcome in heart failure patients with reduced and preserved ejection fraction and the impact of angiotensin receptor blocker treatment: data from the CHARM‐study programme (2016) (54)
Estimated Glomerular Filtration Rate and Albuminuria as Predictors of Outcomes in Patients With High Cardiovascular Risk (2011) (54)
Studies of Left Ventricular Dysfunction (SOLVD) Registry: rationale, design, methods and description of baseline characteristics. (1992) (53)
Sensible guidelines for the conduct of large randomized trials (2008) (53)
Household and personal air pollution exposure measurements from 120 communities in eight countries: results from the PURE-AIR study (2020) (53)
Healthy eating and reduced risk of cognitive decline (2015) (52)
Measures of cardiovascular risk and subclinical atherosclerosis in a cohort of women with a remote history of preeclampsia. (2013) (52)
Lipid lowering for primary prevention (2009) (52)
Characterizing exposure to household air pollution within the Prospective Urban Rural Epidemiology (PURE) study. (2018) (52)
Oxygen therapy in acute coronary syndrome: are the benefits worth the risk? (2013) (52)
Blood pressure and other determinants of new-onset atrial fibrillation in patients at high cardiovascular risk in the Ongoing Telmisartan Alone and in Combination With Ramipril Global Endpoint Trial/Telmisartan Randomized AssessmeNt Study in ACE iNtolerant subjects with cardiovascular Disease studie (2012) (51)
Gene-Centric Meta-Analysis of Lipid Traits in African, East Asian and Hispanic Populations (2012) (51)
Additional events in the RE-LY trial. (2014) (51)
Effects of basal insulin glargine and omega-3 fatty acid on cognitive decline and probable cognitive impairment in people with dysglycaemia: a substudy of the ORIGIN trial. (2014) (51)
The Study of Health Assessment and Risk in Ethnic groups (SHARE): rationale and design. The SHARE Investigators. (1998) (51)
Demographic, behavioral, and cardiovascular disease risk factors in the Saudi population: results from the Prospective Urban Rural Epidemiology study (PURE-Saudi) (2020) (51)
Prevalence of Prediabetes and Undiagnosed Diabetes in Patients with HFpEF and HFrEF and Associated Clinical Outcomes (2017) (51)
Predictors of early and late stroke following cardiac surgery (2014) (51)
Effects of long-term, moderate-intensity oral anticoagulation in addition to aspirin in unstable angina. The Organization to Assess Strategies for Ischemic Syndromes (OASIS) Investigators. (2001) (50)
Association of egg intake with blood lipids, cardiovascular disease, and mortality in 177,000 people in 50 countries. (2020) (50)
Health and peace: time for a new discipline (2001) (50)
The cost-effectiveness of the use of clopidogrel in acute coronary syndromes in five countries based upon the CURE study (2004) (50)
Comparison of the anticoagulant intensities of fondaparinux and enoxaparin in the organization to assess strategies in acute ischemic syndromes (OASIS)‐5 trial (2010) (50)
Clinical outcomes according to baseline blood pressure in patients with a low ejection fraction in the CHARM (Candesartan in Heart Failure: Assessment of Reduction in Mortality and Morbidity) Program. (2008) (50)
Ischemic pain relief in patients with acute myocardial infarction by intravenous atenolol. (1982) (50)
Relationship of electrocardiographic left ventricular hypertrophy to mortality and cardiovascular morbidity in high-risk patients (2003) (50)
Effect of apixaban on brain infarction and microbleeds: AVERROES-MRI assessment study. (2016) (50)
Causes of Death and Influencing Factors in Patients With Atrial FibrillationClinical Perspective (2013) (50)
Prevalence, awareness, treatment and control of hypertension in four Middle East countries (2017) (50)
Effect of long-term therapy with ramipril in high-risk women. (2002) (49)
Effect of drug therapy on survival in chronic congestive heart failure. (1988) (49)
Association between the -455T>C promoter polymorphism of the APOC3 gene and the metabolic syndrome in a multi-ethnic sample (2007) (49)
Significance of elevated MB isoenzyme with normal creatine kinase in acute myocardial infarction. (1987) (49)
Role of Combination Antiplatelet and Anticoagulation Therapy in Diabetes Mellitus and Cardiovascular Disease (2020) (49)
Predicting myocardial infarction and other serious cardiac outcomes using high-sensitivity cardiac troponin T in a high-risk stable population. (2013) (49)
Influenza Vaccination and Major Adverse Vascular Events in High-Risk Patients (2012) (48)
An international prospective cohort study evaluating major vascular complications among patients undergoing noncardiac surgery: the VISION Pilot Study (2011) (48)
The Family Atherosclerosis Monitoring In earLY life (FAMILY) study: rationale, design, and baseline data of a study examining the early determinants of atherosclerosis. (2009) (48)
Concomitant Oral Anticoagulant and Nonsteroidal Anti-Inflammatory Drug Therapy in Patients With Atrial Fibrillation. (2018) (48)
Contribution of cardiac and extra‐cardiac disease burden to risk of cardiovascular outcomes varies by ejection fraction in heart failure (2018) (48)
Comparison of Dabigatran and Warfarin in Patients With Atrial Fibrillation and Valvular Heart DiseaseClinical Perspective (2016) (48)
Basal insulin glargine and microvascular outcomes in dysglycaemic individuals: results of the Outcome Reduction with an Initial Glargine Intervention (ORIGIN) trial (2014) (48)
Importance of persistent elevation of cardiac biomarkers in atrial fibrillation: a RE-LY substudy (2014) (48)
Prevalence, awareness, treatment and control of hypertension in rural and urban communities in Latin American countries. (2019) (48)
Effects of fondaparinux in patients with ST-segment elevation acute myocardial infarction not receiving reperfusion treatment. (2008) (48)
Rationale, design and baseline characteristics of a large, simple, randomized trial of combined folic acid and vitamins B6 and B12 in high-risk patients: the Heart Outcomes Prevention Evaluation (HOPE)-2 trial. (2006) (47)
Tranexamic Acid in Patients Undergoing Noncardiac Surgery. (2022) (47)
Prognostic Significance of Thrombocytopenia During Hirudin and Heparin Therapy in Acute Coronary Syndrome Without ST Elevation: Organization to Assess Strategies for Ischemic Syndromes (OASIS-2) Study (2001) (47)
Beta-blocker therapy for congestive heart failure: a systemic overview and critical appraisal of the published trials. (1998) (47)
Major Gastrointestinal Bleeding Often Is Caused by Occult Malignancy in Patients Receiving Warfarin or Dabigatran to Prevent Stroke and Systemic Embolism From Atrial Fibrillation (2017) (47)
Socioeconomic factors and use of secondary preventive therapies for cardiovascular diseases in South Asia: The PURE study (2015) (47)
Prognostic Impact of Diabetes and Prediabetes on Survival Outcomes in Patients With Chronic Heart Failure: A Post‐Hoc Analysis of the GISSI‐HF (Gruppo Italiano per lo Studio della Sopravvivenza nella Insufficienza Cardiaca‐Heart Failure) Trial (2017) (47)
The Global Epidemic of Atherosclerotic Cardiovascular Disease (2002) (46)
The 24-hour heart rate behavior in long-term survivors of cardiac transplantation. (1988) (46)
Cost Implications of the Use of Ramipril in High-Risk Patients Based on the Heart Outcomes Prevention Evaluation (HOPE) Study (2003) (46)
Tobacco control environment: cross-sectional survey of policy implementation, social unacceptability, knowledge of tobacco health harms and relationship to quit ratio in 17 low-income, middle-income and high-income countries (2017) (46)
Cardiac Mechanics During Development of Heart-failure (1993) (46)
Prognostic validation of a non-laboratory and a laboratory based cardiovascular disease risk score in multiple regions of the world (2017) (46)
Design, history and results of the Thiazolidinedione Intervention with vitamin D Evaluation (TIDE) randomised controlled trial (2011) (46)
Coronary Artery Disease in Asian Indians: Prevalence and Risk Factors. (1993) (46)
D-dimer and factor VIIa in atrial fibrillation – prognostic values for cardiovascular events and effects of anticoagulation therapy (2016) (46)
Association Between Low-Dose Rivaroxaban With or Without Aspirin and Ischemic Stroke Subtypes: A Secondary Analysis of the COMPASS Trial. (2020) (46)
Effect of Rosiglitazone and Ramipril on β-Cell Function in People With Impaired Glucose Tolerance or Impaired Fasting Glucose (2009) (45)
Collaborative pooled analysis of data on C-reactive protein gene variants and coronary disease: judging causality by Mendelian randomisation (2008) (45)
Risk of stroke and other adverse outcomes in patients with perioperative atrial fibrillation 1 year after non-cardiac surgery. (2019) (45)
Contribution of common non-synonymous variants in PCSK1 to body mass index variation and risk of obesity: a systematic review and meta-analysis with evidence from up to 331 175 individuals. (2015) (45)
Tolerability of enalapril initiation by patients with left ventricular dysfunction: results of the medication challenge phase of the Studies of Left Ventricular Dysfunction. (1994) (45)
Design and rationale of the radial versus femoral access for coronary intervention (RIVAL) trial: a randomized comparison of radial versus femoral access for coronary angiography or intervention in patients with acute coronary syndromes. (2011) (45)
Impact of Cigarette Smoking in High-Risk Patients Participating in a Clinical Trial. A Substudy from the Heart Outcomes Prevention Evaluation (HOPE) Trial (2005) (45)
Effect of Insulin Glargine and n-3FA on Carotid Intima-Media Thickness in People With Dysglycemia at High Risk for Cardiovascular Events (2013) (45)
Left ventricular mass and volume with telmisartan, ramipril, or combination in patients with previous atherosclerotic events or with diabetes mellitus (from the ONgoing Telmisartan Alone and in Combination With Ramipril Global Endpoint Trial [ONTARGET]). (2009) (45)
Challenges in the conduct of large simple trials of important generic questions in resource-poor settings: The CREATE and ECLA trial program evaluating GIK (glucose, insulin and potassium) and low-molecular-weight heparin in acute myocardial infarction☆ (2004) (44)
Associations of cereal grains intake with cardiovascular disease and mortality across 21 countries in Prospective Urban and Rural Epidemiology study: prospective cohort study (2021) (44)
Association of cyclooxygenase-2 genetic variant with cardiovascular disease. (2014) (43)
The evolving role of direct thrombin inhibitors in acute coronary syndromes. (2003) (43)
Digoxin–mortality: randomized vs. observational comparison in the DIG trial (2019) (43)
Are we biased in our approach to treating elderly patients with heart disease? (1991) (43)
Quality of individual INR control and the risk of stroke and bleeding events in atrial fibrillation patients: a nested case control analysis of the ACTIVE W study. (2012) (43)
Study design and baseline characteristics of the study to evaluate carotid ultrasound changes in patients treated with ramipril and vitamin E: SECURE. (1996) (42)
Relationship Between Degree of Left Ventricular Dysfunction, Symptom Status, and Risk of Embolic Events in Patients With Atrial Fibrillation and Heart Failure (2015) (42)
Population-Attributable Fractions of Modifiable Lifestyle Factors for CKD and Mortality in Individuals With Type 2 Diabetes: A Cohort Study. (2016) (42)
Early intravenous beta blockade in acute myocardial infarction. (1988) (42)
Relationship of the ApoE polymorphism to plasma lipid traits among South Asians, Chinese, and Europeans living in Canada. (2009) (42)
Risk of stroke in chronic heart failure patients with preserved ejection fraction, but without atrial fibrillation: analysis of the CHARM-Preserved and I-Preserve trials (2016) (42)
Age and Cardiovascular Risk Attributable to Apolipoprotein B, Low‐Density Lipoprotein Cholesterol or Non‐High‐Density Lipoprotein Cholesterol (2016) (42)
Monitoring the randomized trials of the Women's Health Initiative: the experience of the Data and Safety Monitoring Board (2007) (42)
Fixed-dose combination therapies with and without aspirin for primary prevention of cardiovascular disease: an individual participant data meta-analysis (2021) (42)
Eliminating acute rheumatic fever and rheumatic heart disease (2017) (42)
Meeting of the International Working Group on Coronary Artery Disease in South Asians. 24 March 1996, Orlando, Florida, USA. (1996) (42)
Anemia predicts thromboembolic events, bleeding complications and mortality in patients with atrial fibrillation: insights from the RE‐LY trial (2015) (42)
Secondary CV Prevention in South America in a Community Setting: The PURE Study. (2017) (42)
Mortality and morbidity in relation to changes in albuminuria, glucose status and systolic blood pressure: an analysis of the ONTARGET and TRANSCEND studies (2014) (41)
Exposing patients with chronic, stable, exertional angina to placebo periods in drug trials. (1991) (41)
Variability of electrocardiographic and enzyme evolution of myocardial infarction in man. (1981) (41)
Growth‐differentiation factor 15 and risk of major bleeding in atrial fibrillation: Insights from the Randomized Evaluation of Long‐Term Anticoagulation Therapy (RE‐LY) trial (2017) (41)
Fondaparinux compared to enoxaparin in patients with acute coronary syndromes without ST-segment elevation: outcomes and treatment effect across different levels of risk. (2009) (40)
Venous thromboembolism in association with features of the metabolic syndrome. (2007) (40)
Marital Status, Education, and Risk of Acute Myocardial Infarction in Mainland China: The INTER-HEART Study (2012) (40)
Variation at the NFATC2 Locus Increases the Risk of Thiazolidinedione-Induced Edema in the Diabetes REduction Assessment with ramipril and rosiglitazone Medication (DREAM) Study (2010) (40)
Mortality predictors and effects of antithrombotic therapies in atrial fibrillation: insights from ACTIVE-W. (2010) (40)
Capacity planning for cardiac catheterization: a case study. (2007) (40)
Thrombus Aspiration in ST-Segment–Elevation Myocardial InfarctionClinical Perspective (2017) (40)
Tackling the global burden of stroke: the need for large-scale international studies (2009) (40)
Associations of Fish Consumption With Risk of Cardiovascular Disease and Mortality Among Individuals With or Without Vascular Disease From 58 Countries. (2021) (40)
Preoperative N-Terminal Pro–B-Type Natriuretic Peptide and Cardiovascular Events After Noncardiac Surgery (2019) (40)
Evaluating effects of treatment in subgroups of patients within a clinical trial: the case of non-Q-wave myocardial infarction and beta blockers. (1990) (40)
A lifetime of prevention: the case of heart failure. (2002) (40)
Rationale and design of the coronary artery bypass grafting surgery off or on pump revascularization study: a large international randomized trial in cardiac surgery. (2012) (39)
Enalapril prevents clinical proteinuria in diabetic patients with low ejection fraction. (2000) (39)
Cardiovascular disease in India: Lessons learnt & challenges ahead (2010) (39)
Resource utilization and costs in the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM) programme. (2005) (39)
Effects of long-term treatment with angiotensin-converting enzyme inhibitors in the presence or absence of aspirin: A systematic review ☆ (2003) (39)
Resting heart rate is associated with renal disease outcomes in patients with vascular disease: results of the ONTARGET and TRANSCEND studies (2015) (38)
Long-term effect of rosiglitazone and/or ramipril on the incidence of diabetes (2010) (38)
The effect of ramipril and telmisartan on serum potassium and its association with cardiovascular and renal events: Results from the ONTARGET trial (2014) (38)
Accumulation of Deficits as a Key Risk Factor for Cardiovascular Morbidity and Mortality: A Pooled Analysis of 154 000 Individuals (2020) (38)
Maternal and Pregnancy Related Predictors of Cardiometabolic Traits in Newborns (2013) (38)
New evidence on the importance of the renin–angiotensin system in the treatment of higher-risk patients with hypertension (2003) (38)
Psychosocial factors and obesity in 17 high-, middle- and low-income countries: the Prospective Urban Rural Epidemiologic study (2015) (38)
Heart failure in low- and middle-income countries: background, rationale, and design of the INTERnational Congestive Heart Failure Study (INTER-CHF). (2015) (38)
Nutrient estimation from an FFQ developed for a black Zimbabwean population (2005) (38)
Randomized controlled trial of influenza vaccine in patients with heart failure to reduce adverse vascular events (IVVE): Rationale and design (2019) (38)
Dietary risk factors for incidence or progression of chronic kidney disease in individuals with type 2 diabetes in the European Union. (2015) (37)
Patient and System-Related Delays of Emergency Medical Services Use in Acute ST-Elevation Myocardial Infarction: Results from the Third Gulf Registry of Acute Coronary Events (Gulf RACE-3Ps) (2016) (37)
Anthropometric measures and glucose levels in a large multi-ethnic cohort of individuals at risk of developing type 2 diabetes (2010) (37)
Treatment for acute myocardial infarction. Overview of randomized clinical trials. (1996) (37)
INTERLEUKIN-6 AND C-REACTIVE PROTEIN AND RISK FOR DEATH AND CARDIOVASCULAR EVENTS IN PATIENTS WITH ATRIAL FIBRILLATION (2011) (37)
Effects of beta-blockers and calcium channel blockers in acute myocardial infarction. (1993) (37)
White Rice Intake and Incident Diabetes: A Study of 132,373 Participants in 21 Countries (2020) (37)
Correlations between plasma homocysteine and folate concentrations and carotid atherosclerosis in high-risk individuals: baseline data from the Homocysteine and Atherosclerosis Reduction Trial (HART) (2008) (37)
Interventions that potentially limit myocardial infarct size: overview of clinical trials. (1987) (37)
Cardiovascular outcomes and achieved blood pressure in patients with and without diabetes at high cardiovascular risk. (2019) (37)
Rivaroxaban and Aspirin in Patients With Symptomatic Lower Extremity Peripheral Artery Disease: A Subanalysis of the COMPASS Randomized Clinical Trial. (2020) (37)
Effect of long-term ACE-inhibitor therapy in elderly vascular disease patients. (2007) (36)
Designing and Analyzing Clinical Trials with Composite Outcomes: Consideration of Possible Treatment Differences between the Individual Outcomes (2012) (36)
Influence of Hospitalization for Cardiovascular Versus Noncardiovascular Reasons on Subsequent Mortality in Patients With Chronic Heart Failure Across the Spectrum of Ejection Fraction (2013) (36)
Glucose levels compared with diabetes history in the risk assessment of patients with acute myocardial infarction. (2009) (36)
Polypills: essential medicines for cardiovascular disease secondary prevention? (2014) (36)
Quality of life among 5,025 patients with left ventricular dysfunction randomized between placebo and enalapril: the Studies of Left Ventricular Dysfunction. The SOLVD Investigators. (1994) (36)
The effects of multimodal exercise on cognitive and physical functioning and brain-derived neurotrophic factor in older women : a randomised controlled trial (2014) (36)
Choice of clinical outcomes in randomized trials of heart failure therapies: disease-specific or overall outcomes? (2002) (36)
Association of dairy consumption with metabolic syndrome, hypertension and diabetes in 147 812 individuals from 21 countries (2020) (36)
Benefits and safety of candesartan treatment in heart failure are independent of age: insights from the Candesartan in Heart failure--Assessment of Reduction in Mortality and morbidity programme. (2008) (36)
Randomized clinical trials: Slow death by a thousand unnecessary policies? (2004) (35)
Reliability, validity, and responsiveness of the 6-minute walk test in patients with heart failure (2002) (35)
The COMPASS Trial (2020) (35)
Racial differences in outcome and treatment effect in congestive heart failure. (2005) (35)
Rivaroxaban Plus Aspirin in Patients With Vascular Disease and Renal Dysfunction: From the COMPASS Trial. (2019) (35)
Multi-Ethnic Genetic Association Study of Carotid Intima-Media Thickness Using a Targeted Cardiovascular SNP Microarray (2009) (35)
Functional capacity in patients with congestive heart failure. (2000) (35)
Central statistical monitoring: Detecting fraud in clinical trials (2013) (35)
Stroke Outcomes in the Cardiovascular OutcoMes for People using Anticoagulation StrategieS (COMPASS) Trial (2018) (34)
Reevaluation by high-performance liquid chromatography: clinical significance of microalbuminuria in individuals at high risk of cardiovascular disease in the Heart Outcomes Prevention Evaluation (HOPE) Study. (2006) (34)
Obesity genes and risk of major depressive disorder in a multiethnic population: a cross-sectional study. (2015) (34)
Anti-ischaemic effects of ACE inhibitors: review of current clinical evidence and ongoing clinical trials. (1998) (34)
The Inflammatory Hypothesis: Any Progress in Risk Stratification and Therapeutic Targets? (2006) (34)
1145-122 Prevention of atrial fibrillation in symptomatic chronic heart failure by candesartan: Results from CHARM (2004) (34)
The relevance of subgroup-specific treatment effects: the Studies Of Left Ventricular Dysfunction (SOLVD) revisited. (2002) (34)
Potential for altering the natural history of congestive heart failure: need for large clinical trials. (1985) (34)
Impact of rosiglitazone on body composition, hepatic fat, fatty acids, adipokines and glucose in persons with impaired fasting glucose or impaired glucose tolerance: a sub‐study of the DREAM trial (2014) (33)
Rationale and design of the Investigation of the Management of Pericarditis (IMPI) trial: a 2 × 2 factorial randomized double-blind multicenter trial of adjunctive prednisolone and Mycobacterium w immunotherapy in tuberculous pericarditis. (2013) (33)
Towards better hypertension management in India (2014) (33)
The effect of RheothRx Injection on the hemorheological parameters in patients with acute myocardial infarction. (1997) (33)
Effect of PON1 Q192R Genetic Polymorphism on Clopidogrel Efficacy and Cardiovascular Events in the Clopidogrel in the Unstable Angina to Prevent Recurrent Events Trial and the Atrial Fibrillation Clopidogrel Trial With Irbesartan for Prevention of Vascular Events (2012) (33)
Prevention of congestive heart failure and management of asymptomatic left ventricular dysfunction (1999) (33)
Resource and Infrastructure-Appropriate Management of ST-Segment Elevation Myocardial Infarction in Low- and Middle-Income Countries (2020) (33)
ACE inhibition in stable coronary artery disease. (2005) (32)
Homocyst(e)ine and Cardiovascular Disease (2000) (32)
The Role of Combination Antiplatelet and Anticoagulation Therapy in Diabetes and Cardiovascular Disease: Insights from the COMPASS Trial. (2020) (32)
Mechanisms of cardiovascular risk reduction with ramipril: insights from HOPE and HOPE substudies (2003) (32)
Efficacy of hirudin in reducing cardiovascular events in patients with acute coronary syndrome undergoing early percutaneous coronary intervention. (2002) (32)
The Mini‐Mental State Examination, Clinical Factors, and Motor Vehicle Crash Risk (2014) (32)
The INVICTUS rheumatic heart disease research program: Rationale, design and baseline characteristics of a randomized trial of rivaroxaban compared to vitamin K antagonists in rheumatic valvular disease and atrial fibrillation. (2020) (31)
Diurnal variations of QT interval after cardiac transplantation. (1988) (31)
Efficacy and safety of apixaban compared with aspirin in patients who previously tried but failed treatment with vitamin K antagonists: results from the AVERROES trial. (2014) (31)
The CHA 2 DS 2-VASc score identifies those patients with atrial fibrillation and a CHADS 2 score of 1 who are unlikely to benefit from oral anticoagulant therapy (2012) (31)
Preventing vascular events due to elevated blood pressure. (2006) (31)
The environmental profile of a community’s health: a cross-sectional study on tobacco marketing in 16 countries (2015) (31)
Social disparities explain differences in hypertension prevalence, detection and control in Colombia (2016) (31)
The risks of waiting for cardiac catheterization: a prospective study. (2002) (31)
Tackling the growing global burden of atherosclerotic cardiovascular diseases (2003) (31)
Influence of dietary patterns on the risk of acute myocardial infarction in China population: the INTERHEART China study. (2013) (30)
Patient perception of the effect of treatment with candesartan in heart failure. Results of the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM) programme (2005) (30)
Effects of bidi smoking on all-cause mortality and cardiorespiratory outcomes in men from south Asia: an observational community-based substudy of the Prospective Urban Rural Epidemiology Study (PURE). (2017) (30)
Acute and long-term effects of the angiotensin-converting enzyme inhibitor, enalapril, on adrenergic activity and sensitivity during exercise in patients with left ventricular systolic dysfunction. (1997) (30)
Impact of hospitalization for acute coronary events on subsequent mortality in patients with chronic heart failure. (2008) (30)
Incidence of Diabetes Following Ramipril or Rosiglitazone Withdrawal (2011) (30)
Hormone replacement therapy: a time for pause. (2002) (29)
Effects of blood pressure and lipid lowering on cognition (2019) (29)
Assessing global risk factors for non-fatal injuries from road traffic accidents and falls in adults aged 35–70 years in 17 countries: a cross-sectional analysis of the Prospective Urban Rural Epidemiological (PURE) study (2015) (29)
Effects of blood pressure lowering on cardiovascular events, in the context of regression to the mean: a systematic review of randomized trials (2019) (29)
Peripheral Blood MCEMP1 Gene Expression as a Biomarker for Stroke Prognosis (2016) (29)
Emerging approaches in preventing cardiovascular disease (1999) (29)
Resting heart rate and cardiovascular outcomes in diabetic and non-diabetic individuals at high cardiovascular risk analysis from the ONTARGET/TRANSCEND trials. (2020) (29)
Rivaroxaban Plus Aspirin Versus Aspirin Alone in Patients With Prior Percutaneous Coronary Intervention (COMPASS-PCI) (2020) (29)
Severity of renal impairment in patients with heart failure and atrial fibrillation: implications for non‐vitamin K antagonist oral anticoagulant dose adjustment (2016) (29)
The Evolution of β-Blockers in Coronary Artery Disease and Heart Failure (Part 1/5). (2019) (29)
Long-term exposure to outdoor and household air pollution and blood pressure in the Prospective Urban and Rural Epidemiological (PURE) study. (2020) (29)
Third Meeting of the International Working Group on Coronary Artery Disease in South Asians. 29 March 1998, Atlanta, USA. (1999) (28)
Apixaban-Calibrated Anti-FXa Activity in Relation to Outcome Events and Clinical Characteristics in Patients with Atrial Fibrillation: Results from the AVERROES Trial (2017) (28)
Effect of angiotensin‐converting enzyme inhibition on functional class in patients with left ventricular systolic dysfunction—a meta‐analysis (2006) (28)
Efficacy and Safety of Dabigatran Compared With Warfarin in Relation to Baseline Renal Function in Patients With Atrial Fibrillation A RE-LY (Randomized Evaluation of Long-term Anticoagulation Therapy) (2014) (28)
Predictors, Prognosis, and Management of New Clinically Important Atrial Fibrillation After Noncardiac Surgery: A Prospective Cohort Study (2017) (28)
ACC/AHA guidelines for coronary artery bypass graft surgery: executive summary and recommendations (2000) (28)
Rationale and design of the Primary pREvention strategies at the community level to Promote Adherence of treatments to pREvent cardiovascular diseases trial number (CTRI/2012/09/002981). (2013) (28)
Effect of Body Mass Index on Clinical Events After Acute Coronary Syndromes. (2017) (28)
Bariatric Surgery and Cardiovascular Outcomes in Patients With Obesity and Cardiovascular Disease: (2021) (28)
HFSA guidelines for the management of patients with heart failure due to left ventricular systolic dysfunction--pharmacological approaches. (2000) (28)
Gene-centric meta-analyses for central adiposity traits in up to 57 412 individuals of European descent confirm known loci and reveal several novel associations. (2014) (27)
Rationale and design of the steroids in cardiac surgery trial. (2014) (27)
Health-Related Quality of Life and Mortality in Heart Failure (2021) (27)
Increased occurrence of diabetes in people with ischemic cardiovascular disease and general and abdominal obesity. (2003) (27)
Dietary Sodium and Cardiovascular Disease (2015) (27)
Glucose intolerance and diabetes as risk factors for cognitive impairment in people at high cardiovascular risk: results from the ONTARGET/TRANSCEND research programme. (2009) (27)
Cost implications of the use of ramipril in high-risk patients based on the Heart Outcomes Prevention Evaluation (HOPE) study. (2003) (27)
Household, community, sub-national and country-level predictors of primary cooking fuel switching in nine countries from the PURE study (2019) (27)
Environmental Profile of a Community’s Health (EPOCH): An Ecometric Assessment of Measures of the Community Environment Based on Individual Perception (2012) (27)
Clinical Perspective on Antihypertensive Drug Treatment in Adults With Grade 1 Hypertension and Low-to-Moderate Cardiovascular Risk: An International Expert Consultation. (2017) (26)
Effect of Colchicine vs Usual Care Alone on Intubation and 28-Day Mortality in Patients Hospitalized With COVID-19 (2021) (26)
Relative and Combined Prognostic Importance of On-Treatment Mean and Visit-to-Visit Blood Pressure Variability in ONTARGET and TRANSCEND Patients (2017) (26)
Major Bleeding in Patients With Coronary or Peripheral Artery Disease Treated With Rivaroxaban Plus Aspirin. (2019) (26)
Novel Approaches in Primary Cardiovascular Disease Prevention: The HOPE-3 Trial Rationale, Design, and Participants' Baseline Characteristics. (2016) (26)
Safety outcomes in meta-analyses of phase 2 vs phase 3 randomized trials: Intracranial hemorrhage in trials of bolus thrombolytic therapy. (2001) (26)
Design of a Randomized Placebo-Controlled Trial to Assess Dabigatran and Omeprazole in Patients with Myocardial Injury after Noncardiac Surgery (MANAGE). (2018) (26)
Association of Urinary Sodium Excretion With Blood Pressure and Cardiovascular Clinical Events in 17,033 Latin Americans. (2016) (26)
Assessment of Dietary Sodium and Potassium in Canadians Using 24-Hour Urinary Collection. (2016) (26)
Sleep duration, snoring habits and risk of acute myocardial infarction in China population: results of the INTERHEART study (2014) (26)
Effects of Long‐term Enalapril Therapy on Left Ventricular Diastolic Properties in Patients With Depressed Ejection Fraction (1993) (26)
World Heart Federation Cholesterol Roadmap. (2017) (26)
Five-Year Outcomes after Off-Pump or On-Pump Coronary-Artery Bypass Grafting. (2017) (26)
Urgent surgery or procedures in patients taking dabigatran or warfarin: Analysis of perioperative outcomes from the RE-LY trial. (2016) (26)
Modification of Outcomes With Aspirin or Apixaban in Relation to CHADS2 and CHA2DS2-VASc Scores in Patients With Atrial Fibrillation: A Secondary Analysis of the AVERROES Study (2013) (26)
1 Obesity and the risk of myocardial infarction in 27 , 000 participants from 52 countries : a case-control study The Lancet (2005) (26)
Polypill: the evidence and the promise (2009) (26)
Risk factors and clinical outcomes in chronic coronary and peripheral artery disease: An analysis of the randomized, double-blind COMPASS trial (2020) (26)
Rivaroxaban in Rheumatic Heart Disease-Associated Atrial Fibrillation. (2022) (26)
Elevated cholesteryl ester transfer protein (CETP) activity, a major determinant of the atherogenic dyslipidemia, and atherosclerotic cardiovascular disease in South Asians (2015) (25)
EFFECT OF AGE AND RENAL FUNCTION ON THE RISKS OF STROKE AND MAJOR BLEEDING WITH DABIGATRAN COMPARED TO WARFARIN: AN ANALYSIS FROM THE RE-LY STUDY (2010) (25)
Effect of Basal Insulin Glargine on First and Recurrent Episodes of Heart Failure Hospitalization: The ORIGIN Trial (Outcome Reduction With Initial Glargine Intervention). (2018) (25)
Randomised controlled trials in cardiovascular medicine: past achievements, future challenges (1999) (25)
Calcium antagonists in the treatment of ischemic heart disease: myocardial infarction (1994) (25)
Challenges in management and prevention of ischemic heart disease in low socioeconomic status people in LLMICs (2019) (25)
Mortality Benefit of Rivaroxaban Plus Aspirin in Patients With Chronic Coronary or Peripheral Artery Disease. (2021) (25)
Screening for Dysglycemia in Overweight Youth Presenting for Weight Management (2012) (25)
Phenome-wide association analysis of LDL-cholesterol lowering genetic variants in PCSK9 (2018) (25)
The role of serum myoglobin in the detection and measurement of myocardial infarction. (1980) (25)
Ten-year results of the randomized control trials of coronary artery bypass graft surgery: tabular data compiled by the collaborative effort of the original trial investigators. Part 1 of 2. (1994) (25)
Dysglycemia and a History of Reproductive Risk Factors (2008) (25)
Part II: Variations in Cardiovascular Disease by Specific Ethnic Groups and Geographic Regions and Prevention Strategies (2001) (25)
Prognosis in Congestive Heart Failure (1994) (25)
Perioperative Aspirin for Prevention of Venous Thromboembolism: The PeriOperative ISchemia Evaluation-2 Trial and a Pooled Analysis of the Randomized Trials (2016) (25)
The Organization to Assess Strategies for Ischemic Syndromes (OASIS) registry in patients with unstable angina. (1999) (24)
Methodologic Issues in Randomized Controlled Trials of Surgical Interventions (2003) (24)
Risk Factors for Acute Myocardial Infarction in Latin America (2007) (24)
Bleeding and New Cancer Diagnosis in Patients with Atherosclerosis. (2019) (24)
Impact of social isolation on mortality and morbidity in 20 high-income, middle-income and low-income countries in five continents (2021) (24)
Body-mass index, abdominal adiposity, and cardiovascular risk (2011) (24)
Ventricular arrhythmias in long term survivors of orthotopic and heterotopic cardiac transplantation. (1988) (24)
Rationale, design, and baseline characteristics of 2 large, simple, randomized trials evaluating telmisartan, ramipril, and their combination, in high risk patients: The Ongoing Telmisartan Alone and in Combination with Ramipril Global Endpoint Trial/Telm (2004) (24)
Reactivation of coagulation after stopping infusions of recombinant hirudin and unfractionated heparin in unstable angina and myocardial infarction without ST elevation: results of a randomized trial. OASIS Pilot Study Investigators. Organization to Assess Strategies for Ischemic++ Syndromes. (2000) (24)
Associations of unprocessed and processed meat intake with mortality and cardiovascular disease in 21 countries [Prospective Urban Rural Epidemiology (PURE) Study]: a prospective cohort study. (2021) (24)
Primary angioplasty compared with thrombolytic therapy for acute myocardial infarction. (1997) (24)
Direct thrombin inhibitors in acute coronary syndromes: effect in patients undergoing early percutaneous coronary intervention. (2005) (23)
Effect of statin therapy on muscle symptoms: an individual participant data meta-analysis of large-scale, randomised, double-blind trials (2022) (23)
The functional variant rs1048990 in PSMA6 is associated with susceptibility to myocardial infarction in a Chinese population. (2009) (23)
Cardiovascular Risk in Patients with Early Renal Insufficiency (2002) (23)
Efficacy and Safety of Dabigatran vs . Warfarin in Patients With Atrial Fibrillation – Sub-Analysis in Japanese Population in RELY Trial – (2011) (23)
Anti-thrombotic options for secondary prevention in patients with chronic atherosclerotic vascular disease: what does COMPASS add? (2018) (23)
Aliskiren alone or with other antihypertensives in the elderly with borderline and stage 1 hypertension: the APOLLO trial. (2014) (23)
Testing for heterogeneity among the components of a binary composite outcome in a clinical trial (2010) (23)
Ethnicity and cardiovascular disease (2009) (22)
Ethnicity and cardiovascular disease (2009) (22)
The effects of apixaban on hospitalizations in patients with different types of atrial fibrillation: insights from the AVERROES trial. (2013) (22)
The social determinants of cardiovascular disease (2009) (22)
COMPARISON OF DABIGATRAN VERSUS WARFARIN IN PATIENTS WITH ATRIAL FIBRILLATION AND VALVULAR HEART DISEASE: THE RE-LY® TRIAL (2014) (22)
Ethnicity and cardiovascular disease (2009) (22)
Global variations in the prevalence, treatment, and impact of atrial fibrillation in a multi-national cohort of 153,152 middle-aged individuals. (2020) (22)
The International Polycap Study-3 (TIPS-3): Design, baseline characteristics and challenges in conduct (2018) (22)
Rationale and design of a randomized controlled trial evaluating community health worker-based interventions for the secondary prevention of acute coronary syndromes in India (SPREAD). (2014) (22)
Sodium Intake and Health: What Should We Recommend Based on the Current Evidence? (2021) (22)
Variations in knowledge, awareness and treatment of hypertension and stroke risk by country income level (2020) (21)
Impact of Clopidogrel Therapy on Mortality and Cancer in Patients With Cardiovascular and Cerebrovascular Disease: A Patient-Level Meta-Analysis (2018) (21)
EXERCISE AFTER MYOCARDIAL-INFARCTION REDUCES MORTALITY - EVIDENCE FROM RANDOMIZED CONTROLLED TRIALS (RCTS) (1984) (21)
The need to test the theories behind the Polypill: rationale behind the Indian Polycap Study (2009) (21)
Summary of randomized trials of angiotensin converting enzyme inhibitors. (1999) (21)
Computationally estimated apolipoproteins B and A1 in predicting cardiovascular risk. (2013) (21)
Early versus delayed enalapril in patients with left ventricular systolic dysfunction: impact on morbidity and mortality 15 years after the SOLVD trial. (2006) (20)
Effects of Telmisartan on Glucose Levels in People at High Risk for Cardiovascular Disease but Free From Diabetes (2011) (20)
Effect of comorbidities on outcomes and angiotensin converting enzyme inhibitor effects in patients with predominantly left ventricular dysfunction and heart failure (2014) (20)
Effects of Trypanocidal Treatment on Echocardiographic Parameters in Chagas Cardiomyopathy and Prognostic Value of Wall Motion Score Index: A BENEFIT Trial Echocardiographic Substudy (2019) (20)
Genetic determinants of warfarin maintenance dose and time in therapeutic treatment range: a RE-LY genomics substudy. (2016) (20)
Damage to important clinical trials by over-regulation (2010) (20)
Variations in Incidence of Venous Thromboembolism in Low-, Middle- and High-Income Countries. (2020) (20)
Influence of beta blockade on exercise capacity and heart rate response after human orthotopic and heterotopic cardiac transplantation. (1989) (20)
Incidental Magnetic Resonance Diffusion-Weighted Imaging–Positive Lesions Are Rare in Neurologically Asymptomatic Community-Dwelling Adults (2014) (20)
Chronic coronary artery disease: drugs, angioplasty, or surgery? (1996) (20)
Incremental Value of Left Ventricular Systolic and Diastolic Function to Determine Outcome in Patients with Acute ST‐Segment Elevation Myocardial Infarction: The Echocardiographic Substudy of the OASIS‐6 Trial (2014) (20)
High-Sensitivity Troponin I after Cardiac Surgery and 30-Day Mortality. (2022) (20)
Association of nut intake with risk factors, cardiovascular disease, and mortality in 16 countries from 5 continents: analysis from the Prospective Urban and Rural Epidemiology (PURE) study. (2020) (20)
Effects of ethnicity on diabetes incidence and prevention: results of the Diabetes REduction Assessment with ramipril and rosiglitazone Medication (DREAM) trial (2010) (20)
Effects of tissue-type plasminogen activator and anisoylated plasminogen streptokinase activator complex on mortality in acute myocardial infarction. (1990) (20)
Analyses by the Intention‐to‐Treat Principle in Randomized Trials and Databases (1991) (20)
Oral anticoagulant therapy in patients with coronary artery disease. (2003) (19)
Availability and affordability of medicines and cardiovascular outcomes in 21 high-income, middle-income and low-income countries (2020) (19)
Cardiac mechanics during development of heart failure. SOLVD Investigators. (1993) (19)
Combination therapy to prevent cardiovascular disease: slow progress. (2013) (19)
Contrasting Associations Between Diabetes and Cardiovascular Mortality Rates in Low-, Middle-, and High-Income Countries: Cohort Study Data From 143,567 Individuals in 21 Countries in the PURE Study (2020) (19)
Genetic Information and the Prediction of Incident Type 2 Diabetes in a High-Risk Multiethnic Population (2013) (19)
Clinical characteristics and outcomes of patients with angina and heart failure in the CHARM (Candesartan in Heart Failure Assessment of Reduction in Mortality and Morbidity) Programme (2015) (19)
Double blind placebo controlled trial of short term transdermal scopolamine on heart rate variability in patients with chronic heart failure. (1996) (19)
ACE and Type 2 Diabetes Risk: A Mendelian Randomization Study (2020) (19)
Methylprednisolone Does Not Reduce Persistent Pain after Cardiac Surgery (2015) (19)
Saturated Fats and Health: AReassessment and Proposal for Food-Based Recommendations (2020) (19)
Albuminuria and rapid loss of GFR and risk of new hip and pelvic fractures. (2013) (18)
The spectrum of the dyslipidemia in Colombia: The PURE study. (2019) (18)
Long-term evaluation of dabigatran 150 vs. 110 mg twice a day in patients with non-valvular atrial fibrillation. (2016) (18)
Management of stable angina (2009) (18)
Why do people not take life-saving medications? The case of statins (2016) (18)
Physical activity levels, sport activities and risk of acute myocardial infarction: results of the INTERHEART study in China (2013) (18)
Should angiotensin-converting enzyme-inhibitors be used to improve outcome in patients with coronary artery disease and 'preserved' left ventricular function? (2006) (18)
Clinical research and trials in developing countries (2002) (18)
Verapamil following uncomplicated myocardial infarction: promising, but not proven. (1996) (18)
Documenting the global burden of cardiovascular disease: a major achievement but still a work in progress. (2014) (18)
Management and Outcomes of Major Bleeding On Dabigatran or Warfarin (2012) (18)
Should Patients With Cardiovascular Risk Factors Receive Intensive Treatment of Hypertension to <120/80 mm Hg Target? An Antagonist View From the HOPE-3 Trial (Heart Outcomes Evaluation-3). (2016) (18)
Effects of the angiotensin receptor blocker, telmisartan, on cardiovascular events in high-risk patients intolerant to ACE-inhibitors. Erratum of Vol 372(9644):1174-83 (2008) (18)
Randomized trial of fondaparinux versus heparin to prevent graft failure after coronary artery bypass grafting: the Fonda CABG study (2011) (18)
Advances in antithrombotic drug therapy for coronary artery disease. (1995) (18)
Evidence Relating Sodium Intake to Blood Pressure and CVD (2014) (18)
Metabolic Syndrome and Risk of Acute Myocardial Infarction (17)
Coronary artery disease in South Asians. Second meeting of the International Working Group. 16 March 1997, Anaheim, California. (1998) (17)
Blood HER2 and Uromodulin as Causal Mediators of CKD. (2018) (17)
Interrelation between donor and recipient heart rates during exercise after heterotopic cardiac transplantation. (1985) (17)
The cost implications of off-pump versus on-pump coronary artery bypass graft surgery at one year. (2014) (17)
Iatrogenic Adverse Events in the Coronary Care Unit (2009) (17)
Fondaparinux with UnfracTionated heparin dUring Revascularization in Acute coronary syndromes (FUTURA/OASIS 8): a randomized trial of intravenous unfractionated heparin during percutaneous coronary intervention in patients with non-ST-segment elevation acute coronary syndromes initially treated with (2010) (17)
Congestive heart failure complicating non-ST segment elevation acute coronary syndrome: incidence, predictors, and clinical outcomes. (2005) (17)
Cardiovascular outcomes, bleeding risk, and achieved blood pressure in patients on long-term anticoagulation with the thrombin antagonist dabigatran or warfarin: data from the RE-LY trial. (2020) (17)
The Effect of Chromosome 9 p 21 Variants on Cardiovascular Disease May Be Modified by Dietary Intake : Evidence from a Case / Control and a Prospective Study (2011) (17)
The HOPE study and diabetes (2000) (17)
Effect of acute angiotensin converting enzyme inhibition on left ventricular diastolic filling in patients with congestive heart failure: Relation to right ventricular volume (1990) (17)
Underuse of evidence-based warfarin dosing methods for atrial fibrillation patients. (2010) (17)
Digoxin and clinical outcomes in the Global Rheumatic Heart Disease Registry (2018) (17)
Hypertension and Diabetes: Entry Points for Prevention and Control of the Global Cardiovascular Epidemic (2013) (17)
Efficacy and safety of angiotensin receptor blockade are not modified by aspirin in patients with chronic heart failure: a cohort study from the Candesartan in Heart failure – Assessment of Reduction in Mortality and morbidity (CHARM) programme (2010) (17)
Effects of ACE Inhibitors on Mortality When Started in the Early Phase of Myocardial Infarction: Evidence from the Larger Randomized Controlled Trials (1995) (16)
Effects of Off-Pump and On-Pump Coronary-Artery Bypass Grafting at 1 Year (2014) (16)
Heart rate and blood pressure interactions in the development of erectile dysfunction in high-risk cardiovascular patients (2014) (16)
From ACE Inhibitors/ARBs to ARNIs in Coronary Artery Disease and Heart Failure (Part 2/5). (2019) (16)
The use of dabigatran according to body mass index : the RE-LY experience (2014) (16)
The association of grip strength with cardiovascular diseases and all-cause mortality in people with hypertension: Findings from the Prospective Urban Rural Epidemiology China Study (2020) (16)
Influence of socioeconomic status on acute myocardial infarction in the Chinese population: the INTERHEART China study. (2012) (16)
Secretory Phospholipase A2-IIA and Cardiovascular Disease A Mendelian Randomization Study (2017) (16)
Cardiovascular risk factor reduction by community health workers in rural India: A cluster randomized trial. (2019) (16)
Rationale and design of a large study to evaluate the renal and cardiovascular effects of an ACE inhibitor and vitamin E in high-risk patients with diabetes. The MICRO-HOPE Study. Microalbuminuria, cardiovascular, and renal outcomes. Heart Outcomes Prevention Evaluation. (1996) (16)
Efficacy and safety of fondaparinux in patients with ST-segment elevation myocardial infarction across the age spectrum. Results from the Organization for the Assessment of Strategies for Ischemic Syndromes 6 (OASIS-6) trial. (2010) (16)
Association of psychological risk factors and acute myocardial infarction in China: the INTER-HEART China study. (2011) (16)
Development, Testing, and Implementation of a Training Curriculum for Nonphysician Health Workers to Reduce Cardiovascular Disease (2018) (16)
Impact of a Genetic Risk Score on Myocardial Infarction Risk Across Different Ethnic Populations. (2016) (16)
Heart rate and ectopic prematurity in relation to sustained ventricular arrhythmias. (1980) (16)
Telomere Length and Risk of Myocardial Infarction in a MultiEthnic Population: The INTERHEART Study. (2016) (15)
Asians and Non-Asians With Atrial Fibrillation Dabigatran Versus Warfarin : Effects on Ischemic and Hemorrhagic Strokes and Bleeding (2013) (15)
Increased cardiovascular risk after pre‐eclampsia in women with dysglycaemia (2013) (15)
Dabigatran vs. warfarin in relation to the presence of left ventricular hypertrophy in patients with atrial fibrillation— the Randomized Evaluation of Long-term anticoagulation therapY (RE-LY) study (2017) (15)
Effect of methylprednisolone on acute kidney injury in patients undergoing cardiac surgery with a cardiopulmonary bypass pump: a randomized controlled trial (2019) (15)
Reviparin in Acute Myocardial Infarction—Reply (2005) (15)
Low resting heart rates are associated with new‐onset atrial fibrillation in patients with vascular disease: results of the ONTARGET/TRANSCEND studies (2015) (15)
Urate levels as a predictor of cardiac deaths: causal relation or mere association? (2002) (15)
Does greater individual social capital improve the management of hypertension? Cross-national analysis of 61 229 individuals in 21 countries (2017) (15)
DABIGATRAN VERSUS WARFARIN IN ATRIAL FIBRILLATION PATIENTS WITH LOW, MODERATE AND HIGH CHADS2 SCORE: A RE-LY SUBGROUP ANALYSIS (2010) (15)
Screening of Multiple Biomarkers Associated With Ischemic Stroke in Atrial Fibrillation (2020) (15)
Myocardial Infarction in Heart Failure With Preserved Ejection Fraction: Pooled Analysis of 3 Clinical Trials. (2020) (15)
The SPRINT and the HOPE-3 Trial in the Context of Other Blood Pressure-Lowering Trials. (2016) (15)
The population risks of dietary salt excess are exaggerated. (2014) (15)
Coronary Artery Bypass Grafting Surgery Off- or On-pump Revascularisation Study (CORONARY): kidney substudy analytic protocol of an international randomised controlled trial (2012) (15)
Acute coronary syndromes without ST segment elevation (2007) (14)
Reducing Cardiovascular Disease Globally: The World Heart Federation's Roadmaps. (2015) (14)
Effects of Telmisartan on Glucose Levels in People at HighRisk for Cardiovascular Disease but Free FromDiabetes The TRANSCEND study (2011) (14)
Modification of Outcomes With Aspirin or Apixaban in Relation to Female and Male Sex in Patients With Atrial Fibrillation: A Secondary Analysis of the AVERROES Study (2014) (14)
“Cerebral small vessel disease and other influential factors of cognitive impairment in the middle-aged: a long-term observational cohort PURE-MIND study in Poland” (2020) (14)
Is the superiority of apoB over non-HDL-C as a marker of cardiovascular risk in the INTERHEART study due to confounding by related variables? (2013) (14)
EFFECT OF ATENOLOL ON RECOVERY OF THE ELECTROCARDIOGRAPHIC SIGNS OF MYOCARDIAL INFARCTION (1979) (14)
Evidence based cardiology (2002) (14)
Impact of telmisartan on cardiovascular outcome in hypertensive patients at high risk: a Telmisartan Randomised AssessmeNt Study in ACE iNtolerant subjects with cardiovascular Disease subanalysis (2014) (14)
Dietary Sodium and Cardiovascular Disease Risk. (2016) (14)
Characteristics and outcomes of atrial fibrillation in patients without traditional risk factors: an RE-LY AF registry analysis. (2018) (14)
Issues regarding the use of heparin following streptokinase therapy (2005) (13)
Prognostic usefulness of left ventricular hypertrophy by electrocardiography in patients with atrial fibrillation (from the Randomized Evaluation of Long-Term Anticoagulant Therapy Study). (2014) (13)
Effect of betablockade on dynamic exercise in human heart transplant recipients. (1985) (13)
Effect of Insulin Glargine and n-3 FA on Carotid Intima-Media Thickness in PeopleWithDysglycemiaatHighRiskfor Cardiovascular Events The Glucose Reduction and Atherosclerosis Continuing Evaluation Study ( ORIGIN-GRACE ) (2013) (13)
Randomized controlled trial of exercise training in patients with congestive heart failure (EXERT) (1998) (13)
Mendelian Genes and Risk of Intracerebral Hemorrhage and Small-Vessel Ischemic Stroke in Sporadic Cases (2017) (13)
Steroids In caRdiac Surgery (SIRS) trial: acute kidney injury substudy protocol of an international randomised controlled trial (2014) (13)
Self-Reported Prevalence of Chronic Non-Communicable Diseases in Relation to Socioeconomic and Educational Factors in Colombia: A Community-Based Study in 11 Departments (2020) (13)
When it comes to trials, do we get what we pay for? (2013) (13)
Piloting a Novel Algorithm for Glucose Control in the Coronary Care Unit (2011) (13)
Effects of enalapril, candesartan or both on neurohumoral activation and LV volumes and function in patients with heart failure not treated with a beta-blocker (2009) (13)
BRCA2 Variants and cardiovascular disease in a multi-ethnic study (2012) (13)
Genetic variation in hyaluronan metabolism loci is associated with plasma plasminogen activator inhibitor-1 concentration. (2010) (13)
The role of digitalis in the treatment of heart failure. (1999) (12)
Publisher Correction: Multiancestry genome-wide association study of 520,000 subjects identifies 32 loci associated with stroke and stroke subtypes (2019) (12)
An Overview of the Clinical Trials of Agents (Other than β‐Blockers) That Potentially Limit Myocardial Infarct Size (1988) (12)
Factors of importance for QRS complex recovery after acute myocardial infarction. (2009) (12)
Effectiveness and outcome of management strategies for dabigatran- or warfarin-related major bleeding events. (2016) (12)
Dabigatran efficacy‐safety assessment for stroke prevention in patients with atrial fibrillation (2012) (12)
Measuring Sodium Intake in Populations: Simple Is Best? (2015) (12)
The cardiac MRI substudy to ongoing telmisartan alone and in combination with ramipril global endpoint trial/telmisartan randomized assessment study in ACE-intolerant subjects with cardiovascular disease: analysis protocol and baseline characteristics (2009) (12)
Efficacy and safety of rivaroxaban plus aspirin in women and men with chronic coronary or peripheral artery disease. (2020) (12)
What information should a sponsor of a randomized trial receive during its conduct? (2011) (12)
Overestimation of Stroke Risk in Rheumatic Mitral Stenosis and the Implications for Oral Anticoagulation. (2020) (12)
Dabigatran etexilate and reduction in serum apolipoprotein B (2015) (12)
Grading of Recommendations and Levels of Evidence Used in Evidence-based Cardiology (2002) (12)
Cardiac Biomarkers and Left Ventricular Hypertrophy in Relation to Outcomes in Patients With Atrial Fibrillation: Experiences From the RE‐LY Trial (2019) (12)
Role of Magnesium in Reducing Mortality in Acute Myocardial Infarction (1993) (12)
The Fluid Study Protocol: A Randomized Controlled Study on the Effects of Bioimpedance Analysis and Vitamin D on Left Ventricular Mass in Peritoneal Dialysis Patients (2011) (12)
A multinational registry to study the characteristics and outcomes of heart failure patients: The global congestive heart failure (G-CHF) registry. (2020) (12)
[Mortality of acute myocardial infarction]. (1990) (12)
Global cardiovascular research training for implementation science, health systems research, and health policy research. (2015) (12)
Deciphering the causes of cardiovascular and other complex diseases in populations: achievements, challenges, opportunities, and approaches. (2010) (11)
Effect of drug therapy on survival in chronic heart failure. (1986) (11)
Rationale, design, and baseline participant characteristics in the MRI and cognitive substudy of the cardiovascular outcomes for people using anticoagulation strategies trial (2018) (11)
Transforming the scientific, health care, and sociopolitical culture of an entire country through clinical research: the story of GISSI. (2004) (11)
Current and ongoing randomized trials in heart failure and left ventricular dysfunction. (1993) (11)
Determining optimal population rates of cardiac catheterization: A phantom alternative? (2005) (11)
Abstract 2654: Major Bleeding in Patients with Acute Coronary Syndrome Undergoing Early Invasive Management Can Be Reduced by Fondaparinux, Even in the Context of Trans-Radial Coronary Intervention: Insights from OASIS-5 Trial (2006) (11)
One-year Results of a Factorial Randomized Trial of Aspirin versus Placebo and Clonidine versus Placebo in Patients Having Noncardiac Surgery (2020) (11)
What is the economic value of digoxin therapy in congestive heart failure patients? Results from the DIG trial. (2006) (11)
Variation at the DPP4 locus influences apolipoprotein B levels in South Asians and exhibits heterogeneity in Europeans related to BMI (2014) (11)
Should treatment for heart failure with preserved ejection fraction differ from that for heart failure with reduced ejection fraction? (2010) (11)
Response to letters regarding article, “Periprocedural bleeding and thromboembolic events with dabigatran compared with warfarin: results from the Randomized Evaluation of Long-Term Anticoagulation Therapy (RE-LY) Randomized Trial”. (2013) (11)
Are large simple trials for dementia prevention possible? (2019) (11)
The Effect of Steroids in Patients Undergoing Cardiopulmonary Bypass: An Individual Patient Meta-Analysis of Two Randomized Trials. (2019) (11)
Double‐Dose Versus Standard‐Dose Clopidogrel According to Smoking Status Among Patients With Acute Coronary Syndromes Undergoing Percutaneous Coronary Intervention (2017) (11)
Using multimarker screening to identify biomarkers associated with cardiovascular death in patients with atrial fibrillation (2021) (11)
Physical Activity Levels, Sport Activities, and Risk of Acute Myocardial Infarction (2014) (11)
Reducing Premature Cardiovascular Mortality By 2025: The World Heart Federation Roadmap. (2015) (11)
Role of angiotensin converting enzyme inhibitors in patients with left ventricular dysfunction and congestive heart failure. (1994) (11)
Serial measurement of interleukin‐6 and risk of mortality in anticoagulated patients with atrial fibrillation: Insights from ARISTOTLE and RE‐LY trials (2020) (11)
Preserved left ventricular function during supine exercise in patients after orthotopic cardiac transplantation. (1992) (11)
Early intravenous beta-blockade in myocardial infarction. (1982) (11)
Stroke and Cardiovascular Diseases: The Need for a Global Approach for Prevention and Drug Development (2007) (11)
The role of comparative effectiveness research in transfusion medicine clinical trials: proceedings of a National Heart, Lung, and Blood Institute workshop (2012) (11)
Air Pollution Health Impacts - The Knowns and Unknowns for Reliable Global Burden Calculations. (2020) (11)
Meta-analysis of individual patient data from trials of long-term ACE-inhibitor treatment after acute myocardial infarction (SAVE, AIRE, and TRACE studies) (1997) (11)
In a Subgroup of High-Risk Asians, Telmisartan Was Non-Inferior to Ramipril and Better Tolerated in the Prevention of Cardiovascular Events (2010) (11)
Canadian Network and Centre for Trials Internationally (CANNeCTIN): a national network for Canadian-led trials in cardiovascular diseases and diabetes mellitus. (2010) (11)
Antiarrhythmics and VPD suppression. (1991) (10)
Multiplex protein screening of biomarkers associated with major bleeding in patients with atrial fibrillation treated with oral anticoagulation (2021) (10)
The use of beta-adrenergic blocking agents, i.v. nitrates and calcium channel blocking agents following acute myocardial infarction. (1988) (10)
Adapting the World Heart Federation Roadmaps at the National Level: Next Steps and Conclusions. (2015) (10)
Corrigendum to “Effectiveness of comprehensive disease management programmes in improving clinical outcomes in heart failure patients. A meta‐analysis” [Eur J Heart Fail 7 (2005) 1133—1144] (2006) (10)
SAFETY AND EFFICACY OF AGGRESSIVE BLOOD PRESSURE LOWERING AMONG PATIENTS WITH DIABETES: SUBGROUP ANALYSES FROM THE ONTARGET TRIAL (2009) (10)
Low-dose rivaroxaban and aspirin among patients with peripheral artery disease: a meta-analysis of the COMPASS and VOYAGER trials. (2021) (10)
How Robust Is the Evidence for Recommending Very Low Salt Intake in Entire Populations? (2016) (10)
Relation of baseline characteristics to suppression of ventricular arrhythmias during placebo and active antiarrhythmic therapy in patients after myocardial infarction. (1989) (10)
Long-term Effects of Statins, Blood Pressure-Lowering, and Both on Erectile Function in Persons at Intermediate Risk for Cardiovascular Disease: A Substudy of the Heart Outcomes Prevention Evaluation-3 (HOPE-3) Randomized Controlled Trial. (2018) (10)
Effect of Cognitive Reserve on the Association of Vascular Brain Injury With Cognition (2021) (10)
Clinical Profiles and Outcomes of Heart Failure in Five African Countries: Results from INTER-CHF Study (2021) (10)
Cardiovascular risk scoring and magnetic resonance imaging detected subclinical cerebrovascular disease (2019) (10)
Cholesterol Lowering in Intermediate-Risk Persons Without Cardiovascular Disease (2016) (10)
Effect of acute angiotensin converting enzyme inhibition on left ventricular filling in patients with congestive heart failure. Relation to right ventricular volumes. (1990) (10)
Association Between Myocardial Injury and Cardiovascular Outcomes of Orthopaedic Surgery: A Vascular Events in Noncardiac Surgery Patients Cohort Evaluation (VISION) Substudy. (2020) (10)
The global problem of cardiovascular disease. (1998) (10)
Challenges to conducting epidemiology research in chronic conflict areas: examples from PURE- Palestine (2017) (10)
Evolving evidence about diet and health. (2018) (10)
Medical treatment, PCI, or CABG for coronary artery disease? (2011) (9)
Neurohumoral variability in left ventricular dysfunction (1995) (9)
Expanding indications for the use of thrombolytic agents in acute myocardial infarction (1990) (9)
Variations between countries in invasive cardiac procedures (1998) (9)
Efficacy and safety of dabigatran compared with warfarin in patients with atrial fibrillation in relation to renal function over time—A RE‐LY trial analysis (2018) (9)
Cost implications of the use of basal insulin glargine in people with early dysglycemia: the ORIGIN trial. (2014) (9)
Maximizing benefits of therapies in acute myocardial infarction. (1993) (9)
Design, results, and interpretation of randomized, controlled trials in congestive heart failure and left ventricular dysfunction (1993) (9)
Clinical Evidence: Emerging approaches in preventing cardiovascular disease. (1999) (9)
Increased insulin and glucose levels in heart failure (HF) (1998) (9)
Aspirin and Extended-Release Dipyridamole vs. Clopidogrel for Recurrent Stroke (2009) (9)
COVID-19 Vaccination Prioritization on the Basis of Cardiovascular Risk Factors and Number Needed to Vaccinate to Prevent Death (2021) (9)
Rationale and design of a cluster randomized trial of a multifaceted intervention in people with hypertension: The Heart Outcomes Prevention and Evaluation 4 (HOPE-4) Study. (2018) (9)
Fine Mapping of the Insulin-Induced Gene 2 Identifies a Variant Associated With LDL Cholesterol and Total Apolipoprotein B Levels (2010) (9)
Clinical decisions. Management of stable coronary disease. (2007) (9)
The prediction of Metabolic Syndrome alterations is improved by combining waist circumference and handgrip strength measurements compared to either alone (2021) (9)
The Data and Safety Monitoring Committee: Some final thoughts. (2001) (9)
Management of dyspepsia symptoms on dabigatran during RELY-ABLE : long-term follow up study after RE-LY (2013) (9)
Abstract 18321: D-dimer is Prognostic for Stroke, Major Bleeding and Death During Anticoagulation of Atrial Fibrillation - a RELY Substudy (2010) (9)
Ten-year results of the randomized control trials of coronary artery bypass graft surgery: tabular data compiled by the collaborative effort of the original trial investigators. Part 2 of 2. (1994) (9)
The effect of treatment on survival in congestive heart failure (1992) (9)
The cost implications of the use of telmisartan or ramipril in patients at high risk for vascular events: the ONTARGET study (2011) (8)
Risk of intracranial hemorrhage with bolus vs. infusion thrombolytic therapy: a meta-analysis (2001) (8)
Can We Eliminate Rheumatic Fever and Premature Deaths From RHD? (2017) (8)
Associations of cardiometabolic outcomes with indices of obesity in children aged 5 years and younger (2019) (8)
Role of infarct size in explaining the higher mortality in older patients with acute myocardial infarction. (2002) (8)
Lowering cholesterol, blood pressure, or both to prevent cardiovascular events: results of 8.7 years of follow-up of Heart Outcomes Evaluation Prevention (HOPE)-3 study participants (2021) (8)
Gene Expression Profiles for the Identification of Prevalent Atrial Fibrillation (2017) (8)
World Heart Federation Emerging Leaders Program: An Innovative Capacity Building Program to Facilitate the 25 × 25 Goal. (2015) (8)
Is therapy of people with chronic kidney disease ONTARGET? (2010) (8)
Effects of Lidocaine on Ventricular Fibrillation, Asystole, and Early Death in Patients with Suspected Acute Myocardial Infarction (1987) (8)
Diabetes, Brain Infarcts, Cognition and Small Vessels in the Canadian Alliance for Healthy Hearts and Minds Study. (2020) (8)
Rivaroxaban Plus Aspirin in Obese and Overweight Patients With Vascular Disease in the COMPASS Trial. (2020) (8)
Antiplatelet therapy in patients with myocardial infarction without obstructive coronary artery disease (2021) (8)
Impact of ramipril on the circadian periodicity of acute myocardial infarction. (2006) (8)
Primary angioplasty for ST-segment elevation myocardial infarction: ready for prime time? (2003) (8)
The Indian Polycap Study (TIPS) – Authors' reply (2009) (8)
Abstract 1134: Plasma Renin Activity is Associated With Increased Cardiovascular Events and Mortality in the HOPE Study (2009) (8)
A Risk Assessment Tool Incorporating New Biomarkers for Cardiovascular Events in Acute Coronary Syndromes: The Organization to Assess Strategies in Ischemic Syndromes (OASIS) Risk Score. (2016) (8)
Management of myocardial infarction: looking beyond efficacy. (2000) (8)
Factors influencing exercise performance in patients with left ventricular dysfunction. SOLVD Investigators. Studies of Left Ventricular Dysfunction. (1998) (8)
Randomized Comparison of the Effects of Two Doses of Dabigatran Etexilate on Clinical Outcomes Over 4.3 Years : Results of the Rely-Able Double-Blind Randomized Trial (2012) (8)
The Effects of Steroids on Coagulation Dysfunction Induced by Cardiopulmonary Bypass: A Steroids in Cardiac Surgery (SIRS) Trial Substudy. (2017) (8)
Reduced Cognitive Assessment Scores Among Individuals With Magnetic Resonance Imaging–Detected Vascular Brain Injury (2020) (8)
Quantitating loss of life by smoking a single cigarette (2007) (8)
Effects of Vitamin E on Cardiovascular and Microvascular Outcomes in High-Risk Patients With Diabetes (2002) (8)
Effect of angiotensin-converting enzyme inhibitors in left ventricular dysfunction: results of the studies of left ventricular dysfunction in the context of other similar trials. (1993) (8)
The role of the data coordinating center in the DIG trial. (2003) (8)
Metabolic effects of telmisartan in subjects with abdominal obesity: A prospective randomized controlled trial (2014) (8)
Pain relief in acute myocardial infarction by intravenous atenolol (1981) (8)
Varying Effects of Body Mass Index and Mortality in Different Risk Groups. (2018) (8)
FOLFOXIRI and Bevacizumab for Metastatic Colorectal Cancer (2015) (8)
IV NITROGLYCERIN (NG) AND NITROPRUSSIDE (NP) THERAPY IN ACUTE MYOCARDIAL-INFARCTION REDUCES MORTALITY - EVIDENCE FROM RANDOMIZED CONTROLLED TRIALS (RCTS) (1985) (8)
Associations of household solid fuel for heating and cooking with hypertension in Chinese adults. (2020) (7)
Phase I Results of the Randomized Evaluation of Left Ventricular Dysfunction (RESOLVD) Trial (1998) (7)
A letter from CMAJ's editorial board to the CMA. (2002) (7)
Could patents interfere with the development of a cardiovascular polypill? (2016) (7)
HEPARIN IN THE PRESENCE OR ABSENCE OF ANTIPLATELET THERAPY - AN OVERVIEW OF RANDOMIZED TRIALS IN ACUTE MYOCARDIAL-INFARCTION (1992) (7)
Reduced mortality and morbidity with the use of angiotensin-converting enzyme inhibitors in patients with left ventricular dysfunction and congestive heart failure. (1993) (7)
Rivaroxaban for Prevention of Covert Brain Infarcts and Cognitive Decline (2020) (7)
The cost implications of an early versus delayed invasive strategy in acute coronary syndromes: the TIMACS study (2014) (7)
The perilous state of independent randomized clinical trials and related applied research in Canada (2012) (7)
Extreme sodium reductions for the entire population: zealotry or evidence based? (2013) (7)
Abstract 9174: Global Variation in the Etiology and Management of Atrial Fibrillation: Results from a Global Atrial Fibrillation Registry (2011) (7)
Risk factors for stroke in Tanzania. (2013) (7)
Influence of Tea Consumption on Acute Myocardial Infarction in China Population (2015) (7)
Erratum: Food Consumption and its Impact on Cardiovascular Disease: Importance of Solutions Focused on the Globalized Food System: A Report From the Workshop Convened by the World Heart Federation (J Am Coll Cardiol (2015) 66 (1590-1614)) (2015) (7)
Abstract 3294: Fondaparinux versus Control (Placebo or Unfractionated Heparin) as an Adjunct to Thrombolytic Therapy in Acute Myocardial Infarction: an OASIS 6 Substudy (2006) (7)
Identification of Novel Causal Blood Biomarkers Linking Metabolically Favorable Adiposity With Type 2 Diabetes Risk (2019) (7)
HEART FAILURE IN THE 1991S : EVOLUTION OF A MAJOR PUBLIC HEALTH PROBLEM INCARDIOVASCULAR MEDICINE (1993) (7)
The gap between reliable evidence and adoption of therapies. (1999) (7)
The impact of left ventricular dysfunction on outcomes with the implantable defibrillator. (1994) (7)
Clinical experience in protecting the failing heart (1993) (7)
Perioperative myocardial reinfarction: a glimmer of hope--a note of caution. (1983) (7)
ACE inhibitors for myocardial infarction and unstable angina (1993) (7)
Unresolved issues in the management of hypertension. (2010) (7)
The cost of clopidogrel use in atrial fibrillation in the ACTIVE-A trial. (2012) (7)
Efficacy and Safety of Dabigatran Compared with Warfarin in Relation to Baseline Renal Function in Patients with Atrial Fibrillation: A RE-LY Trial Analysis (2013) (7)
Commentary: Accepting what we don't know will lead to progress. (2016) (7)
Abstract 15537: Dabigatran Versus Warfarin in Very Elderly Patients with Atrial Fibrillation: Results from the RE-LY Trial (2012) (7)
Polypill Variants (Quarter Pill Trials) (2018) (7)
Identification of genetic effects underlying type 2 diabetes in South Asian and European populations (2022) (7)
Insulin resistance and cardiovascular outcomes in the ORIGIN trial (2018) (6)
Incremental cost-effectiveness of early and long-term clopidogrel in patients undergoing percutaneous coronary infarction in the CURE trial: The PCI-CURE economic analysis (2003) (6)
1137-77 Long-term cost-effectiveness of clopidogrel in patients having percutaneous coronary intervention early after acute coronary syndrome: Results from PCI-CURE (2004) (6)
Rivaroxaban and aspirin vs. aspirin alone in Asian compared with non-Asian patients with chronic coronary artery disease or peripheral arterial disease: the COMPASS trial. (2022) (6)
Visit-to-visit blood pressure variability and renal outcomes: results from ONTARGET and TRANSCEND trials. (2020) (6)
PP.29.11: EDUCATIONAL LEVEL INFLUENCE IN THE PREVALENCE, AWARENESS, TREATMENT AND CONTROL OF HYPERTENSION IN COLOMBIA (2015) (6)
Impact of access to hospitals with catheterization facilities in the second Gulf Registry of Acute Coronary Events (Gulf RACE-2) (2013) (6)
Association of the FABP2 T54 variant with plasma triglycerides and insulin resistance in a multiethnic population. (2008) (6)
Intracranial haemorrhage with bolus thrombolytic agents (2000) (6)
Effective approaches to address the global cardiovascular disease burden (2017) (6)
Erratum: Reducing Premature Cardiovascular Morbidity and Mortality in People with Atherosclerotic Vascular Disease: The World Heart Federation Roadmap for Secondary Prevention of Cardiovascular Disease (Glob Heart (2015)10 (99-110)) (2015) (6)
Dysglycemia and Cognitive Dysfunction and Ill Health in People With High CV Risk: Results From the ONTARGET/TRANSCEND Studies. (2015) (6)
Association of bedtime with mortality and major cardiovascular events: an analysis of 112,198 individuals from 21 countries in the PURE study. (2021) (6)
Effects of n-3 fatty acids on long-term outcomes of high risk patients with type 2 diabetes mellitus or IGF/IGT with a recent myocardial infarction (2013) (6)
Anger or emotional upset and heavy physical exertion as triggers of stroke: the INTERSTROKE study. (2021) (6)
Diet and health: the need for new and reliable approaches. (2020) (6)
Associations of estimated 24-h urinary sodium excretion with mortality and cardiovascular events in Chinese adults: a prospective cohort study (2020) (6)
Graphical comparisons of relative disease burden across multiple risk factors (2019) (6)
Impact of blood pressure lowering, cholesterol lowering and their combination in Asians and non-Asians in those without cardiovascular disease: an analysis of the HOPE 3 study (2018) (6)
New‐Onset Perioperative Atrial Fibrillation After Coronary Artery Bypass Grafting and Long‐Term Risk of Adverse Events: An Analysis From the CORONARY Trial (2021) (6)
Sodium and health: another challenge to the current dogma. (2021) (6)
Physical Activity to Prevent Cardiovascular Disease: A Simple, Low-Cost, and Widely Applicable Approach for All Populations. (2017) (6)
Impact of lifestyle factors on fracture risk in older patients with cardiovascular disease: a prospective cohort study of 26,335 individuals from 40 countries. (2014) (6)
810-1 Impact of the angiotensin-receptor blocker candesartan in preventing diabetes in patients with heart failure (2004) (6)
Low sodium intake and cardiovascular health: an unanswered question. Response to: Letter from Dr N. Campbell, 'Dissidents and dietary sodium. Concerns about the commentary by O'Donnell et al.' (2016) (6)
Overview of the DIG trial. (2003) (6)
2387Recurrent cardiovascular events and mortality in relation to antiplatelet therapy in patients with myocardial infarction without obstructive coronary artery disease (MINOCA) (2019) (6)
Correction to the PRoFESS Trial Paper by Diener et al. (Cerebrovasc Dis 2007;23:368–380) (2008) (6)
REDUCTION IN INFARCT SIZE, MORBIDITY AND SHORT-TERM MORTALITY BY EARLY INTRAVENOUS BETABLOCKADE (1983) (6)
Long-term management of unstable angina and non-Q-wave myocardial infarction (2000) (6)
The likelihood ratio versus the p value in meta-analysis: where is the evidence? Comment on the paper by S. N. Goodman. (1989) (6)
Beta adrenergic blockade in myocardial infarction (1980) (6)
ATENOLOL, HEPARIN AND THE INTERMEDIATE CORONARY SYNDROME (1981) (6)
Urinary Sodium and Potassium, and Risk of Ischemic and Hemorrhagic Stroke (INTERSTROKE): A Case–Control Study (2020) (6)
From journal to bedside: application of clinical trial results to individual patients. (1997) (6)
Cardiovascular Outcomes According to Polypharmacy and Drug Adherence in Patients with Atrial Fibrillation on Long-Term Anticoagulation (from the RE-LY Trial). (2021) (5)
Corrigendum to ‘Analysing recurrent hospitalizations in heart failure: a review of statistical methodology, with application to CHARM‐Preserved’ [Eur J Heart Fail 2014;16:33–40] (2014) (5)
Population Muscle Strength Predicts Olympic Medal Tallies: Evidence from 20 Countries in the PURE Prospective Cohort Study (2017) (5)
Reasons for hospitalization and risk of mortality in patients with atrial fibrillation treated with dabigatran or warfarin in the Randomized Evaluation of Long-term Anticoagulation Therapy (RE-LY) trial. (2019) (5)
INTERHEART. Authors' reply (2005) (5)
Effect of Ramipril and Vitamin E on Atherosclerosis (2001) (5)
NARROWED CORONARY ARTERIES, HALOTHANE, AND PARADOX (1979) (5)
Preload reserve a determinant of clinical status in patients with left ventricular systolic dysfunction (1991) (5)
The epidemic of cardiovascular disease in South Asians: Time for action (2017) (5)
Antihypertensives and Statin Therapy for Primary Stroke Prevention: A Secondary Analysis of the HOPE-3 Trial (2021) (5)
DABIGATRAN ETEXILATE VERSUS WARFARIN IN PATIENTS WITH DIFFERENT TYPES OF ATRIAL FIBRILLATION: A RE-LY® SUBGROUP ANALYSIS (2011) (5)
INTRAVENOUS STREPTOKINASE FOR ACUTE MYOCARDIAL-INFARCTION - REPLY (1983) (5)
Risk stratification of cardiovascular complications using CHA2DS2-VASc and CHADS2 scores in chronic atherosclerotic cardiovascular disease. (2021) (5)
Renal Impairment and Risk of Acute Stroke: The INTERSTROKE Study (2021) (5)
Obtaining Reliable Information from Randomized Controlled Trials in Congestive Heart Failure and Left Ventricular Dysfunction (1990) (5)
Rosuvastatin for the prevention of venous thromboembolism: a pooled analysis of the HOPE-3 and JUPITER randomized controlled trials. (2021) (5)
Measuring sodium intake: research and clinical applications (2021) (5)
4 – Hypertension in South Asians (2018) (5)
Abstract 12862: Predictors of Hospitalization and Effects of Dabigatran and Warfarin on Hospitalization Rates: An Analysis From The Re-ly Trial (2015) (5)
Impact of Revascularization Procedures in Chronic Coronary Artery Disease on Clinical Outcomes: A Critical Review of the Evidence (2007) (5)
The Use of Beta-Blockers in the Acute Phase of Myocardial Infarction (1985) (5)
PHYSICAL ACTIVITY AND ITS RELATIONSHIP WITH OBESITY HYPERTENSION AND DIABETES IN URBAN AND RURAL CHINA: THE PURE CHINA STUDY (2013) (5)
The Public Health and Clinical Implications of the National Increase in Congestive Heart Failure (1987) (5)
DABIGATRAN VERSUS WARFARIN AND IMPACT OF CHAD2-VASC SCORE ON OUTCOME IN ATRIAL FIBRILLATION PATIENTS: A RE-LY SUBGROUP ANALYSIS (2011) (5)
Household Air Pollution and Cardiovascular Disease Risk: Results from the Prospective Urban and Rural Epidemiological Study (2016) (5)
Evidence-Based Cardiology: Yusuf/Evidence-Based Cardiology (2009) (5)
Efficacy and Safety of Dabigatran Versus Warfarin in Patients with Atrial Fibrillation : Analysis in Asian Population in RE-LY Trial (2012) (5)
Effects of calcium channel blockers on survival after myocardial infarction (1987) (5)
The Anti-Coronavirus Therapies (ACT) Trials: Design, Baseline Characteristics, and Challenges (2022) (4)
Angiotensin II and trials of cardiovascular outcomes. Discussion (2002) (4)
Reduction in Infarct Size, Arrhythmias, Chest Pain and Morbidity by Early Intravenous β-Blockade in Suspected Acute Myocardial Infarction (2012) (4)
The cost implication of primary prevention in the HOPE 3 trial. (2019) (4)
Long-Term Treatment with Apixaban in Patients with Atrial Fibrillation: Outcomes during the Open-Label Extension following AVERROES (2020) (4)
Associations of fats and carbohydrates with cardiovascular disease and mortality—PURE and simple? – Authors' reply (2018) (4)
Prevention of Congestive Heart Failure and Treatment of Asymptomatic Left Ventricular Dysfunction (2007) (4)
on behalf of the RE-LY Atrial Fibrillation Registry Investigators (2014) (4)
Independent design and conduct of clinical trials (2006) (4)
Abstract 12492: Cystatin C is Prognostic for Stroke, Death and Bleeding in Atrial Fibrillation - A RELY Substudy (2011) (4)
Major Adverse Limb Events in Lower Extremity Peripheral Artery Disease: COMPASS Trial (2018) (4)
Response to letter regarding article, "Causes of death and influencing factors in patients with atrial fibrillation: a competing-risk analysis from the randomized evaluation of long-term anticoagulant therapy study". (2014) (4)
Colchicine and the combination of rivaroxaban and aspirin in patients hospitalised with COVID-19 (ACT): an open-label, factorial, randomised, controlled trial (2022) (4)
Rationale and design of the PeriOperative ISchemic Evaluation-3 (POISE-3): a randomized controlled trial evaluating tranexamic acid and a strategy to minimize hypotension in noncardiac surgery (2022) (4)
LBOS 03-01 PREVALENCE, AWARENESS, TREATMENT, AND CONTROL OF HYPERTENSION IN THE MIDDLE EAST: RESULTS FROM THE PROSPECTIVE URBAN RURAL EPIDEMIOLOGY (PURE) STUDY (2016) (4)
Congestive Heart Failure Reliability , validity , and responsiveness of the six-minute walk test in patients with heart failure (2001) (4)
Low levels of awareness, treatment, and control of hypertension in Andean communities of Ecuador (2020) (4)
Canadian-led capacity-building in biostatistics and methodology in cardiovascular and diabetes trials: the CANNeCTIN Biostatistics and Methodological Innovation Working Group (2011) (4)
Prevalence of metabolic syndrome and diabetes mellitus type-2 and their association with intake of dairy and legume in Andean communities of Ecuador (2021) (4)
Candesartan in Heart Failure - Assessment of Reduction in Mortality and Morbidity (CHARM) Study Programme (2000) (4)
Abstract 14808: Importance of Persistent Elevation of Cardiac Biomarkers in Atrial Fibrillation - A RELY Substudy (2012) (4)
From journal to bedside: quantifying the benefits of treatment. (1997) (4)
Ramipril prevents major cardiovascular events in high-risk women: results of the HOPE trial (2002) (4)
Reply: regarding the effect of dabigatran plasma concentrations. (2014) (4)
Monitoring Emerging Data From the COMPASS Trial of an Antithrombotic Agent. (2019) (4)
Stroke risk prediction in patients with atrial fibrillation with and without rheumatic heart disease. (2021) (4)
Influenza vaccine to reduce adverse vascular events in patients with heart failure: a multinational randomised, double-blind, placebo-controlled trial. (2022) (4)
Low-dose rivaroxaban plus aspirin in patients with polypharmacy and multimorbidity: an analysis from the COMPASS trial. (2021) (4)
Enhancing risk prediction with PET coronary flow reserve: can it be clinically useful? (2012) (4)
Case of the PONS study. (2011) (4)
835-5 Candesartan improves functional class across a broad spectrum of patients with chronic heart failure: Results of the candesartan in heart failure-assessment of reduction in mortality and morbidity programme (CHARM) (2004) (4)
Commentary: 'The end of clinical freedom': relevance in the era of evidence-based medicine. (2011) (4)
Recent advances and future directions in myocardial infarction. (1994) (4)
Sodium and cardiovascular disease – Authors' reply (2016) (4)
Glucose-insulin-potassium infusion in acute myocardial infarction. (1983) (3)
Renal outcomes and blood pressure patterns in diabetic and nondiabetic individuals at high cardiovascular risk (2021) (3)
New Trial Data on Prevention: Potassium and CV Risk in Hope (2003) (3)
A 35-year journey to evidence-based medicine: a personal story. (2015) (3)
The CHARM programme (2003) (3)
Clinical outcomes of atrial fibrillation patients receiving NSAIDs in the RE-LY trial (2015) (3)
1069-113 Cause of death across full spectrum of ventricular function in patients with heart failure: The CHARM study (2004) (3)
Randomized trials to assess the long-term effects of therapies on angiographic end points. (1991) (3)
Population attributable fractions for continuously distributed exposures (2020) (3)
LBOS 03-01 PREVALENCE, AWARENESS, TREATMENT, AND CONTROL OF HYPERTENSION IN THE MIDDLE EAST: RESULTS FROM THE PROSPECTIVE URBAN RURAL EPIDEMIOLOGY (PURE) STUDY. (2016) (3)
Response to: 'More on dissidents and dietary sodium'. (2018) (3)
Early intravenous beta-blockade in acute myocardial infarction. (1989) (3)
818b – A Randomized Trial of Proton Pump Inhibitors Versus Placebo to Prevent Upper Gastrointestinal Bleeding in Patients Receiving Rivaroxaban Or Aspirin (2019) (3)
Data Monitoring in the Randomized Evaluation of Strategies for Left Ventricular Dysfunction Pilot Study: When Reasonable People Disagree (2006) (3)
The Indirect Consequences of the Response to the COVID-19 Pandemic∗ (2021) (3)
Effects of aspirin on cardiovascular outcomes in patients with chronic kidney disease. (2022) (3)
Risks of Overinterpreting Interim Data: Lessons From the TOTAL Trial (Thrombectomy With PCI Versus PCI Alone in Patients With STEMI). (2018) (3)
Factors associated with health‐related quality of life in heart failure in 23 000 patients from 40 countries: results of the G‐CHF research programme (2022) (3)
Dual renin-angiotensin system blockade in heart failure. (2009) (3)
The Editor's Roundtable: arterial thrombosis and acute coronary syndromes. (2007) (3)
531 Incidence and predictors of hyperkalemia in patients with heart failure - an analysis of the Candesartan in Heart failure - Assessment of Reduction in Mortality and morbidity (CHARM) program (2006) (3)
BRIEF COMMUNICATION: Does High Inflammatory Diet Increase Risk of Inflammatory Bowel Disease? Results from the Prospective Urban Rural Epidemiology (PURE) study: A Prospective Cohort Study. (2021) (3)
Essay for the CIHR/CMAJ award: impact of the Perioperative Ischemic Evaluation (POISE) trial (2011) (3)
Abstract 13472: NT-proBNP is Prognostic for Stroke and Death in Atrial Fibrillation - a RELY Substudy (2010) (3)
LVS‐HARMED Risk Score for Incident Heart Failure in Patients With Atrial Fibrillation Who Present to the Emergency Department: Data from a World‐Wide Registry (2021) (3)
REDUCTION IN INFARCT SIZE, ARRHYTHMIAS AND MORBIDITY BY EARLY INTRAVENOUS BETA BLOCKADE (1982) (3)
CHANGES IN ALBUMINURIA PREDICT MORTALITY AND MORBIDITY IN PATIENTS WITH VASCULAR DISEASE: PS.3.04 (2010) (3)
Exploring New Models for Cardiovascular Risk Reduction: The Heart Outcomes Prevention and Evaluation 4 (HOPE 4) Canada Pilot Study (2020) (3)
Risk factors for coronary heart disease in Asian Indians (1996) (2)
Efficacy and Safety of Dabigatran Compared With Warfarin in Relation to Baseline Renal Function in Patients With Atrial Fibrillation A RE-LY (Randomized Evaluation of Long-term Anticoagulation Therapy) Trial (2014) (2)
The McMaster-Lancet health and peace conferences (2004) (2)
PARTNERs in the future of surgical aortic valve replacement (2015) (2)
Adiposity and mortality in South Asians: challenges to the existing paradigm. (2018) (2)
Clinical outcomes trials and the cardiovascular effects of thiazolidinediones: implications for the evaluation of antidiabetic drugs. (2010) (2)
Sodium and cardiovascular disease. (2014) (2)
Blood-Pressure and Cholesterol Lowering in the HOPE-3 Trial. (2016) (2)
Access to Essential Medicines for Circulatory Diseases: A Call to Action. (2019) (2)
The Cost Implications of a Polypill for Primary Prevention in the TIPS-3 Trial. (2021) (2)
Obesity and risk of myocardial infarction: the INTERHEART study – Author's reply (2006) (2)
Effects of basal insulin glargine and omega‐3 on lower limb arterial disease outcome in patients with dysglycaemia: An analysis of the Outcome Reduction with an Initial Glargine INtervention (ORIGIN) trial (2019) (2)
Design and implementation of the NHLBI and the VA cooperative studies program collaborative study, “trial to evaluate the effect of digitalis on motality in heart failure” (1992) (2)
1108-109 Low hemoglobin is an independent predictor of adverse fatal and nonfatal outcomes in both reduced and preserved systolic function chronic heart failure: Findings from the candesartan in heart failure assessment of reduction in mortality and morbidity program (CHARM) (2004) (2)
EFFECT OF DABIGATRAN ON SERUM APOLIPOPROTEIN B AND APOLIPOPROTEIN A1 CONCENTRATIONS (2013) (2)
Bundle branch block is associated with worse clinical outcomes in heart failure, especially with reduced systolic function: evidence from the CHARM programme (2005) (2)
(SECURE) Carotid Ultrasound Changes in Patients Treated With Ramipril and Vitamin E Effects of Ramipril and Vitamin E on Atherosclerosis : The Study to Evaluate (2009) (2)
[PP.26.05] BLOOD PRESSURE LOWERING IN INTERMEDIATE RISK PEOPLE WITHOUT VASCULAR DISEASE (2016) (2)
Emerging approaches in the prevention of atherosclerotic cardiovascular diseases. (1998) (2)
Facing cardiovascular risk in Ibero-america. (2020) (2)
CLINICAL OUTCOMES OF ATRIAL FIBRILLATION PATIENTS RECEIVING DIGOXIN IN THE RE-LY® TRIAL (2016) (2)
Abstract 11087: Benefits of Dabigatran versus Warfarin in Hypertensive Patients With Atrial Fibrillation: Results From The Re-ly Trial (2013) (2)
Reply: Anticoagulant-Related Nephropathy. (2015) (2)
Influence of Prior Heart Failure Hospitalization on Cardiovascular Events in Patients with Reduced and Preserved Ejection Fraction Bello et al: Effect of HF Hospitalization on CV Events (2017) (2)
Cholesterol and total mortality (1992) (2)
Abstract 12041: The Risk of Peri-Operative Bleeding with Warfarin Compared to Two Doses of Dabigatran: Results From the RE-LY Trial (2011) (2)
Early Intravenous Atenolol in Suspected Acute Myocardial Infarction: Final Report of a Randomised Clinical Trial (1984) (2)
Geographic Variations in Controlled Trials. (2017) (2)
Long-term Effects of Enalapril On Left-ventricular Diastolic Properties - Evidence for Reversed Remodeling (1992) (2)
Lessons learned from the DIG trial. (2003) (2)
Prognostic Impact of an Ischemic Etiology of Chronic Heart Failure across the Spectrum of Ejection Fractions in the CHARM Program (2012) (2)
Association between exercise frequency with renal and cardiovascular outcomes in diabetic and non-diabetic individuals at high cardiovascular risk (2022) (2)
Response to 'Estimation of sodium excretion should be made as simple as possible, but not simpler: misleading papers and editorial on spot urines'. (2015) (2)
Resting heart rate and decline in cognitive function: observations from the ONTARGET/TRANSCEND studies (2013) (2)
Does treatment with rosiglitazone increase cardiovascular risk of patients with type 2 diabetes mellitus? (2007) (2)
Preface: Reflections on a Career in Health Research, International Collaboration and Mentoring (2011) (2)
What You See is Not Always What You Get: Raising the Bar on Clinical Trial Methodology in Ulcerative Colitis (2013) (2)
Effects of vitamin E on cardiovascular and microvascular outcomes in high-risk diabetic patients (2002) (2)
Aspirin and the Risk of Heart Failure Hospitalization in Patients with Atrial Fibrillation and a Prior History of Heart Failure: An ACTIVE-W Analysis (2006) (2)
Management of unstable angina and myocardial infarction (2000) (2)
Improving worldwide access to inexpensive and effective treatments for common cardiovascular diseases (2018) (2)
Mo1999 How Often Does Major Gastrointestinal Bleeding in Patients Receiving Warfarin or Dabigatran Uncover Cancer? The U.S. Experience From the RELY Trial (2015) (2)
RE-LY and RELY-ABLE : Long-term Follow-up of Patients With Non-valvular Atrial Fibrillation Receiving Dabigatran Etexilate for Up to 6.7 Years (2013) (2)
Strategies for patient recruitment into clinical trials. (1998) (2)
Impact of Bioelectrical Impedance-Guided Fluid Management and Vitamin D Supplementation on Left Ventricular Mass in Patients Receiving Peritoneal Dialysis: A Randomized Controlled Trial. (2021) (2)
Relationship between neurohumoral activation, severity of left ventricular dysfunction (LVD) and clinical status (1991) (2)
SAFETY AND EFFICACY OF LOW BLOOD PRESSURE AMONG PATIENTS WITH DIABETES: SUB-GROUP ANALYSES FROM THE ONTARGET TRIAL: 7E.02 (2011) (2)
Interobserver reliability and validity of the New York Heart Association Functional Classification (NYHA‐FC) in heart failure patients (2000) (2)
Abstract 17352: Incidence and Predictors of Stroke in Patients with Chronic Heart Failure: Does Left Ventricular Function Matter? Insights From the CHARM Program (2011) (2)
Direct thrombin inhibitors in acute coronary syndromes (2002) (2)
Reducing cardiovascular mortality through lifestyle change in Japan. (2012) (2)
Evidence-based cardiovascular medicine: why another journal? (1997) (2)
Abstract 4585: Efficacy and Safety of Clopidogrel in Acute Coronary Syndrome Patients at High Risk of Bleeding: Data from the CURE Trial (2008) (2)
CardioPulse: Prevention of global cardiovascular disease. (2016) (2)
Long-Term Treatment with the Combination of Rivaroxaban and Aspirin in Patients with Chronic Coronary or Peripheral Artery Disease: Outcomes During the Open Label Extension of the COMPASS trial. (2022) (2)
THE CHA2DS2-VASC SCORE IDENTIFIES AF PATIENTS WITH A CHADS2 SCORE OF 0 OR 1 TREATED WITH ANTIPLATELET THERAPY WHO ARE UNLIKELY TO BENEFIT FROM ORAL ANTICOAGULANT THERAPY (2012) (2)
SUBGROUP ANALYSIS OF CLINICAL TRIALS. REPLY (1991) (2)
Mitochondrial DNA Copy Number as a Marker and Mediator of Stroke Prognosis (2021) (2)
5770A novel biomarker-based risk score to predict death in patients with atrial fibrillation: Insights from the ARISTOTLE and RE-LY trials (2017) (2)
Colchicine and aspirin in community patients with COVID-19 (ACT): an open-label, factorial, randomised, controlled trial (2022) (2)
Dyslipoproteinemia in North America: The Lipid Research Clinics Program Prevalence Study. (1986) (2)
BLOOD PRESSURE TARGETS RECOMMENDED BY GUIDELINES AND INCIDENCE OF CARDIOVASCULAR AND RENAL EVENTS IN THE ONTARGET TRIAL: 9A.08 (2011) (2)
Cardiovascular consequences of discontinuing low-dose rivaroxaban in people with chronic coronary or peripheral artery disease (2021) (2)
Effects of Lipid‐Lowering and Antihypertensive Treatments in Addition to Healthy Lifestyles in Primary Prevention: An Analysis of the HOPE‐3 Trial (2018) (2)
Coronary artery bypass grafting versus medical therapy in patients with stable coronary artery disease: An individual patient data pooled meta-analysis of randomized trials. (2022) (2)
Rationale , Design and Baseline Characteristics of Participants in the C ardiovascular O utco m es for P eople Using A nticoagulation S trategie s ( COMPASS ) Trial (2017) (2)
Mortality benefits from U.S. population-wide reduction in sodium consumption: projections from 3 modeling approaches. (2013) (2)
Visit-to-visit blood pressure variability and renal outcomes: results from ONTARGET and TRANSCEND trials. (2020) (2)
Comparison of Investigator-Reported vs Centrally Adjudicated Major Adverse Cardiac Events (2022) (2)
EXTERNAL VALIDATION OF THE BIOMARKER-BASED ABC-BLEEDING RISK SCORE FOR ATRIAL FIBRILLATION (2016) (2)
EFFECTS OF DABIGATRAN VERSUS WARFARIN IN RELATION TO LEFT VENTRICULAR HYPERTROPHY IN ATRIAL FIBRILLATION (2016) (1)
Reply to both letters. (2014) (1)
DYSGLYCAEMIA AND RISK OF CARDIOVASCULAR DISEASE. AUTHORS' REPLY (1996) (1)
WHF Emerging Leaders Program (2017) (1)
With Atrial Fibrillation (RELY-ABLE) Study The Long-Term Multicenter Observational Study of Dabigatran Treatment in Patients (2013) (1)
Effect of PON 1 Q 192 R Genetic Polymorphism on Clopidogrel Efficacy and Cardiovascular Events in the CURE and ACTIVE Trials (2012) (1)
Risk of cardiovascular events in patients with metabolic syndrome: Results of a population-based prospective cohort study (PURE Turkey) (2020) (1)
Intensive insulin-glucose infusion regimens with long-term or standard glucose control did not differ for reducing mortality in type 2 diabetes mellitus and MI. (2005) (1)
Neurohumoral variability in left ventricular dysfunction. SOLVD Investigators. Studies of Left Ventricular Dysfunction. (1995) (1)
Hypertension prevalence but not control varies across the spectrum of risk in patients with atrial fibrillation: A RE-LY atrial fibrillation registry sub-study (2020) (1)
Telmisartan in high-risk patients intolerant of ACE inhibitors – Authors' reply (2009) (1)
Response to letter regarding article, "Cardiac biomarkers are associated with an increased risk of stroke and death in patients with atrial fibrillation: a randomized evaluation of long-term anticoagulation therapy (RE-LY) substudy". (2013) (1)
β-blocker therapy in non-cardiac surgery – Authors' reply (2008) (1)
The INTERSTROKE study on risk factors for stroke – Authors' reply (2017) (1)
Abstract 14433: Balancing the Benefits and Risks of Two Doses of Dabigatran Compared with Warfarin in Atrial Fibrillation (2012) (1)
The secondary prevention of cardiovascular disease (2005) (1)
[PP.11.30] ETHNIC DIFFERENCES IN AWARENESS, TREATMENT AND CONTROL OF HYPERTENSION IN COLOMBIA (2017) (1)
Eggs and diabetes: 1 daily egg a safe bet? (2020) (1)
Urinary sodium excretion measures and health outcomes – Authors' reply (2019) (1)
Recurrent Events and Mortality Among Atrial Fibrillation Patients Treated with Dabigatran or Warfarin in the RE-LY Trial (2013) (1)
Randomized Clinical Trials in Heart Disease-Reply (1989) (1)
Early enalapril therapy reduced cardiovascular morbidity and mortality in patients with left ventricular systolic dysfunction: Results at 15 years in SOLVD (2004) (1)
Discussion: M K B Parmar and David Machin, monitoring clinical trials; Experience of, and proposals under consideration by the Cancer Therapy Committee of the British Medical Research Council (1993) (1)
P47 Randomized controlled trial of aerobic plus resistance exercise training in patients with congestive heart failure (1995) (1)
Statin Use in Primary Prevention: A Simple Trial-Based Approach Compared With Guideline-Recommended Risk Algorithms for Selection of Eligible Patients. (2019) (1)
Rivaroxaban 2.5 mg Twice Daily Plus Aspirin Reduces Venous Thromboembolism in Patients With Chronic Atherosclerosis. (2022) (1)
Rivaroxaban versus aspirin on functional and cognitive outcomes after embolic stroke of undetermined source: NAVIGATE ESUS trial. (2022) (1)
Cardiovascular risk and events and country income stratum. (2015) (1)
Management of unstable coronary-artery disease (2000) (1)
Glycemic Index, Glycemic Load, and Cardiovascular Disease and Mortality. Reply. (2021) (1)
Medications for blood pressure, blood glucose, lipids, and anti-thrombotic medications: relationship with cardiovascular disease and death in adults from 21 high-, middle-, and low-income countries with an elevated body mass index. (2022) (1)
Discussion: Frank W Rockhold and G Enas, data monitoring and interim analyses in the pharmaceutical industry: Ethical and logistical considerations: George W Williams et al, monitoring of clinical trials and interim analyses from a drug sponsor's point of view (1993) (1)
Abstract 844: No Clear Association Between Candidate Gene Variants and Outcomes in 3239 Patients with Chronic Heart Failure: Results from the CHARM Program (2008) (1)
The role of the pharmacy coordinating center in the DIG trial. (2003) (1)
Leaders in Cardiovascular Research: Salim Yusuf. (2020) (1)
Blood pressure and cardiovascular risk in the HOPE study (2002) (1)
Growth differentiation factor 15 is an independent marker of risk of major bleeding in atrial fibrillation : insights from the RE-LY trial (2016) (1)
Clarifying Optimal Sodium InTake In Cardiovasular and Kidney (COSTICK) Diseases: a study protocol for two randomised controlled trials (2021) (1)
Polypharmacotherapy for primary prevention of cardiovascular disease. (2008) (1)
Efficacy and safety of low-dose rivaroxaban on top of aspirin in patients with polypharmacy and multimorbidity: an analysis from the COMPASS trial (2020) (1)
Wealth-related inequalities in the awareness, treatment and control of hypertension in 21 countriesMartin McKee (2016) (1)
stroke Reducing the Global Burden of Cardiovascular Disease , Part 2 Prevention and Treatment of Cardiovascular Disease (2017) (1)
The Role of the Polypill in Hypertension (2012) (1)
63A Utilizing sequential monitoring boundaries for cumulative meta-analysis (1995) (1)
Calibration of Fractionated Metanephrines in Urine: Still an Issue? (2008) (1)
Clarifying Optimal Sodium InTake In Cardiovasular and Kidney (COSTICK) Diseases: a study protocol for two randomised controlled trials. (2021) (1)
Benefit of clopidogrel in patients undergoing percutaneous coronary intervention in the CURE trial receiving and not receiving an intracoronary stent (2003) (1)
Quality of Life and its Determinants in Heart Failure Patients at a Major Tertiary Academic Center in Ontario, Canada (2020) (1)
Which antithrombotic to use during PCI? (2010) (1)
Abstract 6048: An Indirect Comparison of the Efficacy and Safety of Factor Xa Inhibitors with Thrombin Inhibitors nn Preventing Venous Thromboembolism after Hip or Knee Surgery (2008) (1)
CHA2DS2-VASC VERSUS HAS-BLED SCORE FOR PREDICTING RISK OF MAJOR BLEEDING AND ISCHEMIC STROKE IN ATRIAL FIBRILLATION: INSIGHTS FROM RE-LY TRIAL (2016) (1)
Salim Yusuf MD: the physician who wants to improve the world's cardiovascular health. (2015) (1)
URBAN AND RURAL DIFFERENCES OF BLOOD PRESSURE AND HYPERTENSION CONTROL IN CHINESE COMMUNITIES: PURE CHINA STUDY (2013) (1)
Risk Factors for Early Myocardial Infarction in South Asians—Reply (2007) (1)
STROKE RISK PREDICTION IN PATIENTS WITH ATRIAL FIBRILLATION AND RHEUMATIC HEART DISEASE: RESULTS FROM THE RE-LY AF REGISTRY (2019) (1)
Commentary: insights from cross-population studies: Rose revisited. (2005) (1)
Abstract 15542: Impact of Treatment with Apixaban and Aspirin in Patients with Atrial Fibrillation in Relation to the CHADS2 and CHA2DS2-VASc Scores: the AVERROES Study (2011) (1)
Variations in practice patterns and outcomes after stroke across countries at different economic levels: the INTERSTROKE study (2018) (1)
On the economics of managing blood pressure (2017) (1)
Developing the Core Pillars of Training Global Cardiovascular Health Researchers: Companionship, Light, and Fuel. (2019) (1)
Cardiovascular outcomes in patients at high cardiovascular risk with previous myocardial infarction or stroke (2021) (1)
Double-dose clopidogrel in patients undergoing PCI for ACS – Authors' reply (2011) (1)
Letter by Mente et al Regarding Article "Urinary Sodium Excretion, Blood Pressure, and Risk of Future Cardiovascular Disease and Mortality in Subjects Without Prior Cardiovascular Disease". (2019) (1)
Rivaroxaban with or without aspirin for prevention of cardiovascular disease. (2018) (1)
From journal to bedside: obtaining medically useful answers from a meta-analysis. (1997) (1)
Abstract 3296: Effects of Fondaparinux in Patients with ST-Segment Elevation Acute Myocardial Infarction Non-Eligible for Reperfusion Treatment (2006) (1)
Abstract 3677: Work and Leisure Time Related Physical Activity and the Risk of Myocardial Infarction: Results of the INTERHEART Study (2007) (1)
A polypill for cardiovascular disease prevention with a focus on non-alcohol steatohepatitis. (2022) (1)
Abstract 8500: Alcohol Effect on Incident Atrial Fibrillation in Individuals with Cardiovascular Disease: Analysis of Data from the ONTARGET and TRANSCEND Studies (2011) (1)
Abstract 15144: Current Status of Medication Usage for Cardiovascular Disease and Hypertension in China (PURE-China Study) (2012) (1)
Polypill for cardiovascular disease prevention--reply. (2013) (1)
The value of large, robust trials: the HOPE study (2002) (1)
Bongani Mayosi, a hero remembered. (2018) (1)
Urinary Sodium Excretion and Cardiovascular Events—Reply (2012) (1)
818a – Adverse Events Related to Proton Pump Inhibitor Therapy. Results of a Randomized Trial of Pantoprazole Versus Placebo with 53,152 Patient Years of Follow-Up (2019) (1)
827-5 Diabetic patients with acute myocardial infarction have larger infarct size, lower ejection fraction, and higher mortality (2004) (1)
Response to letter regarding article, "Management and outcomes of major bleeding during treatment with dabigatran or warfarin". (2014) (1)
Preventing stroke with ramipril—authors' reply (2003) (1)
Heart protection study. Authors' reply (2003) (1)
Progression of Left-ventricular Dysfunction - Remodeling Or Depressed Contractility (1990) (1)
The Interheart Study: a global study of risk factors for acute myocardial infarction (2008) (1)
Who is fooling us? (2002) (1)
Abstract 18936: Can Biomarkers Improve Risk Stratification of Atrial Fibrillation Patients? Analysis of 3578 Aspirin-treated Patients in ACTIVE and AVERROES (2014) (1)
Response by Smyth et al to Letters Regarding Article, "Physical Activity and Anger or Emotional Upset as Triggers of Acute Myocardial Infarction: The INTERHEART Study". (2017) (1)
Pharmacogenomic study of heart failure and candesartan response from the CHARM programme (2021) (1)
Abstract 3594: Lack of Interaction between Angiotensin Receptor Blocker and Aspirin in Patients with Heart Failure (2006) (1)
Corrigendum to “Heart failure in low- and middle-income countries: Background, rationale, and design of the INTERnational Congestive Heart Failure Study (INTER-CHF)” (Am Heart J. 2015;170[4]:627-634) (2016) (1)
Entry Clinical and ECG Variables Predictive of Eventual Infarct Size and Mortality in Patients with Suspected Myocardial Infarction (1983) (1)
A 026 Healthy Food and Markers of Risk Cardiovascular between Urban and Rural Populations. PURE Study (2009) (1)
Natriuretic peptides predict left ventricular remodeling in response to metoprolol CR in patients with congestive heart failure: the RESOLVD phase II neurohumoral substudy (2002) (1)
Reply. (2021) (1)
What is the Association Between Depression and Cardiovascular Disease?-Reply. (2020) (1)
Clinical Investigations Factors Influencing Exercise Performance in Patients With Left Ventricular Dysfunction (1998) (1)
Transesophageal echocardiography to guide cardioversion in patients with atrial fibrillation. (2001) (1)
Limitation of myocardial infarct size. Present status. (1983) (1)
Prevention of vascular events in atrial fibrillation – Authors' reply (2007) (1)
BLEEDING WITH ASPIRIN AND APIXABAN IN PATIENTS UNSUITABLE FOR VITAMIN K ANTAGONIST THERAPY: THE AVERROES STUDY (2012) (1)
Surrogate endpoints in clinical trials (1985) (1)
Epidemiology and Prevention Association of Diet, Exercise, and Smoking Modification With Risk of Early Cardiovascular Events After Acute Coronary Syndromes (2010) (1)
Ischemic heart disease: the next target for the angiotensin-converting enzyme inhibitors (2000) (0)
The predictive value of interarm systolic blood pressure differences in patients with vascular disease: Sub-analysis of the COMPASS trial (2023) (0)
CHA2DS2-VASc and CHADS2 scores for risk stratification of major adverse cardiovascular events in the COMPASS trial (2020) (0)
Blood pressure analyses from 25 595 patients (from 25 620 randomised) during the ONTARGET trial: reflections on current guidelines (2008) (0)
Response to Letter Regarding Article, “Differential Clinical Outcomes Associated With Hypoglycemia and Hyperglycemia in Acute Myocardial Infarction” (2010) (0)
Peter Sleight (2020) (0)
240-LB: Angiotensin-Converting Enzyme and Type 2 Diabetes Risk: A Mendelian Randomization Study (2019) (0)
Abstract 23231: The Impact of Dual Antiplatelet Therapy on Mortality: A Patient-Level Meta-Analysis (2016) (0)
Response to letter regarding article, "Efficacy and safety of dabigatran compared with warfarin in relation to baseline renal function in patients with atrial fibrillation: a RE-LY (Randomized Evaluation of Long-Term Anticoagulation Therapy) trial analysis". (2014) (0)
The responsibilities of the World Medical Association President (2009) (0)
Enoxaparin versus Unfractionated Heparin in ST-Elevation Myocardial Infarction (2006) (0)
Heart rateandectopic prematurity inrelation tosustained ventricular arrhythmias (1980) (0)
Platelets in Thrombotic and Non-thrombotic Disorders: Design of trials to evaluate antiplatelet agents (2002) (0)
Vegetarianism is protective against myocardial infarction in asian indians (1996) (0)
Short QT Interval and Atrial Fibrillation in Patients Without Structural Heart Disease (2006) (0)
Abstract 3561: Genetic Variants Associated with Acute Myocardial Infarction Risk in Five Ethnic Groups: The INTERHEART genetics study (2007) (0)
Early treatment with enalapril in patients with reduced ejection fractions protected against death and serious cardiovascular morbid events at 12 years in SOLVD (2003) (0)
heart failure use of ramipril for prophylaxis of congestive (2000) (0)
EFFICACY OF LEVAMISOLE AS A SINGLE AGENT IN MAINTAINING REMISSION IN STEROID DEPENDANT NEPHROTIC SYNDROME (2017) (0)
CORNER Case of the PONS study (2011) (0)
Effect of long-term ACE-inhibitor therapy in elderly vascular disease patients. Editorial (2007) (0)
Early enalapril therapy in patients with left ventricular systolic dysfunction reduced cardiovascular morbidity and mortality at 15-years in SOLVD (2004) (0)
Evolution and Prediction of Infarct Size after Acute Myocardial Infarction in Man (1978) (0)
P ifferences in the Management nd Prognosis of Women and Men ho Suffer From Acute Coronary Syndromes (2016) (0)
Impact of Rivaroxaban Alone or in Combination With Aspirin Versus Aspirin in Preventing Graft Occlusion in Patients With CABG Surgery: The COMPASS CABG Analysis (2018) (0)
Title: Analysing recurrent hospitalisations in heart failure: a review of statistical methodology, with application to CHARM-Preserved Short Title: Rogers et al, Analysing recurrent hospitalisations (2015) (0)
Abstract 23084: Marked Global Variability in Cost Effectiveness of Lipid-Lowering and Combination Antihypertensive Therapies in Primary Prevention: Analyses of the HOPE-3 Trial (2017) (0)
Corrigendum to “Randomized controlled trial of influenza vaccine in patients with heart failure to reduce adverse vascular events (IVVE): Rationale and design” [212 (2019) 36–44] (2019) (0)
Response to Letter Regarding Article, “The Inflammatory Hypothesis: Any Progress in Risk Stratification and Therapeutic Targets?” (2007) (0)
At what level should LDL-cholesterol be reduced for secondary prevention? Rationale and design of the NIH Post-CABG clinical trial (1994) (0)
422 Accelerated Adipose Tissue Dysfunction and Cardiovascular Risk in Individuals of South Asian Ethnicity (2012) (0)
VARIATIONS BETWEEN COUNTRIES IN INVASIVE CARDIAC PROCEDURES. AUTHORS' REPLY (1998) (0)
Homocysteine and cardiovascular risk: is it time to treat? (1999) (0)
PATIENT AND SYSTEM-RELATED GAPS IN EMERGENCY MEDICAL SERVICES USE IN ST-ELEVATION MYOCARDIAL INFARCTION: RESULTS FROM THE THIRD GULF REGISTRY OF ACUTE CORONARY EVENTS (2015) (0)
Left Ventricular Mass in Cardiac Disease ffects of Ramipril on Left Ventricular ass and Function in Cardiovascular atients With Controlled Blood Pressure and ith Preserved Left Ventricular Ejection Fraction Substudy of the Heart Outcomes Prevention Evaluation ( HOPE ) (2016) (0)
Cardiovascular risk in hypertension: open questions about HOPE 4 – Authors' reply (2020) (0)
Efficacy and safety of apixaban compared with aspirin in patients who previously tried but failed treatmentwithvitaminKantagonists:resultsfrom (2014) (0)
Ramipril in preventing cardiovascular events. (2000) (0)
Abstract 2292: Dipyridamole Induced Headache Indicates Lower Recurrence Risk in Secondary Prevention of Ischemic Stroke (2012) (0)
Dietary intake and cardiovascular outcomes in patients with chronic vascular disease: insights from the COMPASS trial cohort. (2023) (0)
Emerging Approaches in Cardiovascular Prevention (2007) (0)
Reduction in all-cause mortality and morbidity with candesartan in patients with chronic heart failure and systolic left ventricular dysfunction: results of the CHARM low EF trials (2004) (0)
Genetic determinants of warfarin response, efficacy and safety : a RE-LY genomics substudy (2012) (0)
Placebo and Active Antiarrhythmic Therapy (2005) (0)
Effects of a Polypill, Aspirin, and the Combination of Both on Cognitive and Functional Outcomes: A Randomized Clinical Trial. (2023) (0)
594 Differences between diabetic and non‐diabetic patients with chronic heart failure. Baseline demographics from CHARM (2003) (0)
Reply to GASTRO-D-19-01953 and GASTRO-D-01789. (2019) (0)
92P Inclusion of patients only with low ejection fraction in heart failure trial biases the population against women and the elderly (1994) (0)
Abstract 3700: Impact of Vascular Events on Mortality in AF Patients: Insights from ACTIVE W (2006) (0)
ETHNIC DIFFERENCES IN THE ASSOCIATION BETWEEN HANDGRIP STRENGTH AND THE PREVALENCE OF HYPERTENSION (2021) (0)
Abstract P131: Importance of Algorithm-Consistent Warfarin Dosing in the Quality of Anticoagulation Control in Atrial Fibrillation: A Multilevel Analysis (2011) (0)
Recommendations for national and local regulatory authorities concerning research in aenetic markers of disease : Genetics of coronary heart disease: Current understanding and future prospects (2000) (0)
Ramipril Global Endpoint Trial / Telmisartan Randomized AssessmeNt Study in ACE withTelmisartan , Ramipril , or Both : The ONgoing Telmisartan Alone and in combination Erectile Dysfunction Predicts Cardiovascular Events in High-Risk Patients Receiving (2010) (0)
Responses in Grammar (2011) (0)
Reserving judgement on HRT (2002) (0)
PM276 The Global Rheumatic Heart Disease Study (Remedy) – Data From Sudan (2016) (0)
Salim Yusuf Preventing Vascular Events Due to Elevated Blood Pressure (2006) (0)
Poster Session 4: ECG (2009) (0)
Use of triple and quadruple neurohormonal blockade in heart failure: new data from the candesartan in heart failure assessment of reduction in mortality and morbidity (CHARM)-Added trial (2006) (0)
Beta adrenergic blokade in myocardial infarction (1980) (0)
Abstract 16391: The Impact of Smoking on Clinical Outcomes and the Role of Double-Dose versus Standard-Dose Clopidogrel Among Individuals With Acute Coronary Syndromes Undergoing Percutaneous Coronary Intervention - Insights From the CURRENT-OASIS 7 Trial (2016) (0)
ACTIVE W Substudy Patients Taking Oral Anticoagulation or Combined Antiplatelet Therapy: An Incidence of Stroke in Paroxysmal Versus Sustained Atrial Fibrillation in (2011) (0)
The impact of time to thrombolytic therapy on outcome in patients with acute myocardial infarction (AMI) (1998) (0)
revention of Atrial Fibrillation ith Angiotensin-Converting Enzyme nhibitors and Angiotensin Receptor Blockers (2005) (0)
Clopidogrel in Atrial Fibrillation: Is There Any Justification Now in the Era of New Anticoagulants? (2012) (0)
Health Services and Outcomes Research Influenza Vaccination and Major Adverse Vascular Events in High-Risk Patients (2012) (0)
Powerful Predictor of Long-Term Mortality in Diabetic Patients With Acute Coronary Syndromes (2004) (0)
Guidance adherent dabigatran etexilate treatment versus warfarin in the RE-LY population: an analysis on the basis of the European label recommendations for dabigatran etexilate (2013) (0)
Prevalence,Awareness,Treatment,andControl ofHypertensioninRuralandUrbanCommunities inHigh-,Middle-,andLow-IncomeCountries (2013) (0)
Late‐breaking Trials (2006) (0)
Can social capital overcome barriers to effective management of hypertension. Study in 17 countriesMartin McKee (2016) (0)
BLOOD TRANSFUSIONS ARE ASSOCIATED WITH WORSE OUTCOMES AFTER CORONARY ARTERY BYPASS GRAFTING (2014) (0)
A 025 Prevalence of Cardiovascular Disease, Alcohol Consumption, Tobacco and Exhibition to the Tobacco. PURE Study (2009) (0)
The cost-effectiveness of Rivaroxaban with or without aspirin in the COMPASS trial. (2022) (0)
Abstract 12618: Cluster Randomized Controlled Trial to Test The Effect of a Multifaceted Comprehensive Cardiovascular Care Intervention on Clinical Outcomes in Atrial Fibrillation Patients Receiving Dabigatran (2012) (0)
Rivaroxaban in Stable Cardiovascular Disease. (2018) (0)
Effect of rosiglitazone and ramipril on-cell function in people with impaired glucose tolerance ( IGT ) or impaired fasting glucose ( IFG ) : the DREAM Trial . Running title : Rosiglitazone , ramipril and-cell function (2009) (0)
A cardiovascular study that includes a million subjects. (2013) (0)
794 What is the Clinical Profile of “Life-Threatening” Gastrointestinal Bleeding in Anticoagulated Patients? A Sub-Analysis of the RE-LY Trial (2016) (0)
OC05_03 Variations in Cardiovascular Disease Risk Factors and Outcomes in South Asia (2016) (0)
Effect of beta-blockers on arrhythmias. (1979) (0)
901 Importance of Risk Stratification to Explain International Variations in Results of the Coronary Trial (Off-Pump Vs. On-Pump Cabg Surgery) — the Canadian Results (2012) (0)
Nutrition, tobacco use, and physical activity in the West Bank, occupied Palestinian territory: an environmental profile of community health (2012) (0)
Edinburgh Research Explorer Double-Dose Versus Standard-Dose Clopidogrel According to Smoking Status Among Patients With Acute Coronary Syndromes Undergoing Percutaneous Coronary Intervention (2017) (0)
IN THE LITERATURE Is Angiotensin-Converting Enzyme Inhibitor and Angiotensin Receptor Blocker Combination Therapy Better Than Monotherapy and Safe in Patients With CKD? (2009) (0)
Abstract 3716: Household Car and Television Ownership are associated with an increased risk of Myocardial Infarction: Results from the INTERHEART Study (2007) (0)
Reduction in infarct size and morbidity by early intravenous betablockade (1981) (0)
PT209 Wealth and Cardiovascular Health: An Observational Study of Wealth-Related Inequalities in The Awareness, Treatment and Control of Hypertension in 21 High-, Middle-, and Low-Income Countries (2016) (0)
The relationship of child and family functioning in families of children with complex congenital heart disease : A pilot study (2013) (0)
REDUCTION IN MORTALITY AFTER MYOCARDIAL-INFARCTION BY ACUTE INTERVENTION (1983) (0)
Plasma norepinephrine predicts 12-year survival in patients with reduced ejection fractions from the studies of left ventricular dysfunction (SOLVD) (2003) (0)
PT044 Physical Activity of Adults Residing in Low, Middle and High Income Income Countries: Findings of Pure Study (2016) (0)
Prevention of post-cardiac surgery atrial fibrillation is not associated with decrease in post-operative stroke: meta-analysis (2002) (0)
Socio-economic inequality in the use of secondary prevention of cardiovascular diseaseMartin McKee (2017) (0)
Author Response (2011) (0)
Usefulness of Tachycardic-Stress Perfusion Imaging to Predict Coronary Artery Disease in High-Risk Patients With Chronic Renal Failure (2003) (0)
The pitfalls of inappropriate methods (2005) (0)
Abstract 104: First Stroke Reduced 44 Percent by Well Tolerated Medications. Stroke Outcomes From the Heart Outcomes Prevention Evaluation 3 Study (2018) (0)
Which characteristics of frontline health systems affect the control of hypertension?Martin McKee (2017) (0)
Comprar The Hands-on Guide to Clinical Pharmacology | Salim Yusuf | 9781405120159 | Wiley (2009) (0)
Abstract 5617: Paradoxical Low Use of Coronary Interventions in High-Risk Non-st Segment Acute Coronary Syndromes with Heart Failure. Data from the Oasis-5 Randomized Trial (2008) (0)
1098-79 Renal function predicts outcomes in acute coronary syndromes: Insights from the CURE trial (2004) (0)
Asians Compared With Individuals in Other Countries Risk Factors for Early Myocardial Infarction in South (2010) (0)
Big trials, big results, and huge rewards for Medicine (2009) (0)
Bleeding and thromboembolic outcomes in warfarin-and dabigatran-treated patients in the RE-LY trial who required an urgent surgery or procedure (2015) (0)
Abstract 1535: Obesity Metrics And Their Associations With Type 2 Diabetes And Glucose Levels In A Large International Multi-ethnic Cohort. (2007) (0)
Current treatments of cardiovascular diseases are unlikely to produce more than moderate reductions in mortality (1985) (0)
Using receptor antagonists type 1 angiotensin II for preventing diabetes (2000) (0)
HOPE-‑3, BP treatment, milestones in CV prevention. Dr. Salim Yusuf in an interview with Dr. Akbar Panju and Dr. Roman Jaeschke. (2016) (0)
Clinical Applications of External Evidence (2007) (0)
beta-blocker therapy in non-cardiac surgery - Reply (2008) (0)
The use of an FDA-NDA database to assess the risk of exposing patients with chronic stable angina to placebo-controlled trials (1988) (0)
Causal ordering among risk factors in the PURE study – Authors' reply (2021) (0)
Predicting mortality and morbidity in chronic heart failure independent of left ventricular systolic function: Results from the CHARM program (2004) (0)
AAI cardiac pacing as an alternative to CPAP in a patient with sleep apnea syndrome: case report (2011) (0)
902 Cluster Randomized Controlled Trial to Test the Effect of Computer-Generated Individualized Audit and Feedback to Patients and Physicians on Clinical Outcomes in Atrial Fibrillation Patients Participating in a Large Multi-Center Trial of Dabigatran (2012) (0)
Subject Index, Vol. 84, 1994 (1994) (0)
Combination Therapy to Prevent Cardiovascular Disease (2017) (0)
Risks and benefits of β-blockade (2005) (0)
Absence of Relation between Severity of Myocardial Infarction and Ventricular Arrhythmias (1978) (0)
Surrogate endpoint use in cardiovascular clinical trials (1986) (0)
Contents Vol. 23, 2007 (2007) (0)
THROMBOLYTIC THERAPY FOR ACUTE MYOCARDIAL INFARCTION. AUTHOR'S REPLY (1999) (0)
LONG-TERM TREATMENT WITH APIXABAN OF PARTICIPANTS FOLLOWING CONCLUSION OF AVERROES (2019) (0)
THE RELATIONSHIP OF OBESITY AND LOW HANDGRIP STRENGTH OR SARCOPENIC OBESITY AS A PREDICTOR OF THE PRESENCE OF CARDIOVASCULAR DISEASE (2020) (0)
Effect of time to thrombolytic therapy on infarct size assessed by tomographic sestamibi perfusion imaging (1996) (0)
Thrombolytic therapy for acute myocardial infarction (1999) (0)
Does Acute Kidney Injury Cause Longer-Term Kidney Function Decline? (2015) (0)
Joint Communication from Davos Cardiology Update, February 2017 (2017) (0)
MO201: Effects of Aspirin in Primary Prevention of Cardiovascular (CV) Disease in People with Chronic Kidney Disease (CKD): Results of the TIPS3 Trial (2022) (0)
Abstract 18466: Anemia is Associated with an Adverse Outcome in Patients with Atrial Fibrillation: Insights Form the Re-ly Trial (2012) (0)
Treatment of stroke (2003) (0)
Chapter 5 – Aspirin and Thienopyridines (2004) (0)
640 Total bilirubin and red cell distribution width are powerful independent predictors of outcome in chronic heart failure: results from the CHARM program (2005) (0)
Ramipril and Risk of Diabetes—Reply (2002) (0)
Abstract W MP119: Sensitivity and Reliability of MRI SWI Compared With GRE Sequences for Detecting Microbleeds in a Community Population (2015) (0)
Prevalence of cardiovascular disease risk factors and long-term outcomes in the Saudi population: Results from the Prospective Urban Rural Epidemiology study (PURE-Saudi) (2020) (0)
Salim Yusuf Unresolved Issues in the Management of Hypertension (2010) (0)
Abstract 13687: Legacy of Lipid Lowering in Preventing Fatal and Non Fatal Cardiovascular Events in Individuals Without Cardiovascular Disease During 3 Years of Post -Trial Observation in the Hope 3 (Heart Outcomes Prevention Evaluation 3) Study (2019) (0)
Selection of patients for angiography following myocardial infarction was not based on risk but on young age and availability of angiographic facilities. (1997) (0)
Obesity Genes and Risk of Major Depression in a Multiethnic Population (2015) (0)
, Janice and Stroke in Patients With Coronary Artery Disease Systolic and Diastolic Blood Pressure Changes in Relation With Myocardial Infarction (2014) (0)
COMMENT Imaging Asymptomatic Individuals for Coronary Disease * (2017) (0)
Beta-blockers in immediate treatment of myocardial infarction (1980) (0)
[Authors' reply] Telmisartan in high-risk patients intolerant of ACE inhibitors (2009) (0)
Clopidogrel and percutaneous coronary intervention (2002) (0)
Morbidity and mortality reduction with ramipril: The latest results of the HOPE trial (2000) (0)
Abstract P192: The Gap Between Guidelines and Practice for the Total Cardiovascular Care of Atrial Fibrillation Patients in an Extended Study for Re-ly Patients Receiving Dabigatran (2011) (0)
544 Candesartan improves outcome in patients with low ejection fraction heart failure, irrespective of background dose of ACE inhibitor: a post-hoc analysis of the CHARM-Added trial (2006) (0)
Pulmonary Function In Healthy Non-Smoking Adults From 17 Countries In Different Regions Of The World (2011) (0)
DIURETICS IN PREGNANCY - OVERVIEW OF RANDOMIZED TRIALS - IMPLICATIONS FOR TRIALS OF OTHER AGENTS IN PREGNANCY (1984) (0)
Using ace inhibitors for the prophylaxis of congestive heart failure (2000) (0)
Contents, Vol. 84, 1994 (1994) (0)
Evidence‐Based Decision Making: Patient–Physician Interface (2010) (0)
CKD CLINICAL MO040 EFFECTOF VERY LOW PROTEIN DIET SUPPLEMENTED WITH KETOANALOGUES OF THE ESSENTIAL AMINO ACIDS ON THE PROGRESSION OF CHRONIC KIDNEY DISEASE (2014) (0)
Imaging Asymptomatic Individuals for Coronary Disease. (2017) (0)
Cardiovascular risk and events in different-income countries: the Pure study (2014) (0)
Abstract 19757: Comparison of Contemporary Bleeding Risk Scores in Patients With Non-Valvular Atrial Fibrillation Treated With Dabigatran or Warfarin: Insights From the RE-LY Trial (2016) (0)
Calcium channel blockers in myocardial infarction: Authors' reply (1990) (0)
Characteristics, clinical practice patterns and outcomes of strokes in India: INSPIRE - A multicentre prospective study. (2023) (0)
Large Simple Trials (2004) (0)
On behalf of the Study of Health Assessment and Risk in Ethnic Groups investigators (2008) (0)
Candesartan prevented development of diabetes mellitus in heart failure (2006) (0)
Normalization of the Ecg in Survivors of Myocardial Infarction on β-Adrenoreceptor-Blocking Agents (1979) (0)
Renal outcomes in the ONTARGET study – Authors' reply (2008) (0)
Long-term ambient PM2.5, household air pollution exposure, and blood pressure in the Prospective Urban and Rural Epidemiological (PURE) Study (2016) (0)
Angiotensin Antagonism Effect of Long-Term Therapy With Ramipril in High-Risk Women (2016) (0)
Enzyme Inhibitors in Cardiac and Vascular Protection (2005) (0)
SERUM LIPID PEROXIDATION, BLOOD PRESSURE AND RENAL PROFILE OF DIABETIC ISCHAEMIC STROKE SUBJECTS. (2016) (0)
CONTROL OF HYPERTENSION BY ETHNICS IN COLOMBIA, A SECONDARY ANALYSIS OF COLOMBIA PURE STUDY (2021) (0)
activator complex on mortality in acute myocardial infarction. Effects of tissue-type plasminogen activator and anisoylated plasminogen streptokinase (2013) (0)
Ramipril and risk of diabetes. Author's reply (2002) (0)
Fishing for an Association With Sudden Cardiac Death-Reply. (2021) (0)
Reply to GASTRO-D-19-,01448, GASTRO-D-19-01576, GASTRO-D-19-02060, and GASTRO-D-19-02139. (2020) (0)
Meta-analysis (1998) (0)
Abstract 2420: Effect of Rosiglitazone on Left Ventricular Systolic and Diastolic Function and on NT-proBNP: Results of the Echocardiographic and Biomarker Substudy of the DREAM Trial (2008) (0)
Abstract 329: Barriers To Hypertension Screening, Treatment And Control As Reported By Patients And Healthcare Providers (2013) (0)
Prior and Incident Myocardial Infarction in HFpEF: A Pooled, Patient-Level Analysis of 3 Contemporary Clinical Trials with 8,916 Patients (2019) (0)
We-W31:5 Homocysteine and folic acid levels and relation to carotid atherosclerosis in high-risk individuals (2006) (0)
Numbers can save lives: Janice Pogue (1962–2016) (2016) (0)
Selected Summaries Waist – hip ratio : A thrifty phenotype ? (2007) (0)
Abstracts of the Fast Tracked Online Articles (2013) (0)
Abstract 23086: Impact of Rivaroxaban Alone or in Combination With Aspirin versus Aspirin in Preventing Graft Occlusion in Patients With CABG Surgery COMPASS CABG (2017) (0)
Impact of atrial fibrillation on mortality, strokes, and ischemic events in studies of left ventricular dysfunction patients (1993) (0)
555 Indirect comparison of the effects of adding an aldosterone antagonist or an angiotensin receptor blocker in severe heart failure: new data from the CHARM-Added trial (2006) (0)
Modulation of 5-hydroxytryptamine 4 (5HT4) receptor isoform expression predisposes to atrial fibrillation after coronary artery bypass surgery. (2003) (0)
Ramipril for prevention of cardiovascular events (2000) (0)
311: Development of a Semi-Quantitative Food Frequency Questionnaire for use in United Arab Emirates and Kuwait (2005) (0)
420 ACE-inhibition for myocardial ischaemia /New aspects of nitrate therapy in ischaemic heart disease (2005) (0)
Factors Relating to 6 Minute Walk Performance in Heart Failure Patients (1995) (0)
Ventricular arrhythmias inlongtermsurvivors of orthotopic andheterotopic cardiac transplantation (1988) (0)
Limitation of Myocardial Infarct Size (1983) (0)
Clinical Outcomes of Patients with Previous Transient Ischaemic Attack or Stroke - a Subgroup Analysis of the Long-Term Extension of Dabigatran in Patients with Atrial Fibrillation (RELY-ABLE) Study (2013) (0)
Optimal Sodium InTake In Cardiovasular and Kidney ( COSTICK ) Diseases : a study protocol for two randomised controlled trials (2022) (0)
The MANAGE trial – Authors' reply (2019) (0)
Value ofelectrocardiogra m inpredicting andestimating infarct sizeinman (1979) (0)
Impact of therapy on mortality and morbidity in patients with cardiac failure and left ventricular dysfunction (1990) (0)
The Controversy Surrounding Surgical Care Improvement Project-Venous Thromboembolism Process Measures (2017) (0)
Risk Factors Predicting Nonfatal Myocardial Infarction (2011) (0)
Community health worker based interventions in secondary prevention of CVD in India (SPREAD): methods and baseline results (2013) (0)
RISK FACTORS FOR CORONARY HEART DISEASE IN ASIAN INDIANS. AUTHOR'S REPLY (1996) (0)
Adjunctive therapy for myocardial infarction. (1995) (0)
Data Monitoring in the Heart Outcomes Prevention Evaluation and the Clopidogrel in Unstable Angina to Prevent Recurrent Ischemic Events Trials: Avoiding Important Information Loss (2006) (0)
Relationship between Infarct Size and the P-Wave Terminal Force in Acute Myocardial Infarction (1979) (0)
children must necessarily encompass efforts directed at maintaining optimal health in pregnant women and over the entire lifecourse. Prevention of CVD and promotion of cardiovascular health in women and children: A Call for Action (2012) (0)
Abstract 18220: Impact of Lipid and Blood Pressure Reduction on Erectile Dysfunction in Persons at Intermediate Risk for Cardiovascular Disease (2016) (0)
THE HEART OUTCOMES PREVENTION EVALUATION 4 CANADA: A PILOT STUDY OF A COMMUNITY-BASED, MULTI-FACETED INTERVENTION, LED BY NON-PHYSICIANS TO REDUCE CARDIOVASCULAR RISK IN PEOPLE WITH HYPERTENSION (2019) (0)
Increased risk of early and late mortality with first degree heart block in patients with acute myocardial infarction (1990) (0)
A53 Factors predicting employment and job satisfaction in patients with severe left ventricular dysfunction (1993) (0)
Total Events and Net Clinical Benefit of Rivaroxaban and Aspirin in Patients with Chronic Coronary or Peripheral Artery Disease: The COMPASS Trial (2023) (0)
[Effect of atenolol on the QT interval in the acute phase of myocardial infarction]. (1988) (0)
D-dimer and factor VIIa in atrial fibrillation – prognostic values for cardiovascular events and effects of anticoagulation therapy (2016) (0)
Edinburgh Research Explorer Secretory Phospholipase A2-IIA and Cardiovascular Disease (2018) (0)
Subject Index Vol. 11, Suppl. 2, 2002 (2002) (0)
Risk factors for early myocardial infarction in South Asians. Author's reply (2007) (0)
Could patents interfere with the development of a cardiovascular polypill? (2016) (0)
Abstract 9011: Randomized Trial of Fondaparinux versus Heparin to Prevent Graft Failure After Coronary Artery Bypass Grafting: The Fonda CABG Pilot Study (2010) (0)
Single Dose of Antenatal Corticosteroids (SNACS) Non-Inferiority Randomized Controlled Trial for Pregnancies at Risk of Preterm Delivery (2022) (0)
INFARCTION: FINAL REPORT OF A RANDOMISED CLINICAL TRIAL (1984) (0)
inappropriate methods Digitalis--a new controversy regarding an old drug. The pitfalls of (2011) (0)
Management of dyspepsia symptoms on dabigatran during RELY-ABLE : a long-term follow up of RE-LY patients. (2014) (0)
PT073 Lipoprotein(A) and Risk of Myocardial Infarction in Major Ethnic Groups (2016) (0)
Primary coronary angioplasty is superior to thrombolytic therapy for acute MI. (1998) (0)
The protective effect of the obesity-associated rs9939609 A variant in fat mass- and obesity-associated gene on depression (2013) (0)
Investigating Abdominal Aortic Aneurysm (AAA) Texture Analysis, F-18-FDG Uptake on PET/CT and future growth rate (2012) (0)
Evidence-based cardiology, second edition (2004) (0)
Abstract 3631: Elevated In-hospital Glucose Level, and not Known History of Diabetes Mellitus, Predicts 30-day Mortality Following Acute ST-elevation Myocardial Infarction (2007) (0)
Abstract 2562: Fasting Plasma Glucose is an Independent Predictor of Hospitalization for Congestive Heart Failure in High-Risk Patients (2006) (0)
A 027 Current Data to Demonstrate of Healthy Lifestyle and Cardiovascular Risk Markers Among Populations of Urban and Rural Areas. PURE Study (2009) (0)
The Ten Most Commonly Asked Questions about the Calcium Channel Blocker Controversy (1997) (0)
Reduction -Term Ventricular Arrhythmia ii y Encrlapril in Heart Failure (1995) (0)
Statistical Approaches to Improving Trial Efficiency and Conduct (2014) (0)
Body Mass Index and Prognosis in Patients With Chronic Heart Failure Insights From the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM) Program Heart Failure (2007) (0)
Treatment and outcomes of acute coronary syndromes in India (CREATE) : a prospective analysis of registry data. Commentaries (2008) (0)
OC06_10 Applicability of a Non-Laboratory- and a Laboratory Based Cardiovascular Disease Risk Score Across Seven Regions of the World (2016) (0)
Peter Sleight, Emeritus Professor of Cardiovascular Medicine, Oxford University, Chairman of the ISIS Trials Steering Committee. (2020) (0)
Authors' reply (2003) (0)
1128-120 Importance of an oral glucose tolerance test in identifying high prevalence of dysglycemia in individuals at high cardiovascular risk (2004) (0)
Abstract 3680: Glucose Levels Predict Incident Cardiovascular Events In A Large International Multiethnic Cohort (2007) (0)
Abstract 210: Stroke-Related Specific Mortality and Influencing Factors in Patients with Atrial Fibrillation in the RE-LY Trial (2013) (0)
Emerging RoleofAngiotensin-Converting EnzymeInhibitors inCardiac andVascular Protection (1994) (0)
221 Elevated CETP Activity is Associated With Low Dysfunctional HDL in South Asians (2012) (0)
408 Incremental benefit of candesartan in heart failure - new analyses of CHARM-Added, according to baseline treatment (2005) (0)
Abstract 1305: Erectile Dysfunction Predicts Cardiovascular Events in High Risk Patients Receiving Telmisartan, Ramipril or Both (2009) (0)
Cardiovascular outcomes and renal disease. Authors' reply (2002) (0)
Use of ramipril for preventing diabetes in a patient without preexisting congestive heart failure (2000) (0)
Extra-Cardiac Disease Burden Contributes More Than Cardiac Disease Burden to Risk of Cardiovascular Outcomes in Patient with Preserved Ejection Fraction (2016) (0)
Summary and Recommendations : A Report of the American College of ACC / AHA Guidelines for Coronary Artery Bypass Graft Surgery : Executive (1999) (0)
679 Predictive value of increased body weight and abdominal adiposity for cardiovascular events in high-risk patients a sub-study of the ontarget/transcend trials (2011) (0)
A Lifetime of Prevention (2002) (0)
More than just hype. (2003) (0)
Recommendations for national and local regulatory authorities concerning research in genetic markers of disease. (2000) (0)
Perioperative Myocardial Infarction in Patients Undergoing Noncardiac Surgery (2011) (0)
Diabetes status and fasting plasma glucose are independent determinants of cognitive status in people at high risk for cardiovascular disease (2006) (0)
407 Candesartan is cost‐effective in heart failure ‐ an economic analysis of the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM) programme (2005) (0)
Subject Index Vol. 23, 2007 (2007) (0)
Response to Letter Regarding Article, “Influence of Nonfatal Hospitalization for Heart Failure on Subsequent Mortality in Patients With Chronic Heart Failure” (2008) (0)
How generalisable is INTERSTROKE? – Authors' reply (2010) (0)
PT046 Urinary Sodium Excretion Versus Mortality and Cardiovascular Events in Those With and Without Hypertension (2016) (0)
Real-world evaluation of follow up strategies after implantable cardiac-defibrillator therapies in patients with ventricular tachycardia (REFINE-VT) (2021) (0)
588 Differences between younger and older patients with chronic heart failure. Baseline demographics from CHARM (2003) (0)
STARR (STudy of Atherosclerosis with Ramipril and Rosiglitazone) People With Impaired Glucose Tolerance or Impaired Fasting Glucose: Effect of Ramipril and of Rosiglitazone on Carotid Intima-Media Thickness in (2011) (0)
Hirudin for Acute Coronary Syndromes (2002) (0)
Clinical Trials in Hypertension and Congestive Heart Failure (1986) (0)
Abstract 19004: The Impact of Dual Antiplatelet Therapy on Mortality: A Patient-Level Meta-Analysis (2016) (0)
Abstract 11898: Effects of Insulin Glargine on Left Ventricular Mass and Function in Patients With Dysglycemia (2014) (0)
Hypotension-Avoidance Versus Hypertension-Avoidance Strategies in Noncardiac Surgery (2023) (0)
Rivaroxaban in Rheumatic Heart Disease-Associated Atrial Fibrillation. Reply. (2022) (0)
590 How do men and women with chronic heart failure differ? Baseline demographics from CHARM (2003) (0)
Enhancement of efferent vagal tone in humans (1994) (0)
Polypill in Persons without Cardiovascular Disease. Reply. (2021) (0)
Vitamin E may increase risk for heart failure. (2005) (0)
The CHARM programme - Reply (2003) (0)
Prerandomization adherence aids for clinical trials (1986) (0)
023 Risk Stratification Using CHA2DS2-VASc and CHADS2 Scores in Patients With Chronic Atherosclerotic Cardiovascular Disease Receiving Aspirin With or Without Rivaroxaban: An Analysis of the COMPASS Trial (2020) (0)
Trial Patients Receiving Warfarin in the Randomized Evaluation of Long-Term Anticoagulation Quality of Anticoagulation Control Between Centers and Countries : An Analysis of Variation in Warfarin Dose Adjustment Practice Is Responsible for Differences in the (2012) (0)
Event Adjudication Is Unnecessary in Blinded Trials and May Be Detrimental. (2023) (0)
Glucose intolerance and diabetes as risk factors for cognitive impairment in people at high cardiovascular risk: results from the ONTARGET/TRANSCEND (2009) (0)
The preventive potential of common, easily measured risk factors for cardiovascular disease. (2014) (0)
Abstract 3169: Increase in Risk of Death in Early Months Following Hospitalization for Heart Failure: Observations from the CHARM Program (2006) (0)
COVID-19 Vaccination Prioritization Based on Cardiovascular Risk Factors and Number-Needed-to-Vaccinate to Prevent Death (2021) (0)
Heart failure/transplantAbstractEffects of Candesartan on the Development of a New Diagnosis of Diabetes Mellitus in Patients With Heart Failure (2005) (0)
Method and device for the prediction of cardiovascular events (2003) (0)
RESTING HEART RATE AND CHANGES IN HEART RATE ARE ASSOCIATED WITH ADVERSE OUTCOME IN HEART FAILURE PATIENTS WITHOUT ATRIAL FIBRILLATION: AN ANALYSIS OF THE CHARM PROGRAM (2014) (0)
If a Troponin Falls in a Forest but No One Measures It, Does It Really Matter? (2011) (0)
INTERHEART (2005) (0)
INTERHEART (2005) (0)
The CHARM programme. Authors' reply (2003) (0)
MS06.2 Financial Risk For People Living With Non-communicable Diseases: An Analysis of Households From 18 Countries In the Pure Study (2018) (0)
Cardiovascular Outcomes and Renal Disease (2002) (0)
Congestive heart failure complicating non-ST segment elevation acute coronary syndrome: incidence, predictors, and clinical outcomes 1 (2005) (0)
Heart Protection Study (2003) (0)

This paper list is powered by the following services:

Other Resources About Salim Yusuf

en.wikipedia.org

What Schools Are Affiliated With Salim Yusuf?

Salim Yusuf is affiliated with the following schools:

Salim Yusuf's Academic­Influence.com Rankings

Why Is Salim Yusuf Influential?

Salim Yusuf's Published Works

Published Works

Other Resources About Salim Yusuf

What Schools Are Affiliated With Salim Yusuf?

Salim Yusuf's AcademicInfluence.com Rankings